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Abstract 
 
Alzheimer’s disease (AD) is a neurodegenerative disease that accounts for most cases of dementia.  
The pathological hallmarks of AD include extracellular Aȕ plaques, intracellular tau 
accumulations or neurofibrillary tangles, as well as neuroinflammation. As of 2018, there exists 
no disease modifying treatment for AD and the cause of sporadic AD remains elusive. We 
investigated the contribution of the spleen tyrosine kinase (SYK) in AD pathobiology. Syk is well-
known for its involvement in B-cell receptor (BCR) signaling but our previous data have 
demonstrated that SYK is also involved in tau hyperphosphorylation and Aȕ production, therefore 
suggesting that SYK could contribute to the formation of AD pathological lesions.  
The goals of our present studies were to determine whether SYK activation occurs in the 
brain of mouse models of AD and investigate whether the levels of SYK activation vary with the 
amount of AD pathological lesions. In addition, we aimed to examine the role of SYK in the 
autophagic degradation of tau via the mammalian target of rapamycin (mTOR) pathway in vitro 
and in vivo. We investigated SYK activation in different age-groups of Aȕ and tau overexpressing 
mice, as well as human AD specimens. We characterized the activation of SYK in relation to AD 
pathological lesions including amyloid plaques, activated microglia and astroglia, as well as 
hyperphosphorylated tau. In addition, our mechanistic in vitro experiments delineated SYK as a 
regulator of autophagic tau degradation via the mTOR pathway. These data were confirmed in an 
in vivo study, assessing the effects of a 12-week chronic SYK inhibition on tau burden, 
neurodegeneration, behavior, and neuroinflammation in a mouse model with established 
tauopathy.  
Identifying new targets like SYK that act downstream of Aȕ and tau and in turn exacerbate 
these known pathologies, is crucial to find a treatment for AD.   
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1 Introduction 
 
1.1 Alzheimer’s Disease 
 
1.1.1 History 
 
Alzheimer’s disease (AD) is the most common form of dementia, accounting for 60-70% of all 
dementia cases as of 2018 (WHO). The pathology of AD was first described by the eponym Alois 
Alzheimer at a conference in Tübingen, Germany in 1906 and in his subsequent research article 
“Über eine eigenartige Erkrankung der Hirnrinde” (Alois Alzheimer 1907). In his research article, 
he delineates the three major hallmarks of AD that are still used for diagnosis today. He describes 
the psychological changes of a 51 year old woman including increased memory loss and formation, 
temporal and spatial disorientation and many other behavioral and cognitive abnormalities (Alois 
Alzheimer 1907). After 4.5 years, his patient died and he further described the pathological 
changes in the brain including brain atrophy and arteriosclerosis of the larger vessels (Alois 
Alzheimer 1907). In his analysis, he speaks of “merkwürdige Veränderungen der Neurofibrillen” 
(strange changes of the neurofibrils) that lead to a degeneration of the cell, thereby referring to 
what we now know as neurofibrillary tangles of the microtubule-associated protein (MAP) tau. He 
hypothesized that a “chemical transformation of the fibril substance took place” and that this 
“chemical transformation seems to go hand in hand with the deposition of a not yet investigated, 
pathological metabolite into the (ganglion) cell” (Alois Alzheimer 1907). In addition, Alzheimer 
described the pathological hallmark that is today known as Aȕ-plaques (or ȕ-amyloid plaques). He 
mentions that there were “miliare Herdchen” (miliar nidi) caused by “deposition of a strange 
substance into the cortex”, even visible without staining. Furthermore, the “glia formed plenty of 
fibers” and show “big fat bags” (Alois Alzheimer 1907). This was his description of the 
neuroinflammation that we now know is the third major pathological hallmark of the disease 
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named after him. In summary, Alois Alzheimer already described the extracellular Aȕ-plaques, 
intracellular neurofibrillary tau tangles and neuroinflammation (microgliosis and astrogliosis) that 
are today’s standard for the pathological description of the disease.  
 
1.1.2 Demography & Etiology 
 
Nearly, 112 years after Alzheimer’s first public description of his findings, there is still no cure for 
the devastating disease and the numbers of AD cases are rapidly increasing (Alzheimer's disease 
facts and figures 2018). Today (2018), there are approximately 5.7 million living with AD in the 
US and approximately 50 million people are affected worldwide. Estimates suggest that these 
numbers could increase to 14 million in the US and 130 million worldwide by 2050 (Alzheimer's 
disease facts and figures 2018). AD is the 6th leading cause of death in the US, as one in three 
seniors dies with AD or another dementia. Not only does AD negatively affect the lives of millions 
of people, but it also represents a major burden for the governments. The medical and care costs 
are as high as 277 billion dollars in the US and could increase to 1.1 trillion dollars by 2050 
(Alzheimer's disease facts and figures 2018). These facts imply the undisputed need for a cure for 
AD. However, most recent clinical trials aiming to remove the Aȕ and tau pathologies failed to 
meet their endpoint criteria (Watt et al. 2014; St-Amour et al. 2016; Rosenblum 2014) (for a more 
detailed discussion and review on clinical trials see chapter 1.3).                    
AD can be divided into a familial and sporadic forms. The familial form is caused by 
genetic mutations. In the early 1990s, the first genetic mutations were found to cause AD. These 
mutations include point/missense mutations in the gene encoding the amyloid precursor protein 
(APP) (e.g. APP V717I (London) (Goate et al. 1991), APP KM670/671NL (Swedish) (Mullan et 
al. 1992). In the following years, many more studies found various other mutations in the APP 
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gene that lead to an early onset of AD (EOAD). Interestingly, one variant (APP A673T (Icelandic)) 
was identified in 1993 (Peacock et al. 1993) and later confirmed to be protective against AD and 
age-related cognitive decline (Jonsson et al. 2012). Since the A673T mutation is in close proximity 
to the beta-secretase (BACE) cleavage site,  the substrate characteristic of APP changes, resulting 
in lower Aȕ production levels by BACE (Jonsson et al. 2012). In addition to mutations in the APP 
gene, mutations in genes encoding subunits of the Ȗ-secretase, presenilin 1 and 2 (PS1, PS2), 
represent another cause of EOAD by affecting the cleavage of APP (Strooper et al. 1998; Wolfe 
et al. 1999), while PS1 mutations are the most common and PS2 mutations are the least common 
cause of EOAD (Sherrington et al. 1995; Sherrington et al. 1996; Cai et al. 2015). More than 180 
mutations in PS1/2 have been reported so far (http://www.molgen.ua.ac.be/ADMutations/). The Ȗ-
secretase cleaves type I transmembrane proteins including APP, leading to the production of Aȕ. 
Presenilin mutations cause a shift towards longer Aȕ peptides that have a higher tendency to 
aggregate than shorter forms (Aȕ42 compared to Aȕ38), thereby contributing to the formation of 
amyloid aggregates (Duff et al. 1996; Citron et al. 1997; Borchelt et al. 1996).  
Although intracellular neurofibrillary tangles (NFTs) composed of the microtubule 
associated protein tau (MAPT) are one of the main hallmarks of AD, mutations of the MAPT gene 
are only known to cause frontotemporal dementia (FTD) and not directly cause AD, although, a 
recent study showed the MAPT gene influences the AD risk (Desikan et al. 2015).     
In contrast to the rare familial forms of AD that only comprise a very small percentage of 
all cases and lead to an early onset of the disease, the sporadic form of AD is much more common 
and is characterized by a late onset (LOAD) (Barber 2012). The etiology of LOAD is still not fully 
understood. However, there are several risk factors, including risk genes, for sporadic AD that 
have been identified. The greatest risk factor for LOAD remains age, as the risk for developing 
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AD doubles every five years after the age of 65 resulting in a nearly 50% chance at the age of 85 
(Alzheimer's disease facts and figures 2018). Besides the deterministic genes mentioned above 
(APP, PS1, PS2), mutations in risk genes have been identified that increase the probability to 
develop LOAD.  
In 1993, an isoform of the apolipoprotein E (ApoE) was found to increase the risk of AD 
and represents to date the highest genetic risk factor (Corder et al. 1993). ApoE is responsible for 
the binding and transport of lipids (Getz and Reardon 2009). Different variants of the genes 
encoding the apolipoprotein E exist (e.g. ApoE-ε1, ApoE-ε2, ApoE-ε3, and ApoE-ε4). ApoE has 
been found to associate with Aȕ (Sanan et al. 1994) and enhance the fibril formation (Wisniewski 
et al. 1994). Furthermore, ApoE has been shown to disrupt the clearance of Aȕ across the BBB in 
an isoform specific manner (Deane et al. 2008).  The ApoE-ε4 isoform reduced the clearance of 
Aȕ the most by shifting the clearance via the low density lipoprotein receptor-related protein 1 
(LRP1) to the slower very-low-density-lipoprotein receptor (VLDLR) (Deane et al. 2008). In 
contrast, another study suggested that the interaction between ApoE and Aȕ are minimal in the 
extracellular milieu and that ApoE and soluble Aȕ compete for the LRP1-dependent uptake in 
astrocytes, thereby providing a different explanation for the impact of ApoE on Aȕ metabolism 
(Verghese et al. 2013). Furthermore ApoE-ε4 has been suggested to exacerbate the tau pathology 
in vivo (Shi et al. 2017). Heterozygous carriers of the ApoE-ε4 gene exhibit a 2-4 fold risk of 
developing AD, while the risk for homozygous carriers increases up to 8-15 fold (Qian et al. 2017). 
Interestingly, the ApoE-ε2 seems to be protective and reduce the risk for AD by 2-4 fold (Corder 
et al. 1994).    
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In addition, mutations in the gene encoding the triggering receptor expressed on myeloid cells 2 
(TREM2) are not only a known cause of the autosomal recessive early-onset dementia called Nasu-
Hakola disease (NHD), but are also a known risk factor for AD and FTD (Borroni et al. 2014; 
Ulrich et al. 2017; Dardiotis et al. 2017). Variants of TREM2 can increase the risk for AD 2-4 fold 
(Ulrich and Holtzman 2016). TREM2 is a known receptor that is expressed in monocytes 
(Fahrenhold et al. 2017) and the more differentiated microglia (Yao et al. 2016; Filipello et al. 
2018) and infiltrating macrophages (Turnbull et al. 2006; Jay et al. 2015) in the brain, thereby 
mediating the inflammatory response and phagocytosis in the CNS. TREM2 has been shown to 
promote microglia-mediated phagocytosis of Aȕ (Kim et al. 2017). However, the impact of 
TREM2 on the tau pathology remains controversial, as many studies show opposing results. 
TREM2 deficiency has been shown to exacerbate (Bemiller et al. 2017), as well as ameliorate 
(Leyns et al. 2017) tau pathology in vivo. Interestingly, ApoE has been shown to be a ligand of 
TREM2 (Atagi et al. 2015; Bailey et al. 2015), thereby linking two risk factors of AD to each 
other. 
Besides these well-known deterministic genes and risk factors that result in the observed 
AD pathologies, the impaired degradation of intracellular proteins via the autophagy/lysosome 
pathway has been observed in AD and other forms of dementia and seems to play a key role in the 
formation of Aȕ deposits and tau aggregates (Nilsson et al. 2013; Piras et al. 2016) (detailed 
information on autophagy can be found in chapter 1.1.6).        
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1.1.3 Amyloid pathology 
 
The ȕ-amyloid peptide (Aȕ) that is now known to be a cleavage product of the APP and the 
building block of the extracellular plaques observed in AD (Masters et al. 1985), has first been 
isolated, purified and sequenced from the cerebrovasculature of AD and trisomy 21 patients 
(Glenner and Wong 1984a, 1984b). Glenner and Wong (1984a) already hypothesized that Aȕ had 
to be a derivate of a precursor that was located on chromosome 21. Subsequent molecular cloning 
experiments confirmed their hypothesis (Kang et al. 1987; Goldgaber et al. 1987; Tanzi et al. 1987; 
Robakis et al. 1987). The knowledge about the apparent genetic link between APP, PS1/2 and the 
amyloid plaque pathology in AD (see also chapter 1.1.2) triggered the postulation of the amyloid 
hypothesis (Selkoe 1991; Hardy and Higgins 1992).  
The amyloid hypothesis positions the known missense mutations of APP, PS1 and PS2 at 
the basis of its rationale (Hardy and Selkoe 2002). These mutations lead to an increased Aȕ42 
production and accumulation, resulting in Aȕ oligomerization and deposition (Hardy and Selkoe 
2002). The Aȕ oligomers are said to cause synaptic and neuritic injury while microglia and 
astrocytes become activated (Hardy and Selkoe 2002). As an extension of the amyloid cascade 
hypothesis, the oligomer cascade hypothesis emerged, as an increasing amount of studies 
suggested that Aȕ oligomers, rather than Aȕ fibrils may initiate AD pathogenesis (Hayden and 
Teplow 2013). This, in turn, leads to changes in neuronal homeostasis, oxidative injury and 
importantly, to changes in kinase and phosphatase activity, resulting in tau hyperphosphorylation 
and ultimately, in tau tangles (Hardy and Selkoe 2002). At the end of the hypothesis stands the 
pervasive neuritic and neuronal dysfunction, along with cell death leading to dementia (Hardy and 
Selkoe 2002).   
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In their review ten years after their postulation of the amyloid hypothesis, the authors 
discuss advances and weaknesses but conclude that the weaknesses mainly point to knowledge 
gaps and that no alternative hypothesis has emerged so far that could explain the AD pathologies 
as well as the amyloid hypothesis does (Hardy and Selkoe 2002). Furthermore, they suggested 
treatments for AD including inhibition of ȕ-and Ȗ-secretases and Aȕ immunization to enhance its 
clearance (Hardy and Selkoe 2002). In their review 25 years after the emergence of their 
hypothesis, the authors conclude that the dyshomeostasis of Aȕ remains the most compelling 
therapeutic target that has been validated by numerous previous studies (Selkoe and Hardy 2016). 
In addition, they mention that the results of clinical trials that used Aȕ antibodies to remove Aȕ 
from the brain (e.g. solanezumab, crenezumab, and aducanumab) suggest that the cognitive decline 
was slowed in patients with mild AD (Selkoe and Hardy 2016). In regards to their endpoint criteria, 
however, all clinical trials involving Aȕ immunization and BACE or Ȗ-secretase inhibitors failed 
(Mehta et al. 2017; Mullard 2018). The failure of those studies caused many scientists in the field 
to propose tau as the main factor driving AD progression and development (Kametani and 
Hasegawa 2018).  
However, the simple removal of one or both main pathologies after a profound metabolic 
dyshomeostasis has already been established in patients with full-blown AD, may not suffice to 
restore normal brain function and reverse cognitive decline. As recent clinical trials suggest, 
successful interventions at different stages of AD may have to differ in their approach and duration. 
Future therapies may have to act downstream of the main pathologies and focus on re-establishing 
a homeostasis in the brain in addition to stemming the main pathologies.          
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1.1.3.1 APP processing 
 
In order to understand the amyloid pathology, the deposition of Aȕ in the brain of AD patients and 
possible treatments that aim to reduce the amyloid pathology, it is crucial to understand the 
processing of the APP in detail. 
The APP is a type I transmembrane protein and is expressed in large amounts in the brain. 
The processing of APP can be divided into two pathways that differ in the involvement of different 
sets of proteases: the amyloidogenic pathway and the non-amyloidogenic pathway. The names 
already imply that a shift towards the amyloidogenic pathway ultimately leads to the generation 
and accumulation of Aȕ and a shift towards APP processing via the non-amyloidogenic pathway 
prevents said event (Webb and Murphy 2012) (Figure 1). 
The non-amyloidogenic pathway is initiated by the α-secretase proteolytic cleavage of APP 
within the Aȕ sequence, therefore preventing the formation of Aȕ and leading to the release of the 
soluble ectodomain sAPPα and the membrane anchored C-terminal fragment α (CTFα). Following 
endocytosis of the CTFα, the Ȗ-secretase localized in endosomes further cleaves CTFα into the 
APP intracellular domain (AICD) and P3 (Webb and Murphy 2012) (Figure 1).  
In contrast to the non-amyloidogenic pathway described above, the amyloidogenic 
pathway is initiated by the endocytosis of APP and the proteolytic cleavage by the ȕ-secretase 
(Webb and Murphy 2012) (Figure 1). In order to function properly, the ȕ-secretase requires an 
acidic milieu (low pH), as it is found in endosomes (Das et al. 2013; Prasad and Rao 2015). The 
ȕ-secretase cleaves APP into the soluble ectodomain sAPPȕ and the C-terminal fragment ȕ 
(CTFȕ). The final step in the amyloidogenic pathway leads to the production of ȕ-amyloid, as the 
Ȗ-secretase further cleaves the CFTȕ into AICD and Aȕ. Following exocytosis, both Aȕ and sAPPȕ 
are released into the extracellular milieu (Webb and Murphy 2012) (Figure 1).  
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In conclusion, a shift in the equilibrium of the APP processing towards the amyloidogenic 
pathway, represents one mechanistic reason for the accumulation of soluble Aȕ and later 
aggregation into Aȕ plaques observed in AD.  
However, the overproduction and aggregation of Aȕ, represents just one of the hallmarks 
of AD. As mentioned before, the aggregation of hyperphosphorylated tau into intracellular NFTs 
is another known and well-described hallmark of the AD pathologies. 
 
 
 
 
 
 
Figure 1: APP Processing 
The amyloid precursor protein (APP) can be processed via the amyloidogenic or non-
amyloidogenic pathway. The amyloidogenic pathway involves an endocytosis and a cleavage by 
the ȕ-secretase resulting in CFTȕ and sAPPȕ and a subsequent cleavage by the Ȗ-secretase, 
resulting in Aȕ and AICD. The non-amyloidogenic pathway involves a cleavage by the α-secretase 
resulting in CFTα and sAPPα and a subsequent endocytosis and cleavage by the Ȗ-secretase, 
resulting in P3 and AICD (as described by (Webb and Murphy 2012)).   
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1.1.4 Tau pathology 
 
Tau is a microtubule associated protein (MAP). Under physiological conditions, tau stabilizes the 
microtubule network. The MAPT gene that encodes for human tau is located on chromosome 17 
and comprises 16 exons (Andreadis 2006; Wang and Mandelkow 2016). Alternative splicing of 
the transcript leads to the generation of six distinct isoforms of tau (Guo et al. 2017). Each of those 
isoforms can be divided into N-terminus, the proline-rich domain (PRD), the microtubule binding 
domain (MTBD), and the C-terminus (Guo et al. 2017) (Figure 2). The different tau isoforms either 
comprise zero, one or two N-terminal inserts (0N, 1N, 2N) (Guo et al. 2017) (Figure 2). The PRD 
and the C-terminus remain the same for the six isoforms. Another difference between the tau 
isoforms is the existence of three or four repeats (3R or 4R) within the MTBD (Guo et al. 2017). 
Exons 9-12 of the MAPT gene encode for the four repeats (Guo et al. 2017). The second MTBD 
repeat is encoded by exon 10 and is missing in 3R tau isoforms (Guo et al. 2017) (Figure 2). The 
3R and 4R tau isoforms are expressed in equal amounts in the adult human brain under 
physiological conditions (Goedert et al. 1989). In the brain of adult mice, however, the 4R isoforms 
are predominant (Kosik et al. 1989). The ratio of 0N, 1N, and 2N, however is not equally 
distributed, as the human CNS comprises 54% of 1N, 37% of 0N and only 9% of 2N tau isoforms 
(Goedert and Jakes 1990).    
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The PRD contains seven motifs comprised of Pro-X-X-Pro. These motifs can potentially be 
recognized by several kinases carrying a Src-homology-3 (SH3) domain, including the proto-
oncogene tyrosine-protein kinase Fyn, lymphocyte-specific protein tyrosine kinase (LcK), 
phosphoinositide 3-kinase (PI3K), and phospholipase C (PLC) (Morris et al. 2011).  
Many post-translational modifications of tau have been identified, including the most 
frequently investigated phosphorylation of tau but also acetylation, glycation, O-GlcNAcylation, 
nitration, sumoylation, ubiquitination (Martin et al. 2011; Morris et al. 2015). In total, 85 
Figure 2: Tau isoforms 
There are six different tau isoforms, comprising different numbers of repeat domains 
(R1-R4) in the MTBD and different numbers of N-terminal inserts (N0, N1, N2) (as 
described by (Guo et al. 2017)).  
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phosphorylation sites have been identified, including 45 at serine residues, 35 at threonine residues 
and 5 at tyrosine residues (Hanger et al. 2009). Increased phosphorylation or hyperphosphorylation 
of tau is associated with pathology and seen in various forms of dementia, including AD and FTD 
(Guo et al. 2017). In general, tau phosphorylation reduces its binding affinity to microtubules, 
leading to its detachment from microtubules and mislocalization (Guo et al. 2017). Soluble, 
hyperphosphorylated tau, detached from the microtubule network, can bind to tau instead of the 
microtubules and is therefore prone to oligomerization and aggregation (Guo et al. 2017; Iqbal et 
al. 2013). Phosphorylation of tau within the MTBD (e.g. at Ser262) decreases tau’s binding affinity 
to microtubules (Drewes et al. 1995; Sengupta et al. 1998). Furthermore, the dissociation of tau 
from the microtubule network following phosphorylation at Thr231 and Ser235 has been shown 
in previous studies (Sengupta et al. 1998). In addition, tau phosphorylation at Ser356 by Nuak1, 
an AMPK-related kinase has been suggested to stabilize tau and promote its accumulation and 
aggregation, while Nuak1 reduction drastically decreased total tau levels in vivo (Lasagna-Reeves 
et al. 2016). Phosphorylation of tau within the PRD is said to lead to a disruption of microtubule 
assembly (Eidenmuller et al. 2001) and phosphorylation of tau within the C-terminal domain 
increases tau aggregation (Liu et al. 2007).  
Tau hyperphosphorylation can occur if the activity of tau kinases is increased or the activity 
of tau phosphatases is decreased or both. Tau kinases are divided into three major groups including 
proline directed serine/threonine-protein kinases, non-proline-directed serine/threonine-protein 
kinases, and protein kinases that are specific for phosphorylation of tyrosine residues. Important 
representatives of the first group include mitogen-activated protein kinases (MAPKs), cyclin-
dependent kinase-5 (Cdk5), glycogen synthase kinase 3 (GSK3)-α/ȕ (Hanger et al. 2009; Guo et 
al. 2017). The protein kinase B (or Akt), cAMP-dependent protein kinase A (PKA), protein kinase 
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N, 5′ adenosine monophosphate-activated protein kinase (AMPK), and protein kinase C (PKC), 
belong to the second group of non-proline-directed serine/threonine-protein kinases (Guo et al. 
2017). The third group is comprised of tyrosine kinases including proto-oncogene tyrosine-protein 
kinase Src, Fyn, and the spleen tyrosine kinase (SYK) (Guo et al. 2017; Martin et al. 2011).  
GSK3-ȕ plays a major role in the pathological phosphorylation of tau, as it seems to co-localize 
with pathological tau changes in AD (Pei et al. 1997; Leroy et al. 2002). Although GSK3-ȕ 
inhibition has been shown to have positive effects on neuronal loss, tau phosphorylation and 
neurite degeneration in pre-clinical studies (Caccamo et al. 2007; Leroy et al. 2010; Serenó et al. 
2009) in clinical trials, the inhibition of GSK3-ȕ by lithium were not successful in a 12-month 
double-blind trial for amnestic mild cognitive impairment (aMCI) (Forlenza et al. 2011).   
Tyrosine kinases like Src-family kinases, Lck, Fyn, and SYK can directly phosphorylate 
tau (Scales et al. 2011; Lebouvier et al. 2008). The effects of SYK on tau phosphorylation and AD 
pathologies are described in a different chapter of this thesis (1.2).               
There are five known tyrosine residues at Tyr18, Tyr29, Tyr197, Tyr310, Tyr394 
(Derkinderen et al. 2005a; Lebouvier et al. 2009). Tau phosphorylation at tyrosine residues has 
been shown to correlate with tau aggregation (Vega et al. 2005). 
As mentioned before, the phosphorylation process of tau is not only mediated by kinases 
but also by phosphatases. One of the major phosphatases in the brain is the protein phosphatase 
2A (PP2A) (Liu et al. 2005) which is also involved in regulating tau (de)phosphorylation (Gong 
et al. 2000). Interestingly, PP2A has been shown to be decreased in AD brains by approximately 
50%, suggesting a possible contribution of PP2A to tau hyperphosphorylation in AD (Liu et al. 
2007). An interplay between tau kinases and phosphatases has been observed, as well. PP2A 
dephosphorylates GSK3-ȕ at its inhibitory Ser9 site, thereby rendering GSK3-ȕ more active (Lee 
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et al. 2005). Furthermore, GSK3-ȕ can inhibit PP2A (Yao et al. 2011). The inhibition of the 
mammalian target of rapamycin (mTOR), a serine/threonine kinase, activates PP2A (Meske et al. 
2008). This may suggest an important regulatory role of key players of the mTOR pathway 
including GSK3-ȕ, Akt and mTOR in interplay with PP2A in tau phosphorylation (Meske et al. 
2008).      
Pathological dyshomeostasis of tau kinases and phosphatases is one of the key post-
translational mechanisms by which tau hyperphosphorylation can occur. In AD and other 
tauopathies, tau becomes hyperphosphorylated resulting in a detachment of tau from microtubules 
and increased cytosolic tau, finally leading to the formation of insoluble paired helical filaments 
(PHFs) and NFTs (Kidd 1963; Terry 1963; Šimić et al. 2016). Cytosolic tau, unbound to 
microtubules, can interact with several molecules, including ApoE, PS1, α-synuclein, and F-actin 
(Correas et al. 1990; Jensen et al. 1999; Huang et al. 1995; Takashima et al. 1998). 
For characterization of the pathological progression of AD, six different so called Braak 
stages were proposed that describe a characteristic NFTs spread but the distribution of the neuritic 
amyloid plaques seemed to vary a lot between different individuals (Braak and Braak 1991). The 
tau pathology spreads from the transentorhinal/peripheral cortex (Braak I), to the CA1 of the 
hippocampus (Braak II), to the limbic system (Braak III), to the amygdala, claustrum and thalamus 
(Braak IV), isocortical areas (Braak V), and primary sensory, motor, and visual regions (Braak VI) 
(Braak and Braak 1991).  
The spreading of the tau burden is an essential part of the disease progression. 
Neuroinflammation has been shown to enhance tau propagation. Activated microglia have been 
suggested to mediate tau propagation via exosomes, since inhibition of exosome synthesis and 
depletion of microglia can lead to a decreased tau spread in vitro and in vivo (Asai et al. 2015).  
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Tau can be secreted and exist extracellularly (Yamada 2017). There it can be recognized 
by microglia and activate the MAPK pathway which in turn leads to the release of pro-
inflammatory cytokines including tumor necrosis factor alpha (TNFα), interleukin-6 (IL6), and 
interleukin-1ȕ (IL-1ȕ) (Kovac et al. 2011), which could further enhance neuronal tau 
phosphorylation (Quintanilla et al. 2004).  
The tau pathology correlates best with the cognitive decline in AD, despite the proposed 
key role of Aȕ plaques in AD pathogenesis (Bejanin et al. 2017; Nelson et al. 2012). However, 
synaptical loss and cognitive decline show the greatest correlation in AD (Masliah 1995). 
The mechanism by which the Aȕ and tau pathologies interact in the disease progression is 
not completely understood. The amyloid hypothesis proposes the Aȕ pathology to be an upstream 
event of the tau pathology, as APP overexpressing mice show tau hyperphosphorylation and 
transgenic tau mice injected with Aȕ exhibit an increased tau pathology (Götz et al. 2001; Lewis 
et al. 2001). In addition, there is no known tau mutation that causes AD, further highlighting the 
important role of Aȕ  in AD pathogenesis which is known to increase many years before the 
clinical onset of AD (Insel et al. 2017). However, autopsies of very young individuals that 
exhibited tau accumulations in the subcortical nuclei (e.g. locus coeruleus) have suggested that the 
tau pathology may emerge prior to the Aȕ pathology (Braak and Del Tredici 2011; Jack et al. 
2013).  
The first mutation identified in the MAPT gene was the P301L mutation, associated with 
FTLD, that leads to neuronal loss caused by a dysfunction of tau (Hutton et al. 1998). Although 
many other tau mutations have been identified, importantly, none of these mutations has been 
shown to lead to the classical AD pathology.    
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The P301L mutation occurs within a six-residue segment within the MTBD called PHF6. 
The second and third repeat domains of the MTBD each contain such a six-residue segment that 
can form a ȕ-sheet structure and therefore represents a basis for tau’s propensity of self-
aggregation (Bergen et al. 2001). Since 4R tau isoforms contain two six-residue segments (PHF6* 
and PHF6) instead of one that is present in 3R tau isoforms, the 4R tau isoforms are more likely 
to aggregate than 3R tau isoforms. In addition, the P301L mutation increases tau’s propensity to 
form a ȕ-sheet and thereby increases the probability of tau aggregation (Bergen et al. 2000).  
It is important to mention, that the composition of NFTs varies depending on the type of 
tauopathy. In AD, the tangles were found to contain 3R, as well as 4R tau isoforms (Espinoza et 
al. 2008), while in FTLD the isoform ratio depends on the tau mutation causing the disease (Silva 
et al. 2006). Pick bodies in FTLD cases only contain 3R tau isoforms, while familial FTLD cases 
associated with exon 10, including P301L, exhibit 4R NFTs and the R406W mutation showed 
NFTs containing both 3R and 4R tau isoforms (Silva et al. 2006). Sporadic FTLD cases without 
Pick bodies exhibit 4R tau isoform pathology (Silva et al. 2006).    
The toxicity of insoluble tau tangles is still subject of debate (Spires-Jones et al. 2011). 
However, the soluble tau species, including tau oligomers, seem to be more neurotoxic (Spires-
Jones et al. 2011), as they have been suggested to activate the mitochondrial apoptotic pathway 
and inhibit the synaptic energy production via the mitochondrial complex I (Lasagna-Reeves et al. 
2011). 
Another important outcome of tauopathies is the impaired axonal transport resulting from 
a dysfunction of motor proteins and a compromised microtubule network.  Impaired axonal and 
dendritic transport have been found in neurons bearing tau tangles (Millecamps and Julien 2013; 
Vos et al. 2008). It is known that the interaction of tau with microtubules can be disturbed 
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following certain post-translational modifications, like phosphorylation, ultimately leading to a 
destabilization of the microtubule network (Martin et al. 2011). Tau is mainly present in axons 
under physiological conditions. Early in the pathogenesis of AD, phosphorylated tau is 
mislocalized to dendrites, thereby contributing to the disruption of the axonal transport (Hoover et 
al. 2010). In addition, tau has an impact on the transport along the microtubule network by directly 
interacting with the motor proteins dynein and kinesin (Dixit et al. 2008; Vershinin et al. 2008). 
Interestingly, it has been shown that GSK3-ȕ can phosphorylate kinesin and thereby cause an 
inhibition of anterograde transport in vitro and in vivo (Morfini et al. 2002).  
In summary, tau can become hyperphosphorylated under pathological conditions, detach 
from microtubules and localize in dendrites of neurons, thereby destabilizing the microtubule 
network and impairing the intracellular transport via the microtubule network.  
However, there are mechanisms by which pathological tau can be degraded and cleared 
from the brain including the ubiquitin-proteasome system (UPS) and the autophagic-lysosomal 
system. The autophagic degradation is described in another chapter of this thesis (1.1.6).         
Tau has been the target of many different therapeutic interventions to treat AD. The aim 
was to target the tau pathology by preventing tau oligomerization or lowering tau aggregation. A 
recent phase III clinical trial that used of leuco-methylthioninium-bis(hydromethanesulfonate) 
(LMTM) to target aggregated tau has proven not to be successful as a treatment for mild to 
moderate AD (Gauthier et al. 2016). Besides using small molecules, tau has been targeted by active 
and passive immunization using tau polypeptides or antibodies against tau, respectively. One 
example for using active tau immunization (tau residues 294–305) is the ongoing phase II clinical 
trial of AADvac1 (Axon Neuroscience) for mild to moderate AD that will end in 2020. Examples 
of clinical trials using passive immunization with antibodies against tau include the phase Ib trial 
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for mild to moderate AD by AC Immune SA and Janssen that target the 393-408 residues of tau 
phosphorylated at Ser396/404 (ACI-35). Bristol-Myers Squibb uses an antibody targeting N-
terminally truncated extracellular tau (residues 9-18) in a phase II clinical trial for progressive 
supranuclear palsy (PSP) and AC Immune SA, Genentech, and Hoffmann-La Roche use an 
antibody targeting phosphorylated tau at Ser409 in a phase I clinical trial for mild to moderate AD. 
AbbVie and C2N Diagnostics use an antibody targeting aggregated tau (residues 25-30) in two 
different phase II clinical trials for PSP and AD (more information on clinical trials for AD can be 
found in chapter 1.3).       
These approaches using antibodies against tau have been criticized because tau is known 
to be mainly intracellular and also forms its aggregates intracellularly and the antibodies would 
have to enter the neurons in order to effectively label pathological tau and trigger its removal by 
microglia. However, it has also been shown that antibodies against tau can reduce tau spreading 
without microglia engagement and thereby prevent the progression of the disease in animal models 
(Lee et al. 2016). Nevertheless, the direct intervention at the presumed roots the diseases will still 
have to prove successful and the results of the abovementioned ongoing clinical trials will shed 
light on this topic.      
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1.1.5 Neuroinflammation  
 
Inflammation generally describes the biological response following the exposure to harmful agents 
including exogenous pathogens like bacteria or viruses but also endogenous ones like misfolded 
or aggregated proteins. The immune response evoked by exogenous or endogenous signals can be 
described as either innate or adaptive. The innate immune response is considered to be an 
unspecific reaction mediated by a certain subset of cells, whereas the adaptive immune response 
is a specific answer of the organism to an antigen, involving a different subset of immune cells. 
Besides the categorization into innate and adaptive another temporal differentiation of the immune 
response has been introduced. The initial response in presence of the pathogen is called acute 
immune response. If the immune response and the resulting inflammation persists for a prolonged 
period of time, however, the affected organism can reach a state of dyshomeostasis that cannot be 
easily resolved and therefore enters a chronic inflammation (Kaur et al. 2013). Inflammation can 
be specific to certain tissues and is therefore differentiated spatially. The inflammation of the 
nervous system (central (CNS) or peripheral (PNS)) is called neuroinflammation. The CNS plays 
a special role, as it has specific immune cells compared to the periphery and is additionally 
protected from pathogens by the blood-brain-barrier (BBB). Insults to the BBB are therefore 
considered to be very harmful as the exposure of the CNS and therefore also the likelihood of an 
infection is increased.  
Neuroinflammation is known to play an important role in traumatic brain injury (TBI) and 
in neurodegenerative diseases like AD. In AD, the quantity of endogenous pathogens like Aȕ and 
hyperphosphorylated tau increases over time and their persistence can cause a chronic 
inflammation in the brain (Fuster-Matanzo et al. 2013).  
 33 
The inflammatory response in the brain is mainly mediated by microglia and astroglia. The 
increased proliferation of astrocytes is called astrogliosis. Astrogliosis is also described by 
hypertrophy and increase in intermediate filaments (IF, e.g. glial fibrillary acidic protein (GFAP)). 
The activation of microglia involves a change in morphology, from ramified to amoeboid, resulting 
in a change of motility to enable their movement to affected brain areas. This process is called 
microgliosis and also involves an increased proliferation of microglia. The ionized calcium-
binding adapter molecule 1 (Iba-1) is often used as a marker for microglial activation since its 
expression increases in activated microglia (Carson et al. 2006).  
Both the initial astrogliosis and microgliosis are said to be neuroprotective events (Carson 
et al. 2006), but the role of prolonged microgliosis and astrogliosis in AD remains controversial, 
despite extensive research. While some studies support the necessity of microglia for Aȕ clearance, 
others show the detrimental effects of the prolonged microgliosis in AD, including an increased 
neurodegeneration and an impaired Aȕ clearance (Frautschy et al. 1998; Hickman et al. 2008; 
Rogers et al. 2002; Yoon and Jo 2012).  
An increased number of microglia can be found around Aȕ deposits in brains of AD 
patients, as well as AD mouse models (Frautschy et al. 1998; Perlmutter et al. 1990). In addition, 
it has been shown that microglia can phagocytose Aȕ (Frackowiak et al. 1992). However, the same 
authors first estimated that the actual Aȕ degradation by microglia to be low, as the phagosomal 
appearance of Aȕ persisted after 20 days in culture (Frackowiak et al. 1992). The phagocytosis of 
Aȕ by microglia was later confirmed in vivo, in addition to the migration of microglia and the 
extension of their processes towards ȕ-amyloid deposits (Bolmont et al. 2008).   
The notion of the microglial inability to phagocyte and thereby degrade Aȕ deposits has 
been supported by later in vivo studies involving amyloid-overexpressing mouse models (Wegiel 
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et al. 2001; Wegiel et al. 2004). A following study has suggested that the microglial phagocytosis 
of Aȕ is impaired by pro-inflammatory cytokines and can be relieved by treatment with anti-
inflammatory cytokines or drugs (Koenigsknecht-Talboo and Landreth 2005). The same study 
showed that FcR-mediated phagocytosis is not impacted by pro-inflammatory cytokines (e.g. IL-
1ȕ, TNFα, IFNȖ) and therefore the authors concluded that immunotherapies, involving antibodies 
directed against Aȕ (IgG), can to successfully induce the microglial clearance of Aȕ deposits 
(Koenigsknecht-Talboo and Landreth 2005; Schenk et al. 1999). One study has shown that ablation 
of microglia had no effect on the size or number of Aȕ-deposits over a short timeframe (4 weeks), 
however, soluble Aȕ was largely increased, suggesting that microglia may play a role in the 
clearance of soluble, rather than fibrillar Aȕ (Grathwohl et al. 2009). However, another ablation 
study showed a 13% increase in plaque size after just one week, suggesting that microglia can limit 
the growth of Aȕ deposits (Zhao et al. 2017). Differences in animal models and the agent used for 
ablation, as well as the age of the mice may account for the different findings but the role of 
microglia in Aȕ plaque formation and maintenance still remains controversial.  
Microglia not only respond to Aȕ (Doens and Fernández 2014), but also to tau. Tau 
oligomers and fibrils have been shown to activate microglia (Morales et al. 2013) and in addition, 
microglia have been proposed to play an important role in the spread of the tau pathology (Perea 
et al. 2018). It has been suggested that excess tau could be released by neurons and internalized by 
microglia (Bolos et al. 2015) and that this internalization is, at least in part, mediated by the 
CX3CR1 receptor (Bolós et al. 2017). The ablation of microglia, as well as the inhibition of 
exosome synthesis resulted in a reduction of tau propagation over a time course of four weeks, 
further supporting the idea of the microglial involvement in tau propagation and highlighting the 
exosome secretion as a possible mechanism of tau propagation (Asai et al. 2015).     
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Microglia are known to produce signaling molecules called cytokines, including interferon (IFN) 
and interleukins (IL). Cytokines are often labelled as pro-inflammatory (e.g. IFNȖ, IL-1ȕ, TNFα, 
IL-6) or anti-inflammatory (e.g. IL-4, IL10), however, it has been argued that this categorization 
is too simplistic because the action of the respective cytokine may depend largely on other factors 
like the amount released, the timing, the target cell and the experimental model (Cavaillon 2001).  
It is generally believed that microglia are overactive in AD brains and produce more pro-
inflammatory and less anti-inflammatory cytokines (Su et al. 2016; Wang et al. 2015a), thereby 
creating an imbalance in the cytokine household and further contributing to the disease 
progression. The pro-inflammatory cytokines IL-1ȕ, IL-6 and TNFα have been shown to be 
elevated in AD and may, at least in part, be caused by Aȕ-induced microgliosis (Wang et al. 
2015a). Pro-inflammatory cytokines can also contribute to abnormal phosphorylation of tau 
(Domingues et al. 2017). Lipopolysaccharide (LPS) has been shown to induce the release of pro-
inflammatory cytokines by stimulating toll-like receptor 4 (TLR4) (Lu et al. 2008). TLR4 is also 
involved in the clearance of Aȕ deposits (Tahara et al. 2006). Interestingly, SYK has been shown 
to associate with TLR4 and play a role in the TLR4 signaling cascade (Chaudhary et al. 2007; 
Dennehy et al. 2008). Therefore, SYK could be an important mediator of the LPS or Aȕ-induced 
pro-inflammatory response and regulate the release of cytokines. LPS is not only known to evoke 
a release of cytokines but has also been shown to exacerbate the tau pathology in vivo (Kitazawa 
et al. 2005). The simultaneous activation of TLR4 and the IFNȖ receptor resulted in neuronal 
dysfunction and neuronal death in organotypic brain slice cultures (Papageorgiou et al. 2016). This 
was found to be mainly mediated by an increased inducible nitric oxide synthase (iNOS) 
expression and subsequent nitric oxide (NO) release (Papageorgiou et al. 2016). This means that 
a pro-inflammatory signaling cascade in activated microglia, that could be induced by cytokines 
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and amyloid, can potentially cause neurodegeneration. NO is known to be a signaling molecule 
that can freely move across cell membranes (Sierra et al. 2014). It can be neuroprotective (Brown 
2010; Mejia-Garcia and Paes-de-Carvalho 2007), however, in presence of NADPH oxidase, the 
production of peroxynitrite can lead to neuronal death (Mander and Brown 2005). Therefore, iNOS 
inhibition may have neuroprotective effects (Mander and Brown 2005). Genetic ablation of iNOS 
in mouse models of AD seemed to decrease the cerebral plaque load, microgliosis and astrogliosis 
(Nathan et al. 2005). 
It is known that iNOS is also expressed in astrocytes and can be induced by certain 
cytokines including IFNȖ and IL-1ȕ (Jana et al. 2005; Saha and Pahan 2006). Similar to microglia 
that, for example, play an important role in synaptic pruning (Paolicelli et al. 2011) or 
neuroprotection (Chen and Trapp 2016), astrocytes support neuronal health under physiological 
conditions for example by engaging in neurotransmitter uptake (Kreft et al. 2012) or maintaining 
the integrity of the BBB (Cabezas et al. 2014). Astrocytes can also potentially regulate 
neurotransmission and play an active role in neuroplasticity by releasing gliotransmitters (e.g. 
glutamate or gamma-aminobutyric acid (GABA)) (Covelo and Araque 2018).   
In neurodegenerative diseases like AD, however, the prolonged exposure to Aȕ may alter 
the functional state of astrocytes (Thal 2012). Aȕ can decrease the astrocytic glutamate uptake 
which could contribute to the NMDA receptor-mediated excitotoxicity observed in AD (Matos et 
al. 2008; Hynd et al. 2004). In addition, Aȕ has been shown to induce astrocytic glutamate release, 
thereby further contributing to NMDA receptor-mediated synaptic damage (Talantova et al. 2013). 
The NMDA receptor antagonist memantine was able to prevent Aȕ-induced synaptic damage 
(Talantova et al. 2013). The Aȕ-induced activation of astrocytes can be mediated by the receptor 
for advanced glycation end products (RAGE) which can in turn activate the NFκB signaling 
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pathway that leads to the increased expression and release of pro-inflammatory cytokines 
(Gonzalez-Reyes and Rubiano 2018). Pro-inflammatory cytokines like TNFα, IFNȖ and IL-1ȕ can 
in turn increase BACE-1, APP and Aȕ levels (Blasko et al. 2000; Zhao et al. 2011). Furthermore, 
it has been argued that Aȕ can induce a production and exosomal release of astrocytic p-tau via 
the activation of the calcium sensing receptor (CaSR) (Chiarini et al. 2017), thereby linking both 
tau and amyloid pathology to astrocytes. Interestingly, astrocytes derived from Tg Tau P301S mice 
(1 week postnatal) (see chapter 1.1.7.3) seem to decrease the survival of neurons in a co-culture 
and their conditioned media decreased synaptophysin and PSD-95 in primary cortical neurons, 
implying early functional deficits of Tg Tau P301S astrocytes and a potential role of astrocytes in 
neurodegeneration (Sidoryk-Wegrzynowicz et al. 2017). Furthermore, the cytokine S100B 
produced by astrocytes has been found to increase tau phosphorylation via JNK and GSK3-ȕ 
(Esposito et al. 2008).  
Other studies have also argued that reactive astrocytes that cause neurotoxicity can be 
induced by activated microglia in neurodegenerative disorders, thereby implying a positive 
feedback between the two types of glial cells that exacerbates neuroinflammation (Liddelow et al. 
2017). Interestingly, neuroinflammation has also been shown to impair the autophagic flux (Du et 
al. 2017) and may therefore additionally contribute to AD and proteinopathies in a different way. 
The next chapter will describe the mTOR pathway and its involvement in autophagy (1.1.6).   
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1.1.6 Autophagy and the mTOR pathway 
 
Macroautophagy (hereafter called autophagy) describes the degradation of proteins and organelles 
and is essential to maintain the cellular homeostasis (Feng et al. 2014). The complex process of 
autophagy involves various autophagy-related (Atg) proteins for the initiation and sequestration 
of proteins (Feng et al. 2014). After autophagy initiation, autophagosomes fuse with late 
endosomes. Finally, the cargo of these amphisomes gets degraded by lysosomes (Sanchez-
Wandelmer and Reggiori 2013).  
During autophagy initiation, the cytosolic form of the microtubule-associated protein 1 
light chain 3 (LC3-I) gets conjugated to phosphatidylethanolamine (PE) and turns into LC3-II (Ge 
et al. 2014) which mediates the formation of autophagosomes and remains associated with the 
membrane of the autophagic vesicles (AVs) until lysosomal degradation (Sarkar 2013). LC3-II is 
either degraded in the lumen after fusion with lysosomes or is de-lipidated and recycled on the 
surface of AVs (Sarkar 2013). Hence, the ratio of LC3-I and LC3-II is often used to monitor the 
level of autophagic flux (the rate of autophagy initiation and lysosomal degradation) but its correct 
interpretation remains controversial because it is influenced by autophagy initiation and lysosomal 
degradation (Tanida et al. 2008). Since increased LC3-II levels following a drug treatment could 
be indicative of either an increased in autophagy initiation or a decreased in lysosomal degradation, 
lysosome inhibitors like chloroquine (CQ) are often used to determine the rate of autophagy 
initiation, as previously described (Mizushima and Yoshimori 2007; Tanida et al. 2008). CQ 
accumulates in the lysosomes and raises their pH. Thereby, CQ decreases the functionality of 
lysosomal proteases and inhibits the fusion of lysosomes and autophagosomes. Therefore, CQ 
allows the observation of the conversion rate of LC3-I to LC3-II (autophagy initiation) by limiting 
the degradation of LC3-II. 
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Besides using LC3 as a marker, members of the mammalian target of rapamycin (mTOR) 
pathway are often monitored since mTOR and its downstream targets are major regulators of 
autophagy (Munson and Ganley 2015). The main triggers of autophagy are insulin, growth factors 
and amino acids (Efeyan and Sabatini 2013). Insulin and growth factors bind to cell surface 
receptors (e.g. insulin receptor (IR) or insulin-like growth factor 1 (IGF-1) receptor) and activate 
the phosphoinositide 3-kinase (PI3K) via insulin receptor substrates (IRS) (Boucher et al. 2014) 
which, in turn, leads to a downstream activation of the protein kinase B (PKB, also known as Akt) 
(Hemmings and Restuccia 2012). Akt inhibits the tuberous sclerosis complex 1/2 (TSC1/2)  (Inoki 
et al. 2002) which, in turn, also has an inhibitory effect on a GTP-binding protein, the Ras homolog 
enriched in brain (Rheb) (Inoki et al. 2003a). Rheb activates mTOR and thereby inhibits autophagy 
(Bai et al. 2007). This means that each member of the mTOR pathway or upstream elements of 
the mTOR pathway can potentially interfere with autophagy. 
mTOR can inhibit the eukaryotic translation initiation factor 4E-binding protein 1 (EIF 
4EBP1) (Wu et al. 2017) and activate the ribosomal protein S6 kinase (S6K) (Easley et al. 2010). 
This means that mTOR can potentially regulate translation. S6K can initiate a negative feedback 
loop through inhibition of the insulin receptor substrate 1 (IRS1) (Zhang et al. 2008). The S6K 
phosphorylation level (T389) is often used to monitor mTOR activity (Sarkar 2013).  
Amino acids can activate Rag GTPases which causes mTOR recruitment to the lysosomes, 
activation of mTOR and autophagy inhibition. In addition, the mTOR activation on the lysosomal 
surface causes sequestration of the transcription factor EB (TFEB) which is involved in 
transcription of autophagy-related and lysosomal genes (Sarkar 2013), additionally contributing to 
the inhibition of autophagy. 
 40 
The pathways mentioned are complemented by activation of the 5' AMP-activated protein kinase 
(AMPK) and the corresponding AMPK/TSC/mTOR pathway that can be influenced by ATP 
(Sarkar 2013). It has been shown that AMPK phosphorylates (activates) TSC2 under energy 
starvation, thereby increasing autophagy via mTOR inhibition, which prevents energy deprivation-
induced apoptosis (Inoki et al. 2003b). The same authors concluded in a subsequent study that the 
TSC2 phosphorylation mediated by AMPK represents a priming event for subsequent 
phosphorylation by GSK3-ȕ (Inoki et al. 2006). This would have an opposing effect on the TSC1/2 
inhibition mediated by Akt and thereby negatively modulate the PI3K/Akt/TSC/mTOR pathway 
(Inoki et al. 2006). However, these findings imply that inhibition of GSK3-ȕ would decrease 
autophagy and several previous studies have shown the opposite, demonstrating that autophagy is 
increased (mTOR inhibited) following GSK3-ȕ inhibition or knockdown (Ren et al. 2016; Weikel 
et al. 2016). It may be possible, that different results were obtained in those studies because 
different inhibitors were used. It is also possible, that GSK3-ȕ inhibition enhances autophagy by 
phosphorylating the mTOR-associated scaffold protein raptor (regulatory-associated protein of 
mTOR) at the Ser859 site and thereby reduces the interaction of raptor and mTOR, leading to a 
decreased mTOR signaling and increased autophagic flux (Stretton et al. 2015). Furthermore, 
many studies have shown that GSK3-ȕ can interact with various members of the mTOR pathway 
and therefore the effect of GSK3-ȕ on the mTOR pathway has been described as very complex 
(Hermida et al. 2017). Additionally, some studies have shown that GSK3-ȕ inhibition can increase 
lysosomal biogenesis and increase lysosomal acidification (Parr et al. 2012; Azoulay-Alfaguter et 
al. 2015), suggesting that GSK3-ȕ can potentially affect the autophagy initiation, as well as the 
lysosomal degradation.  
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Autophagy and lysosomal degradation have been shown to be impaired in AD leading to an 
accumulation of autophagic vesicles in the large swellings of dystrophic neurites (Nixon et al. 
2005; Piras et al. 2016). The accumulation of CTFȕ (C99) in dystrophic neurites has been found 
to be both responsible for and the result of the autophagic and lysosomal impairment in 3xTg AD 
mice (Lauritzen et al. 2016). Furthermore, mutations in presenilin-1 (PS1) are likely to be a cause 
of the dysfunctional degradation of proteins in AD since PS1 is required for targeting the v-ATPase 
to lysosomes (Lee et al. 2010). Pathological alteration of this targeting caused by PS1 mutations 
may lead to impaired acidification of the autolysosomes and hence, an impairment of the lysosomal 
proteases (Lee et al. 2010). In fact, the inhibition of lysosomal proteolysis has been shown to 
disrupt the axonal transport of proteolytic vesicles and cause axonal dystrophy in cultures of 
murine primary cortical neurons (Lee et al. 2011). A different study identified that pathological 
tau phosphorylation, Aȕ oligomers and decreased levels of kinesin and dynein are responsible for 
accumulation of AVs in dystrophic neurites (Sanchez-Varo et al. 2012). Interestingly, the ApoE-
ε4 isoform has been associated with impaired astrocytic autophagy and reduced Aȕ clearance 
(Simonovitch et al. 2016). ApoE-ε4 astrocytes were found to store rather than digest large amounts 
of Aȕ protofibrils and releasing incompletely digested, toxic Aȕ (Sollvander et al. 2016).          
In AD, the PI3K/Akt/mTOR pathway and downstream targets such as p70S6K, 4EBP1, 
and GSK3-ȕ are upregulated, resulting in a reduced level of autophagy (Tramutola et al. 2015). 
The upregulation of mTOR has been associated with increased cytosolic tau and increased tau 
secretion (Tang et al. 2015). Inhibition of mTOR by rapamycin, on the other hand, has been 
suggested to be protective against Aȕ-induced synaptotoxicity in hippocampal neurons and to 
prevent tau-induced neuronal loss in Tg P301L mice (Ramirez et al. 2014; Siman et al. 2015). 
Another in vivo study showed that impaired autophagy not only leads to increased intracellular Aȕ 
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accumulation but also to increased Aȕ plaque formation due to an upregulated Aȕ secretion in 
APP23 mice (Nilsson et al. 2013). Furthermore, rapamycin has been shown to prevent neuritic 
dystrophy in PC12 cells and superior cervical ganglion neurons (Yang et al. 2014).  
Interestingly, the in vivo conditional knockout (cKO) of autophagy-related protein 7 (Atg7) 
in postnatal forebrain-specific neurons leads to an age-dependent neurodegeneration along with 
p62, GSK3-ȕ and p-tau accumulations (Inoue et al. 2012). Since tau and GSK3-ȕ are both known 
to regulate autophagy (Ren et al. 2016; Lin et al. 2003) these findings suggest a feedback loop in 
which autophagy defects can lead to accumulations of phosphorylated tau and GSK3-ȕ which in 
turn influences the autophagy (Inoue et al. 2012).  
It has been shown that the inhibition of lysosomal function by lysosomotropic agent 
chloroquine (CQ) that decreased the activities of cathepsins B, L and D led to the accumulation of 
tau in human neuroblastoma cells that inducibly express tau (Hamano et al. 2008). 
Pharmacological inhibition of autophagy also resulted in tau accumulation and aggregation 
(Hamano et al. 2008), suggesting that autophagy and lysosomal degradation are crucial for the 
degradation of tau and that a malfunction of the autophagic-lysosomal pathway may contribute to 
the formation of tau pathologies.   
Furthermore, the inhibition of mTOR activity by rapamycin, which increases autophagy 
initiation, also decreased total and phosphorylated tau in Tg Tau P301S mice (Caccamo et al. 
2013). Interestingly, heterozygous TSC2 +/- mice exhibited elevated total tau and phosphorylated 
tau because of an increased activation of mTOR signaling (Caccamo et al. 2013). As mentioned 
before TSC1/2 are known negative regulators of mTOR (Caccamo et al. 2013). The same study 
also showed an important link between GSK3-ȕ and mTOR signaling. The phosphorylation at the 
inhibitory GSK3-ȕ S9 site was decreased in heterozygous TSC2 +/- mice and increased after 
 43 
rapamycin treatment of Tg Tau P301S mice, indicating that GSK3-ȕ inhibition is linked to 
increased autophagy and decreased tau pathology (Caccamo et al. 2013).    
In conclusion, the pharmacological induction of autophagy via suppression of the mTOR 
pathway represents a promising therapeutic approach against AD pathologies and pure 
tauopathies. 
 
1.1.7 Mouse models of Alzheimer’s disease 
 
Many different transgenic mouse models of AD that recapitulate some of the pathological aspects 
of AD have been developed. This chapter will describe the three mouse models that we used in 
our studies. 
 
1.1.7.1 Tg APPsw mice (Tg 2576) 
 
The transgenic APPsw (Tg APPsw or Tg 2576) mice were used among two other mouse models 
to determine whether Aȕ accumulation can affect of SYK activation in the CNS. Tg APPsw mice 
overexpress the Swedish mutation (KM670/671NL) of human APP695 under the control of the 
hamster prion protein promoter (Hsiao et al. 1996) and therefore exhibit elevated levels of Aȕ and 
typically develop Aȕ deposits at the age of 11 months (Irizarry et al. 1997). Tg APPsw mice 
develop Aȕ deposits much later than the double transgenic Tg PS1/APPsw mice (described below). 
Tg APPsw mice also show a loss of dendritic spines in the CA1 region of the hippocampus as early 
as 4.5 months of age, before the formation of ȕ-amyloid deposits (Lanz et al. 2003), suggesting 
that soluble forms of Aȕ are synaptotoxic. Neuroinflammation becomes evident at 10-16 months 
in these mice, as Aȕ plaque-associated microglia increase in abundance and size (Frautschy et al. 
1998). Additionally, Tg APPsw mice develop dystrophic neurites in and around Aȕ plaques and 
exhibit tau hyperphosphorylation without forming NFTs (Tomidokoro et al. 2001). The described 
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age-dependent pathological changes in Tg APPsw are also accompanied by behavioral 
abnormalities. At 3 months of age, the animals perform normally in learning and spatial memory 
tasks but display impairments at 9 months of age (Hsiao et al. 1996). 
 
1.1.7.2 Tg PS1/APPsw mice 
 
Tg PS1/APPsw mice that carry the APP KM670/671NL (Swedish) and the PSEN1 M146L 
mutations were also used for investigating the influence of the ȕ-amyloid pathology on SYK 
activation in the CNS. Tg PS1/APPsw mice were generated by crossing Tg APPsw (Tg2576) mice 
with Tg PS1(M146L) mice. In all our studies, the mice were heterozygous for the for the APP and 
PS1 transgenes. The overexpression of the human APPsw is driven by the hamster prion protein 
gene promoter, whereas the overexpression of the human PSEN1 M146L is driven by the PDGF-
ȕ promoter. The double transgenic mice develop cortical and hippocampal amyloid deposits at 6 
months of age; much earlier than the single transgenic APPsw (described above). Furthermore, the 
total Aȕ burden is increased in the double transgenic compared to the single transgenic mice 
(Holcomb et al. 1998). As in Tg APPsw mice, the Aȕ deposits are associated with dystrophic 
neurites that occur at 12 months of age (Gordon et al. 2002). Additionally, these mice display an 
increase in Aȕ plaque-associated microglia and astrocytes at 6 months of age, with increased 
microglial activity occurring at 12 months of age (Gordon et al. 2002). Although Tg PS1/APPsw 
mice do not overexpress tau like the Tg Tau P301S mice (see below) and do not form NFTs, 
hyperphosphorylated tau has been detected in some dystrophic neurites at 24 weeks of age (Kurt 
et al. 2003).   
The accumulation of Aȕ in the brain of these mice is also responsible for the development 
of cognitive impairment. Although their learning ability is still normal in the water maze at the age 
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of 9 months (Holcomb et al. 1999), their spatial memory assessed by the Y-maze seems to be 
impaired at 3 months. Moreover, memory acquisition and working memory have been shown to 
be impaired in 15 months old animals, as assessed by the Morris water maze and the radial arm 
water maze (Arendash et al. 2001). 
 
1.1.7.3 Tg Tau P301S mice (Line PS19) 
 
Besides the amyloid overexpressing mouse models described in the two previous subchapters, we 
used another mouse model overexpressing the human tau protein. The transgenic tau P301S (line 
PS19) mice were used, to investigate the possible impact of the tau pathology on SYK activation 
in the CNS. In addition, we used the Tg Tau P301S mice to determine the effects of chronic SYK 
inhibition on tau hyperphosphorylation and oligomerization, neurodegeneration, 
neuroinflammation, and behavioral deficits induced by the tau pathology. Tg Tau P301S mice 
overexpress the human tau with the P301S mutation.  
The P301S mutation in the tau gene on chromosome 17 has been associated with autosomal 
dominantly inherited frontotemporal dementia and parkinsonism (FTDP-17) and the P301S 
mutation in exon 10 causes a reduced ability of tau to promote microtubule assembly and might 
furthermore contribute to tau hyperphosphorylation (Bugiani et al. 1999; Lossos et al. 2003; 
Sperfeld et al. 1999).  
The expression of the P301S mutated tau is  driven by the mouse prion protein promoter 
and fivefold higher than the endogenous mouse tau protein (Yoshiyama et al. 2007). The P301S 
tau overexpression leads to a progressive synaptic loss at 3 months and neuronal loss at 9 months 
of age, spreading from the hippocampus to the cortex. NFTs emerge at 6 months of age and also 
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spread from the hippocampus to the cortex. Microgliosis has been observed as early as 3 months 
of age, preceding astrogliosis (Yoshiyama et al. 2007).  
As a consequence of these pathological changes, the behavior of these mice is also altered. 
Tg Tau P301S mice have been found to exhibit spatial learning and memory impairments at 6 
months of age (Takeuchi et al. 2011). Apart from the cognitive deficits, the mice also display a 
progressive motor decline culminating in paralysis at approximately 10 months of age. This also 
leads to a mortality rate of 80% at 12 months (Yoshiyama et al. 2007). In contrast to Tg 
PS1/APPsw and APPsw mice (described above), the Tg Tau P301S mice do not develop ȕ-amyloid 
plaques.    
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1.2 The Spleen Tyrosine Kinase 
 
The spleen tyrosine kinase (SYK) is a non-receptor protein-tyrosine kinase (PTK) that mediates 
inflammatory responses (Geahlen 2014). PTKs like SYK are part of receptor-mediated signal 
transduction cascades that require their intracellular association with integral membrane receptors. 
These receptors contain cytoplasmic immunoreceptor tyrosine-based activating motifs (ITAMs).  
The SYK protein can be divided into different domains, including the N-terminal Src homology 
domains (SH2) that are linked by an interdomain A, and the C-terminal kinase domain that is 
linked to the SH2 domains by an interdomain B (Sada et al. 2001). SYK can be activated through 
autophosphorylation or binding to ITAM-containing receptors (Tsang et al. 2008).  
SYK phosphorylation plays an important role in its activation. In the resting state, the 
kinase domain of SYK is inactive. It has been speculated that SYK adopts an autoinhibitory 
conformation in the absence of ITAM binding, similar to the ζ-chain-associated protein kinase of 
70 kDa (ZAP-70) that is known as a SYK homologue (Mócsai et al. 2010). For activation of SYK, 
the N-terminal SH2 domains need to bind to the C-terminally phosphorylated tyrosines of the 
ITAM (Futterer et al. 1998; Mócsai et al. 2010) or the linker regions interdomain A or B need to 
be phosphorylated (Tsang et al. 2008). The latter activation enables SYK to stay active for a 
prolonged period of time, beyond the ITAM-mediated signaling (Tsang et al. 2008).  
SYK autophosphorylation is also known to influence its activation. Several 
autophosphorylation sites of SYK have been identified: Tyr130, Tyr290, Tyr317, Tyr 342, Tyr346, 
Tyr358, Tyr519/520, Tyr525/526 and Tyr623/624/625 (Mócsai et al. 2010; Furlong et al. 1997; 
Tsang et al. 2008; Zhang et al. 2000). The phosphorylation sites Tyr519/520 and Tyr525/526 play 
an important role in the activation of SYK and the propagation of receptor-mediated signaling 
events, as they are part of the kinase activation loop that regulates the enzymatic activity of SYK 
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(Zhang et al. 2000; Tsang et al. 2008). In the non-activated SYK, the tyrosines of the activation 
loop occupy the catalytic center and prevent ATP or substrate binding, while phosphorylation of 
those tyrosines induces a conformational change that allows the binding of ATP and substrate 
(Zhang et al. 2000). Since tyrosine phosphorylation in the activation loop has been shown to be 
the best indicator for functional activation of SYK (Zhang et al. 2000), in this thesis, we focused 
on the Tyr525/526 phosphorylation site for assessment of SYK activation. Many previous studies 
have used the Tyr525/526 phosphorylation site to monitor SYK activation (Feldman et al. 2008; 
Speich et al. 2008; Aouar et al. 2016; Satoh et al. 2012).   
Several receptors are known to activate SYK. Amongst these are toll-like receptors (TLRs). 
TLRs can, for example, mediate the host defense against infections and initiate the innate immune 
response. The TLR-triggered inflammatory response has been shown to activate SYK and PI3K 
(Han et al. 2010). SYK has also been shown to be required for the collaborative response of TLR2 
and the ȕ-glucan receptor Dectin-1 that are involved in the cytokine response in macrophages 
(Dennehy et al. 2008).  
SYK has also been shown to be activated by FcεRI  (high-affinity receptor for the fragment 
crystallizable (Fc) of immunoglobulin E (IgE)) receptor as part of the Lyn-SYK-Akt pathway 
leading to AMPK inhibition (Lin et al. 2016).  
SYK has also been suggested to play a role in the FcεRI-initiated histamine release from 
basophils during an allergic response (Youssef et al. 2002). The same study found that a 
ubiquintin/proteasome-dependent mechanism regulates SYK levels in human basophils (Youssef 
et al. 2002). The CbI-interacting 85-kDa multi-adaptor protein (CIN85), a negative regulator of 
FcεRI-mediated degranulation that is involved in endocytosis and vesicle trafficking, could 
decrease SYK levels by increasing the ubiquitin-proteasome degradation (Peruzzi et al. 2007). 
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  The CD40 receptor is known to play an important role in B-cell proliferation and activation 
(Faris et al. 1994). It has been shown that the CD40 signaling pathway involves PTKs, including 
Lyn, Fyn, and SYK (Faris et al. 1994; Ying et al. 2011). Interestingly, the CD40 expression in 
microglia has been found to be increased after treatment with Aȕ and in microglia derived from 
Tg APPsw mice (Tan et al. 1999). Since SYK is involved in CD40 signaling, this could suggest 
that SYK also plays a role in Aȕ-induced signaling via CD40. It has also been shown that CD40 
deficiency leads to a decreased amyloid burden and decreased tau hyperphosphorylation in vivo 
(Laporte et al. 2006), suggesting that CD40 signaling is involved in amyloid and tau pathogenesis 
and microglial activation. This could imply a role of SYK in the generation of the amyloid and tau 
pathology and microgliosis seen in AD via the CD40 receptor. 
 SYK has also been shown to be involved in TNFR-mediated signaling (Takada and 
Aggarwal 2004). In T-cells, TNF activated SYK and resulted in a downstream signaling cascade 
involving JNK, MAPK and NFκB (Takada and Aggarwal 2004). Furthermore, pharmacological 
SYK inhibition and knockdown of SYK using shRNA led to the suppression of the TNFR 
signaling cascade (Takada and Aggarwal 2004).  
 In addition, two engulfment receptors, Jedi-1 and MEGF10, expressed in glial precursor 
cells and involved in phagocytosis, have been shown to recruit and activate SYK through their 
ITAMs (Scheib et al. 2012). The same study suggested that SYK was involved in phagocytosis of 
apoptotic neurons by glial precursor cells, as SYK inhibition by BAY61-3606 and knockdown of 
STK blocked the phagocytosis (Scheib et al. 2012).  
 SYK activation can also be induced by integrin receptors (Jakus et al. 2007) that are 
involved in cell adhesion. APP has been shown to co-localize with ȕ1-integrin receptors 
(Yamazaki et al. 1997), suggesting an involvement of APP in neuronal adhesion processes. 
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Interestingly, one study has demonstrated that APP is involved in ȕ1-integrin-mediated adhesion 
in murine microglia and human monocytes leading to a recruitment of Lyn and SYK, mediating a 
pro-inflammatory response (Sondag and Combs 2004). This suggests that APP may be able to act 
as a pro-inflammatory receptor in monocytes and further links SYK to the pathobiology of AD.   
TREM2 is another receptor expressed in microglia that can mediate SYK activation (TREM2 
mediated activation of SYK is described in the chapter 1.2.2).   
SYK is mainly localized at the plasma membrane but is also actively transported to the 
centrosomes, suggesting a role of SYK in cell division (Zyss et al. 2005). This transport depends 
on the phosphorylation site Tyr130 of SYK (Zyss et al. 2005). It has also been shown that SYK 
co-localizes with Ȗ-tubulin, persists during interphase and is degraded by the proteasome during 
mitosis, suggesting an inhibitory effect of SYK on cell division (Zyss et al. 2005). However, SYK 
activity is also known to be increased and act as a pro-survival factor in certain rapidly proliferating 
tumor cells and SYK inhibition has therefore been suggested as a therapeutic strategy for targeting 
certain types of cancer, especially hematopoietic malignancies (Geahlen 2014).      
In addition, SYK is involved in ERK (extracellular signal-regulated) activation during 
differentiation of neuron-like P19 cells (Tsujimura et al. 2001). In neurons, SYK is also involved 
in axonal growth cone collapse and acts as a switch between adhesive and repulsive responses 
during axonal outgrowth (Noraz et al. 2016). 
SYK was shown to phosphorylate microtubules which could have an effect on microtubule 
polymerization or the interaction of signaling molecules with the microtubule network (Faruki et 
al. 2000). Hence, Tsujimura et al. (2001) argue that microtubule phosphorylation by SYK may 
affect the formation of supernumerary neurites. Furthermore, pharmacological SYK inhibition has 
been found to stabilize microtubules through dephosphorylation of microtubules and microtubule-
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associated proteins (MAPs) (Yu et al. 2015). In the same study, the authors found that SYK 
inhibition by small molecules (R406) or shRNA and paclitaxel co-treatment had a synergistic 
cytotoxic effect on ovarian cells (Yu et al. 2015). Certain tumor cells were previously found to 
express higher levels of SYK (Yu et al. 2015). In B-cell lymphoma cells for example, inhibition 
of SYK by cerdulatinib resulted in blockage of Janus kinase (JAK)/signal transducer and activator 
of transcription (STAT) signaling and subsequent cell death (Ma et al. 2015), suggesting that SYK 
regulates the JAK/STAT pathway. 
 
 
1.2.1 The role of SYK in Alzheimer’s disease 
 
The previous work in our laboratory with the antihypertensive dihydropyridine (DHP) nilvadipine 
has led to the identification of SYK as a potential target for AD (Paris et al. 2011; Paris et al. 2014). 
Nilvadipine is a known L-type calcium channel (LCC) antagonist (Paris et al. 2011; Paris et al. 
2014). Nilvadipine is a racemic compound consisting of equal amounts of (+)-nilvadipine and (-)-
nilvadipine. The (+) enantiomer is a potent LCC antagonist, while the (-) enantiomer is a much 
weaker LCC blocker (Paris et al. 2014). Interestingly, both enantiomers decrease Aȕ production 
and increase Aȕ clearance across the blood-brain barrier (BBB) in vitro to the same extent 
(Bachmeier et al. 2011; Paris et al. 2011; Paris et al. 2014). In addition, both enantiomers decrease 
Aȕ accumulation in the brains of Tg PS1/APPsw mice with similar potency and improve learning 
and spatial memory (Paris et al. 2011; Bachmeier et al. 2011; Paris et al. 2014). Interestingly, other 
L-type calcium channel blockers were unable to lower Aȕ levels (Paris et al. 2011). Taken 
together, these findings suggests that the effects of nilvadipine on Aȕ are independent of LCC 
inhibition and mediated by another target (Paris et al. 2014). Subsequent mechanistic experiments 
with nilvadipine revealed SYK as a target by showing a direct binding of nilvadipine to SYK and 
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a consequential inhibition of SYK activity in a cell-free assay (Paris et al. 2014). This implies that 
SYK inhibition by nilvadipine could be responsible for its Aȕ-lowering activity (Paris et al. 2014). 
Indeed, our previous studies showed that pharmacological inhibition of SYK, as well as genetic 
suppression of SYK, downregulate Aȕ production and BACE-1 expression in SH-SY5Y cells, 
thereby mimicking the effects of nilvadipine (Paris et al. 2014).  Furthermore, our previous studies 
showed that acute treatments with (-)-nilvadipine or with the Syk inhibitor BAY61-3606 reduced 
tau hyperphosphorylation in Tg Tau P301S mice (Paris et al. 2014).  
Importantly, the acute pharmacological inhibition of SYK with the selective inhibitor 
BAY61-3606 had the same effects as the treatment with (-)-nilvadipine and increased 
phosphorylation of GSK3-ȕ at the inhibitory Ser9 site and reduced p-Akt (Ser473) levels 
significantly (Paris et al. 2014), thereby confirming the hypothesis that the Aȕ-lowering activity 
of nilvadipine may be mediated by SYK inhibition. The impact on GSK3-ȕ was found to be 
mediated by the cAMP-dependent protein kinase (PKA) which also phosphorylates the cAMP 
response element-binding protein (CREB), involved in neuronal plasticity (Paris et al. 2014). SYK 
also has a major impact on neuroinflammation since it acts upstream of NFB, which is known to 
control the inflammatory response but also regulates BACE-1 expression, the rate-limiting enzyme 
in Aȕ production (Paris et al. 2014). In fact, BACE-1 expression was significantly decreased 
following SYK inhibition (Paris et al. 2014). SYK inhibition by BAY61-3606 also increased Aȕ 
clearance across the blood-brain barrier (BBB) like nilvadipine and reduced Aȕ levels in Tg 
PS1/APPsw mice, thereby recapitulating the different biological effects of nilvadipine observed 
on Aȕ and tau (Paris et al. 2014). More specifically, the acute treatment with BAY61-3606 had a 
profound impact on tau hyperphosphorylation at Ser396/404 (PHF-1), Ser202 (CP13) and partially 
prevented Tyr18 (9G3) phosphorylation in Tg Tau P301S mice (Paris et al. 2014). SYK and Src 
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family kinases have been shown to phosphorylate tau directly at Tyr18 (Lebouvier et al. 2009) 
which could explain the partial inhibition of tau Tyr18 phosphorylation observed following SYK 
inhibition. Tau tyrosine phosphorylation is considered an early pathological change in AD 
(Derkinderen et al. 2005b; Lebouvier et al. 2009). 
In addition to our previous experiments, in vitro experiments performed by other groups 
have shown that Aȕ oligomers can activate and trigger an inflammatory response in cultured 
primary microglial and monocytic cells. This response was mediated by the tyrosine kinases Lyn 
and SYK and elicited an intracellular calcium release that triggered the activation of the protein 
kinase C (PKC) (Combs et al. 1999; McDonald et al. 1997). The calcium-sensitive tyrosine kinase 
PYK2 then triggered the activation of the mitogen-activated protein kinases (MAPKs) and the 
extracellular signal-regulated kinases 1 and 2 (ERK1/2) (Combs et al. 1999). Importantly, SYK 
inhibition resulted in a reduced Aȕ-mediated neurotoxicity in vitro (Combs et al. 1999). A 
subsequent study also showed that SYK was the mediator of the Aȕ-induced elevated cytokine 
production in microglia, including tumor necrosis factor alpha (TNFα) and interleukin 1 beta (IL-
1ȕ) via a NFκB-dependent mechanism (Combs et al. 2001).  
      
1.2.2 The role of SYK in Nasu-Hakola disease 
 
In addition to the receptors mentioned above, TREM2 can also mediate  the recruitment and 
activation of SYK (Lanier and Bakker 2000). TREM2 is a type I transmembrane protein and part 
of the immunoglobulin (Ig) receptor superfamily. An adaptor protein DNAX-activating protein of 
12 kDa (DAP12, also known as TYROBP) is needed for TREM2 signal transduction, since 
TREM2 does not have any cytoplasmic signaling motifs. DAP12 interacts with the transmembrane 
domain of TREM2 and the cytoplasmic domain of DAP12 contains an ITAM (see above 1.2).  
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Nasu-Hakola disease (NHD) is a rare autosomal recessive disorder that is caused by a loss-
of-function mutation of TREM2 or DAP12 (Paloneva et al. 2002). Symptoms of NDH include 
multifocal bone cysts and presenile dementia. In contrast to AD patients, the onset of dementia 
occurs very early in NHD patients (30 years of age) (Paloneva et al. 2001). Interestingly, NHD 
specimens show ȕ-amyloid pathology and tau pathology (NFTs) but too a much lesser extent than 
AD specimens (Ghezzi et al. 2017; Satoh et al. 2018). However, considering the fact that the 
homozygous TREM2 or DAP12 mutations lead to death at the age of 40 (Paloneva et al. 2001), 
the period of exposure to the disease-causing mutations is not long enough to build up full-blown 
AD-like pathologies. Nevertheless, these studies suggest that TREM2 mutations could promote 
the development of AD pathological lesions and further highlight the importance of myeloid cells 
(microglia, macrophages, monocytes) in the pathogenesis of AD. Importantly, SYK activity is 
increased in NHD neurons compared to controls (p-SYK, Tyr525/526) (Satoh et al. 2012). The 
authors also found p-SYK to be mainly present in microglia and macrophages but not in astrocytes 
or oligodendrocytes. This further supports the idea that SYK plays an important role in TREM2-
mediated signaling and implies a contribution of SYK to the pathobiology of NHD.  
A described before (1.1.3, 1.1.4),  TREM2 mutations have been associated with neurodegenerative 
diseases including AD (Finelli et al. 2015), Parkinson’s disease (PD) (Benitez and Cruchaga C 
2013) and frontotemporal dementia (FTD) (Borroni et al. 2014), thereby suggesting that microglia 
and neuroinflammation play important roles in these diseases, as TREM2 is exclusively expressed 
in myeloid cells. Although rare, heterozygous TREM2 variants are associated with an increased 
risk for developing AD (Kober et al. 2016). TREM2 immunoreactivity is upregulated in Aȕ 
plaque-associated microglia and neurites of human AD temporal cortices (Lue et al. 2015). 
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Additionally, increased TREM2 expression positively correlated with tau phosphorylation and 
caspase 3 activity (Lue et al. 2015). 
 TREM2 has been shown to be a receptor for Aȕ (Zhao et al. 2018). They furthermore 
found, that Aȕ enhanced the interaction of TREM2 and DAP12, thereby regulating the activation 
of downstream kinases including SYK and GSK3-ȕ (Zhao et al. 2018). Since TREM2 is an 
established risk factor for AD, this Aȕ-induced SYK activation mediated by TREM2 further 
highlights SYK as an important kinase in the pathobiology of AD.     
Interestingly, ApoE has been found to be a ligand of TREM2 (Atagi et al. 2015; Bailey et 
al. 2015). It has been shown that ApoE modulates the Aȕ clearance in mouse models of AD. 
Binding of ApoE to TREM2 induces microglial phagocytosis of apoptotic N2a cells (Atagi et al. 
2015). Interestingly, the missense TREM2-R47H mutation that is associated with AD in particular, 
exhibited reduced binding of all ApoE isoforms, thereby linking two risk factors of AD (Atagi et 
al. 2015). 
In APP23 transgenic mice, expressing human APP containing the Swedish mutation under 
the murine Thy1 promoter, TREM2 appears to be upregulated in microglia associated with ȕ-
amyloid plaques (Frank et al. 2008). However, the effects of TREM2 deficiency on AD 
pathological lesions in animal models remains highly controversial (see introduction on tau for 
more examples 1.1.4). TREM2 deficiency has been shown to reduce inflammation, ameliorate 
amyloid and tau pathologies in AD mouse models (APPPS1-21 and 5xFAD) (Jay et al. 2015). The 
opposite has been shown in two studies by Jiang et al. (2014a; 2015) in which they conclude that 
TREM2 upregulation ameliorates the neuropathology and rescues the spatial cognitive impairment 
in APPsw/PS1ΔE9 and Tg Tau P301S mice. In a subsequent study, they also suggested that 
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TREM2 overexpression causes downregulation of GSK3-ȕ, cyclin-dependent kinase (CDK5) and 
a suppression of neuroinflammation through M2 activation of microglia (Jiang et al. 2016).  
APPPS1-21 mice, expressing only one copy of TREM2, exhibit altered microglial 
phenotypes and a decrease in microglia around Aȕ plaques (Ulrich et al. 2014). This suggest an 
important role of TREM2 in the Aȕ-mediated microglial response (Ulrich et al. 2014). 
Interestingly, no differences in ȕ-amyloid plaque burden were detected (Ulrich et al. 2014). In 
contrast, Wang et al. (2015b) and Yuan et al. (2016) found that TREM2 deficiency and 
haploinsufficiency exacerbate amyloid pathology in AD mouse models.  
Although TREM2 has been established as a well-known risk factor for AD, the 
abovementioned contradicting results show that its function is not fully understood and remains 
subject of debate. Nevertheless, given that TREM2 is known to mediate SYK activation and that 
certain TREM2 mutations have been shown to induce SYK activation in neurons and microglia in 
NHD, this could suggest that a dysregulation of SYK activity plays a role in the development of 
AD. 
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1.3 Clinical trials for Alzheimer’s disease 
 
To date, there is no cure available to AD patients, as none of the drugs approved by the food and 
drug administration (FDA) halts the cognitive decline. There are five approved AD drugs (as of 
August 2018), three of which are acetylcholine esterase inhibitors (donepezil, galantamine, 
rivastigmine), one NMDA receptor antagonist (memantine) and one drug that combines donepezil 
and memantine, meaning that there are just two different forms drugs in terms of mechanism of 
action (MOA) that are currently approved by the FDA. Memantine has been the last drug approved 
by the FDA in 2003, meaning that there has been no approval of a drug for AD during the last 15 
years. Furthermore, the currently approved drugs are not disease-modifying therapies (DMT) that 
will prevent or delay the onset or slow the progression of the disease but are categorized as 
symptomatic cognitive enhancers. While symptomatic cognitive enhancers may help patients in 
the short term by boosting their cognitive performance, they do not alter the advance of the disease 
in the long term. Therefore, FDA approved DMTs are needed to successfully treat AD.  
As of the beginning of 2018, there were 112 drugs in the pipeline according to 
clinicaltrials.gov (Cummings et al. 2018). Of those 112 drugs only 63% were DMTs. 17 DMTs 
were in phase III and the drugs targeted amyloid (14 drugs), had a tau-related target (1 drug), 
involved neuroprotection (1 drug), or had a metabolic MOA (Cummings et al. 2018). Six of the 
DMTs were immunotherapies targeting amyloid, five BACE inhibitors, and three drugs aiming to 
prevent the amyloid aggregation (Cummings et al. 2018).  
Passive immunotherapies against Aȕ include for example the antibodies solanezumab, 
aducanumab and BAN2401. Solanezumab is a humanized monoclonal IgG1 antibody directed 
against the Aȕ mid-domain. The antibody recognizes soluble monomeric Aȕ but not fibrillar Aȕ.  
Solanezumab has been in many phase II and phase III clinical trials but the last phase III was 
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terminated because of “insufficient scientific evidence that solanezumab would likely demonstrate 
a meaningful benefit to participants with prodromal AD as defined by study protocol” (clinical 
trials.gov; NCT02760602). The previous solanezumab phase III trial for mild AD failed to meet 
the primary endpoints (Doody et al. 2014; Honig et al. 2018). However, there is a phase III trial 
ongoing that enrolled asymptomatic or very mildly symptomatic individuals that may be at risk 
for memory loss because of biomarker evidence of brain amyloid deposition (NCT02008357).  
The aducanumab trials involve a fully human IgG1 monoclonal antibody directed against 
aggregated Aȕ (conformational epitope). The antibodies are derived from aged, healthy, 
cognitively normal donors who were said to have successfully resisted AD. The phase I 
aducanumab trial that started in 2012 and involved 166 prodromal or mild AD individuals is still 
ongoing (NCT01677572) and one year of monthly aducanumab intravenous infusions seemed to 
dose- and time-dependently reduce brain Aȕ and slow the clinical decline, as measured by CDR-
SB and MMSE (Sevigny et al. 2016). However, the ongoing two phase III clinical trials 
(NCT02477800, NCT02484547), both involving 1350 mild MCI or mild AD patients, will show 
if aducanumab is suitable as a treatment for AD.  
BAN2401 is a humanized IgG1 antibody directed against large, soluble Aȕ protofibrils. 
The phase II clinical trial that enrolled 856 MCI or mild AD patients (MMSE ≥22) showed a dose 
dependent reduction of amyloid PET values and, more importantly, slowing in cognitive decline 
after 18 months of treatment with the highest dose (ADAS-cog, 47%) (NCT01767311). However, 
APOE-ε4 carriers are prone to develop amyloid related imaging abnormalities-edema (ARIA-E) 
following Aȕ antibody treatment and therefore a significant number of APOE-ε4 individuals were 
moved out of the highest dose arm. APOE-ε4 carriers are at higher risk for developing AD and 
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exhibit a faster progression, Therefore, the positive results of the phase II BAN2401 trial have to 
be considered with caution. 
The CAD106 trials involve an active immunization strategy using the Aȕ1-6 peptide 
derived from the N-terminal B-cell epitope of Aȕ, coupled to a bacteriophage Qȕ (virus-like) 
particle. An ongoing phase II/III study that enrolled 1340 homozygous APOE-ε4 carriers (60-75 
years of age) not only aims to test CAD106 but also compare it to the BACE inhibitor CNP520 
(NCT02565511).  
BACE inhibitors aim to limit the production of Aȕ. The phase III clinical trial of the BACE 
inhibitor verubecestat (NCT01739348) failed to slow cognitive and functional decline in 
individuals with mild-to-moderate AD despite target engagement (90% reduction of Aȕ 
production with the highest dose) and another phase III including individuals with prodromal AD 
(NCT01953601) was terminated in 2018 because it was unlikely to have a positive benefit/risk.  
Nevertheless, other phase III BACE inhibitors continue. Elenbecestat, for example, is 
currently being tested in two phase III trials (NCT02956486, NCT03036280) that both enrolled 
1350 MCI and prodromal AD patients. Previously elenbecestat had shown a 70% reduction of CSF 
Aȕ in a phase II clinical trial (NCT02322021). An interesting approach is also the combination of 
BACE inhibitors and Aȕ antibodies. TRAILBLAZER (NCT03367403) is the name of the study 
that will test LY3002813, a humanized IgG1 antibody directed against a N-terminally truncated 
pyro-glutamate modified Aȕ (specifically localized in Aȕ plaques), and the LY3202626 BACE 
inhibitor, in order to achieve maximal target engagement of the amyloid pathway. Interestingly, 
this trial enrolls early symptomatic AD patients based on amyloid and tau burden (PET).           
The first drugs targeting tau were aiming to reduce tau aggregation and failed to meet their 
primary endpoints. TRx0237, also known as LMT-X, methylene blue or tau aggregation inhibitor 
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(TAI) is the chemical methylthioninium chloride (MTC) and is a drug that predates the FDA and 
is a re-purposed malaria drug. Between the years there were three different phase III clinical trials 
for all-cause dementia or mild AD (NCT01689233), mild to moderate AD (NCT01689246), and 
the behavioral variant of frontotemporal dementia (NCT01626378). All phase III TRx0237 trials 
failed to meet their primary endpoints. Nevertheless, another phase II/III TRx0237 for all-cause 
dementia and AD is underway and will end in 2019 (NCT03446001). There are only a few clinical 
trials involving small molecules whose MOA involves tau. In fact, besides TRx0237 there is no 
other small molecules in a phase III and only four in a phase II clinical trial, including ANAVEX2-
73, a sigma-1 receptor agonist, nicotinamide (vitamin B3), the re-purposed drug nilotinib (FDA-
approved to treat adult chronic myeloid leukemia), is said to inhibit the tyrosine kinase Abl, and 
another compound with a similar MOA, AZD0530 or saracatinib (NCT02167256), an inhibitor of 
the Src/Abl family of kinases. The rational of using AZD0530 is mainly based on targeting Fyn 
and thereby decreasing the phosphorylation of tau and Aȕ burden (Nygaard et al. 2014). Therefore, 
the use of AZD0530 for the treatment of AD represents an approach that is, to some extent, similar 
to targeting SYK. The 12-months phase II clinical trial that included 152 AD patients (MMSE 18-
26 and 18F-Florbetapir PET scan with evidence of elevated Aȕ) ended in February 2018 and the 
analysis will give additional information about the efficacy of targeting a tyrosine kinase similar 
to SYK in the brain of AD patients.  
However, there are currently active and passive tau immunotherapies in phase I and II 
trials. Among the tau immunotherapies in phase II trials are active immunotherapy AADvac-1 
(NCT02579252), passive immunotherapy ABBV-8E12 (NCT02880956), antisense 
oligonucleotides (ASO) based IONIS-MAPTRx or BIIB092 (NCT03186989), and passive 
immunotherapy BIIB092 (NCT03352557). The AADvac-1 trial involves a treatment with a 
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synthetic peptide derived from amino acids 294 to 305 of the tau sequence. The peptide is supposed 
to evoke an immune response against pathologically modified forms of tau protein because tau 
cleavage has been found to generate N-terminally truncated fragments (Kontsekova et al. 2014; 
Paholikova et al. 2015). The results of the 24-months phase II trial including 185 mild-to-moderate 
AD patients will presumably be available in 2019 and give first hints about the efficacy of an active 
tau vaccination. The ABBV-8E12 trial involves a treatment with a humanized IgG4 antibody 
directed against aggregated, extracellular tau species, in order to prevent or reduce the 
transneuronal tau propagation (Braak and Del Tredici 2011; Clavaguera et al. 2009). Therefore, 
its MOA does not require a neuronal uptake. The phase II 96-weeks-long trial included 400 AD 
patients (CDR 0.5, MMSE≥22) and is currently ongoing. The IONIS-MAPTRx or BIIB092 trial 
is the first clinical approach using antisense oligonucleotides (ASO) to target tau expression 
(DeVos et al. 2013; DeVos et al. 2017). The phase I/II trial will assess adverse events and 
pharmacokinetic parameters and will end in 2020. The BIIB092 trial involves the use of another a 
humanized IgG4 monoclonal anti-tau antibody. Similar to the ABBV-8E12 approach, the antibody 
is directed against extracellular, N-terminally fragmented forms of tau. The phase 2 trial started in 
May 2018, involves 528 mild MCI and mild AD patients with positive amyloid PET scan and will 
end in 2021.  
None of the DMTs in phase III enrolled patients with severe AD in their studies and only 
one phase II DMT included severe AD patients, while six trials of symptoms-reducing small 
molecules in phase II and III enrolled patients with severe AD (Cummings et al. 2018). Cummings 
et al. state that there is trend towards enrolling patients with milder forms of AD (also mild 
cognitive impairment (MCI), prodromal AD) or even cognitively normal individuals with signs of 
amyloid pathology as measured in the cerebrospinal fluid (CSF) or by positron emission 
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tomography (PET). The approach of developing DMTs only for milder or moderate forms of AD 
bears the danger of neglecting patients with severe AD although there are millions of people with 
AD dementia worldwide (Cummings et al. 2018). Considering that there are currently no DMTs 
approved that could slow down the progression of AD, this means that many mild-to-moderate 
AD patients will soon have progressed into the severe AD stage. Another important factor to 
consider for studies only including patients in the earliest stages of AD is trial length. The earlier 
clinical trials aim to intervene, the longer the clinical trials have to be – an approach that increases 
the costs for clinical trials dramatically and increases the time from patent filing to drug approval, 
thereby making it financially less attractive for pharmaceutical companies to work on drugs for 
AD. Failures of previous anti-amyloid clinical trials enrolling more severe cases of AD lead to the 
belief that it is too late to intervene during a state of established dementia when neurodegeneration 
has already progressed (Sperling et al. 2011).   
As mentioned before, nilvadipine is an anti-hypertensive drug, a L-type CCB of the 
dihydropyridine (DHP) group (Rosenthal 1994) that our team found to inhibit SYK (Paris et al. 
2014) and it was also found to increase cerebral blood flow in rats (Furuichi et al. 1992), mouse 
models of AD (Tg APPsw) (Paris et al. 2004), as well as humans (Ogasawara et al. 2003). Anti-
hypertensive drugs have been associated with lower incidence of AD (Khachaturian et al. 2006). 
Nilvadipine has been re-purposed and shown to prevent cognitive decline in a small study 
including MCI patients with essential hypertension, as nilvadipine is lipophilic and can cross the 
BBB (Hanyu et al. 2007). Pre-clinical studies performed by our team have shown that nilvadipine 
facilitates the clearance of Aȕ across the BBB (Bachmeier et al. 2011), inhibits Aȕ production in 
vitro and decreased Aȕ burden in vivo (Paris et al. 2011), and furthermore, reduced tau 
hyperphosphorylation in vivo (Paris et al. 2014).  
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The Roskamp Institute team was involved in launching a European multicenter double-
blind placebo-controlled 18-months phase III clinical trial for AD, including 511 mild-to-moderate 
AD patients treated with 8mg of nilvadipine daily and the trial ended in 2017 (NILVAD, 
NCT02017340). Primary outcome measures included Alzheimer's Disease Assessment Scale 
(ADAS)-Cog 12. Secondary outcome measures included Clinical Dementia Rating Scale Sum of 
Boxes (CDR-SB) and Disability Assessment for Dementia (DAD).  
The pre-specified primary outcome measure did not show any treatment benefit of 
nilvadipine for individuals with mild-to-moderate AD and the decline from baseline in ADAS-
Cog 12 on placebo was 0.79 (95% CI: -0.07 to 1.64) at 13 weeks, 6.41 (5.33 to 7.49) at 52 weeks, 
and 9.63 (8.33 to 10.93) at 78 weeks and on nilvadipine was 0.88 (0.02 to 1.74) at 13 weeks, 5.75 
(4.66 to 6.85) at 52 weeks, and 9.41 (8.09 to 10.73) at 78 weeks. However, there were some 
limitations to the study, as more severe AD cases were enrolled and, as in many other clinical 
trials, there was a lack of biomarker confirmation (PET scans or CSF amyloid measurements) for 
the diagnosis of AD. In addition, the dose of 8mg daily may have been too low.  
Nevertheless, the sub-group exploratory analyses showed interesting results, as there was 
less cognitive decline in the mild AD group (MMSE ≥20 at baseline) on nilvadipine compared to 
placebo and a greater decline seen in the moderate AD group (MMSE ≤19 at baseline) treated with 
nilvadipine, furthermore indicating that earlier interventions may yield a more favorable outcome 
(Sperling et al. 2011). In the NILVAD trial, males showed less cognitive decline than females on 
nilvadipine compared to placebo. Furthermore, APOE4 carriers showed less cognitive decline than 
non-carriers on nilvadipine. In summary, the results of the exploratory analyses suggest that the 
treatment with nilvadipine may be beneficial for individuals in the early stage of AD. These 
findings have to be confirmed in future clinical trials with nilvadipine.  
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Interestingly, nilvadipine has also been shown to impact cytokine and T-cell levels in 
systemic autoimmune disorders complicated with hypertension (Kagawa et al. 1999). Patients 
treated with nilvadipine over a period of six months exhibited lower levels of IL-1ȕ, IL-2, IL-6 
and TNFα, while levels of helper/activated T-cells decreased in the peripheral blood, suggesting 
that nilvadipine inhibits the cytokine production in T lymphocytes. It is very likely that this effect 
on the immune system is mediated by SYK, as the racemic compound nilvadipine is also a SYK 
inhibitor (Paris et al. 2014).  
The findings mentioned in the previous paragraphs further underline the importance of 
investigating and advancing new potential DMTs to the clinic and because of the data presented 
in this thesis, the development of specific SYK inhibitors represents a new and promising treatment 
strategy for AD. To this date, there have only been oral SYK inhibitors in clinical trials or FDA 
approved that aim to treat conditions like rheumatoid arthritis, autoimmune thrombocytopenia, 
autoimmune hemolytic anemia, IgA nephropathy, and lymphoma (fostamatinib/R788/R406), 
relapsed or refractory chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) 
or non-Hodgkin lymphoma (entospletinib/GS-9973) (Liu and Mamorska-Dyga 2017; Sharman et 
al. 2015). There have also been clinical trials for CLL investigating the dual SYK/JAK1/2 inhibitor 
cerdulatinib/PRT062070 (Blunt et al. 2015), and for advanced solid tumors or lymphoma or 
relapsed or refractory acute myelogenous leukemia (R/R AML), investigating the dual SYK/FMS-
like tyrosine kinase 3 (FLT-3) inhibitor TAK-659 (Liu and Mamorska-Dyga 2017) and for 
urticaria and cutaneous lupus erythematosus, investigating GSK2646264. Fostamatinib became 
the first FDA approved SYK inhibitor in 2018 for the treatment of chronic immune 
thrombocytopenia (ITP). This means that past and present clinical trials have investigated specific 
SYK inhibitors mainly for the treatment of cancer and autoimmune diseases. Only a small number 
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of teams have been working on SYK as a target for the treatment of CNS diseases, thereby mainly 
focusing on AD. However, the scientific field around SYK inhibitors may expand in the near 
future, as the role of SYK in several important processes within the CNS becomes more apparent 
to the scientific community. 
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1.4 Aims of the studies 
 
The aims of the studies were to further elucidate the role of SYK in the pathobiology of AD and 
to investigate SYK as a possible target for the treatment of AD.  
 
This thesis can be divided into 3 major parts:  
 
1) The first aim was to determine whether SYK activation occurs in different animal models 
of AD, and in human AD specimen in relation to the ȕ-amyloid and tau pathologies. 
 
 
2) The second aim was to study the impact of SYK inhibition on tau and to delineate the 
molecular mechanism responsible for the effects of SYK on tau in vitro. 
 
 
3) The third aim was to conduct an in vivo study to investigate the effects of a 12-week-long 
chronic pharmacological SYK inhibition on tau phosphorylation and tau accumulation, as 
well as neuroinflammation in Tg Tau P301S mice and determine whether some of the 
molecular pathways mediating the effects of SYK on tau (identified in aim 2) are also 
triggered following SYK inhibition in vivo. 
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2 Assessment of the activation pattern of SYK in 3 distinct mouse 
models of AD and human AD specimens 
 
2.1 Introduction 
 
SYK is a known to be involved in BCR and in some cases TCR-signaling (Geahlen 2014) and is 
therefore a regulator of the peripheral immune response. However, very little is known about the 
role of SYK in the CNS. The knowledge about the functional role of SYK in the CNS is limited 
to in vitro studies involving cultured microglia and macrophages (Combs et al. 1999; Combs et al. 
2001; McDonald et al. 1997), as well as experiments involving neuronal cell cultures that 
suggested a SYK-dependent regulation of the early neuronal neuritogenesis (Angibaud et al. 2011; 
Richards et al. 2006). Our previous findings that highlighted SYK as a potential target for the 
treatment of AD (see 1.2.1 for further information), triggered us to investigate the cellular 
expression and activation of SYK in human AD brains and mouse models of AD, including Tg 
PS1/APPsw, Tg APPsw and Tg Tau P301S mice AD (see 1.1.7 for further information) in relation 
to the development of Aȕ and tau pathologies. The data and conclusions presented in this chapter 
have been peer-reviewed and published (Schweig et al. 2017). 
As described in the introduction of this thesis, the AD pathological hallmarks include 
extracellular amyloid deposits, intracellular tau aggregates and neuroinflammation. Various 
studies have emphasized the importance of the Aȕ-induced neuroinflammation in the pathogenesis 
of AD and suggested that a therapeutic strategy can only be successful if it counteracts the 
neurotoxicity caused by neuroinflammation (McGeer and McGeer 2013; Prokop et al. 2013).  
Aȕ oligomers have been shown to trigger an inflammatory response in primary microglial 
and monocytic cells via an activation of the tyrosine kinases Lyn and SYK (Combs et al. 1999; 
McDonald et al. 1997). Importantly, SYK inhibition appears to prevent Aȕ-mediated neurotoxicity 
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in vitro (Combs et al. 1999). A subsequent study also showed that SYK mediates the Aȕ-induced 
cytokine production including tumor necrosis factor alpha (TNFα) and interleukin 1 beta (IL-1ȕ) 
by activated microglia (Combs et al. 2001), suggesting that SYK may be a key kinase responsible 
for the pro-inflammatory activity of Aȕ. Furthermore, SYK was suggested to play a role microglial 
phagocytosis (Hadas et al. 2012). Recruitment and activation of SYK can also be mediated by 
activation of TREM2 which is known to be expressed in microglia (Lanier and Bakker 2000). 
Several TREM2 variants are associated with an increased risk to develop AD and have been shown 
to alter AD pathology including Aȕ deposition, tau hyperphosphorylation, neuroinflammation and 
synaptic loss in AD mouse models (Kober and Brett 2017).  
The in vitro studies mentioned in the previous paragraph strongly suggest a role of SYK in 
microglia and the Aȕ-induced immune response of the CNS. Moreover, we have shown previously 
that pharmacological inhibition of SYK appears to reduce Aȕ production by decreasing BACE-1 
expression in vitro in SH-SY5Y neuron-like cells (Paris et al. 2014). Therefore, one of our goals 
of this study was to investigate the possible expression of SYK in microglia in vivo and if the 
activation of SYK differs in activated versus non-activated microglia in vivo. Another part of this 
experiment was to analyze SYK activation in close proximity to Aȕ-deposits observed in AD and 
mouse models thereof.  
As stated in detail in the first chapter (1.1.4), there exist many different tau phosphorylation 
sites and various kinases responsible for tau hyperphosphorylation have been identified as 
contributors to tau pathogenesis. Tau tyrosine phosphorylation is considered an early pathological 
change in AD (Derkinderen et al. 2005b; Lebouvier et al. 2009). SYK and Src family kinases have 
been shown to phosphorylate tau directly at Y18 (Lebouvier et al. 2009; Nisbet et al. 2015). SYK 
has also been shown to phosphorylate microtubules which could have an effect on microtubule 
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polymerization or the interaction of signaling molecules with the microtubule network (Faruki et 
al. 2000). In addition, pharmacological SYK inhibition has been found to stabilize microtubules 
through dephosphorylation of microtubules and microtubule associated proteins (MAPs) (Yu et 
al. 2015). Our previous studies revealed that SYK regulates the activation of GSK3-ȕ, one of the 
main tau kinase that phosphorylates tau at multiple sites present in neurofibrillary tangles (Paris et 
al. 2014). Furthermore, we have shown that pharmacological inhibition of SYK appears to reduce 
tau hyperphosphorylation both in vitro and in vivo (Paris et al. 2014). 
Taking into consideration that SYK has been found to phosphorylate tau and the 
microtubule network, and regulate the activity of other tau kinases, we were prompted to also 
examine the expression and activation of SYK in neurons, especially in neurons displaying the tau 
pathology. 
SYK activation can, at least in part, be regulated by phosphorylation (see 1.2 for more 
information). Since tyrosine phosphorylation in the kinase activation loop has been shown to be 
the best indicator for functional activation of SYK (Zhang et al. 2000), we therefore focused on 
the SYK phosphorylation site Y525/526 to monitor SYK activation and analyzed its association 
with AD pathological hallmarks in the present study. The Y525/526 phosphorylation sites are 
located within the activation loop of the SYK kinase domain which means, when SYK is 
catalytically active, it is phosphorylated at these sites. Many previous studies have used the 
Tyr525/526 phosphorylation site to monitor SYK activation (Feldman et al. 2008; Speich et al. 
2008; Aouar et al. 2016; Satoh et al. 2012).   
Our analysis of images, obtained by high-resolution confocal microscopy, revealed that SYK 
activation is increased in a subset of activated microglia and in dystrophic neurites around Aȕ 
plaques of Tg APPsw and Tg PS1/APPsw mice. Interestingly, p-SYK (Y525/526) is also age-
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dependently increased in neurons of Tg Tau P301S mice, presenting tau pathological lesions. The 
degree of co-localization between p-SYK and tau is largely dependent on the tau epitope 
investigated and differs between various p-tau epitopes and tau oligomers/conformers. The level 
of SYK activation, as measured by fluorescence intensity, correlates with the amount of 
pathological tau species detected. In addition, we show that SYK overexpression in a human 
neuroblastoma cell line (SH-SY5Y) results in increased total tau and tau phosphorylation levels at 
multiple epitopes suggesting the activation of SYK contributes to the formation of tau pathological 
lesions.  
In summary, our results show that ȕ-amyloid and tau pathological species both activate SYK 
in vivo and conversely, that SYK is involved in microglial activation, plays a role in the 
pathogenesis of dystrophic neurites (DNs) and contributes to the formation of pathological tau 
species therefore exacerbating the formation of AD pathological lesions. Interestingly, human AD 
brain sections exhibit the same pattern of SYK activation as the mouse models of ȕ-amyloidosis 
and tauopathy combined. Human AD brain sections show an increase in p-SYK (Y525/526) levels 
in DNs around ȕ-amyloid plaques and in neurons immunopositive for hyperphosphorylated tau 
(Y18) and pathological tau conformers (MC1), whereas brain sections from non-demented 
controls do not show any p-SYK increase. Altogether, these data suggest a crucial role of SYK in 
the pathobiology of AD and further highlight SYK as a promising therapeutic target in AD.  
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2.2 Materials & Methods  
 
2.2.1 Animals 
 
Tg PS1/APPsw, Tg APPsw, Tg Tau P301S and wild-type mice were generated and maintained in 
a C57BL/6 genetic background as previously described (Paris et al. 2014). All mice were 
maintained under specific pathogen free conditions in ventilated racks in the Association for 
Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited 
vivarium of the Roskamp Institute. All experiments involving mice were reviewed and approved 
by the Institutional Animal Care and Use Committee of the Roskamp Institute before 
implementation and were conducted in compliance with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals.  
 
2.2.2 Tissue Processing 
 
All mice were humanely euthanatized and their brains were collected and fixed in 4% 
paraformaldehyde (PFA) for 48 hours. The method of euthanasia used follow the AVMA 
(American Veterinary Medical Association) guidelines for the euthanasia of animals. Briefly, mice 
were rendered unconscious through inhalation of 5% isoflurane in oxygen using a vaporizer and a 
gas chamber. While under anesthesia, after verifying the absence of reflexes, mice were 
euthanatized by exsanguination (blood was withdrawn from cardiac puncture). 
Subsequently, the hemispheres were processed in a Sakura Tissue-Tek VIP (Leica 
Biosystems Inc., IL, USA) vacuum infiltration processor. Brains were then embedded in paraffin 
with the Sakura Tissue-Tek (Leica Biosystems Inc., IL, USA) and stored at 4˚C for two days for 
subsequent cutting with a Leica RM2235 microtome (Leica Biosystems Inc., IL, USA). All brains 
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were cut at a thickness of 12μm. Sagittal slices were mounted on glass slides and dried for 48 hours 
at 37˚C for subsequent immunofluorescence staining and confocal imaging.  
  
2.2.3 Immunofluorescence 
 
Paraffin sections were washed in two baths of histoclear (National Diagnostics, USA) and 
progressively rehydrated with ethanol gradients and phosphate buffered saline (PBS, Sigma 
Aldrich, MO, USA). Brain sections were subjected to antigen retrieval for seven minutes in citric 
acid buffer (pH 6) at 100˚C. All sections were treated with 0.05% Sudan Black in 70% ethanol to 
quench autofluorescence. Sections were then blocked in PBS containing 10% donkey serum 
(Abcam, MA, USA) for one hour. Sections were incubated in PBS containing 1% donkey serum 
and the respective panel of primary antibodies overnight at 4˚C. The following antibodies were 
used: CP13 (anti(α)-phospho-tau (p-tau) S202, 1:200, Dr. Peter Davies’ Lab), MC1 (α-
conformational tau, 1:200, Dr. Peter Davies’ Lab), TOC1 for detection of tau oligomers (1:200, 
Dr. Lester Binder’s Lab), PHF-1 (α -p-tau S396/404, 1:200, Dr. Peter Davies’ Lab), 9G3 (α-p-tau 
Y18, 1:200, MediMabs Inc., QC, Canada), DA9 (α-total-tau (t-tau), 1:200, Dr. Peter Davies’ Lab), 
α-BACE1 (1:200 Cell Signaling, MA, USA), α-sAPPȕ with Swedish mutation (1:100 Immuno-
Biological Laboratories Co, Ltd., Japan), α-Iba1 (1:300, Abcam, MA, USA), α-GFAP (1:5000, 
Aves Labs, OR, USA), α-p-SYK (Y525/526, 1:200, Cell Signaling, MA, USA). In addition to the 
α-p-SYK (Y525/526, 1:200, Cell Signaling, MA, USA), we used the α-p-SYK (Y525/526, 1:100, 
Abgent, CA, USA) and obtained similar results. After three washing steps in PBS for five minutes, 
sections were incubated in a solution containing PBS, 1% donkey serum and the respective panel 
of secondary antibodies for one hour in the dark at room temperature in a humidified chamber. 
The following secondary antibodies were used: donkey α-rabbit, α-goat, α-mouse conjugated to 
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Alexa 488, 568 and 647, respectively (1:500, Life technologies). After three washing steps in PBS 
for five minutes, sections were mounted in Fluoroshield with or without DAPI (Sigma Aldrich, 
MO, USA). All images were acquired using the confocal microscope LSM 800 (Carl Zeiss AG, 
Germany), the ZEN Blue 2.1 (Carl Zeiss AG, Germany) software and a 20x or 63x objective. The 
acquisition settings were kept the same for all genotypes within the same experiment. 
For qualitative analysis of the p-SYK burden in Tg PS1/APPsw and Tg APPsw mice 
compared to age-matched WT littermates (n=6 for each genotype, equal amount of male and 
female), 116±13.5 (AVG±SEM) weeks of age were stained and analyzed as described above 
(Figure 3).  
For qualitative analysis of the p-SYK burden in Tg Tau P301S mice compared to WT 
littermates, hippocampi and cortices of sixteen male and female mice ranging from 8 to 56 weeks 
of age were stained and analyzed as described above.  
For the quantitative analysis of the p-SYK burden (Figure 5), 140 randomly-selected 
microscopic fields of four non-consecutive brain slices (containing the hippocampus) from six 
animals per genotype (equal number of male and female) were acquired. The area covered with 
the p-SYK immunopositive staining was quantified with Fiji (Schindelin et al. 2012) in 
microscopic fields containing Aȕ plaques as well as in microscopic fields not containing Aȕ 
deposits. The PS1/APPsw, APPsw and WT mice of the younger cohort were on average 45±0.3 
(AVG±SEM) weeks old. The average age of the mice of the older cohort was 116±13.5 weeks 
(±SEM). The p-SYK burden of the transgenic mice was normalized to the level of p-SYK burden 
quantified in wild-type littermates of the respective age-group. As a negative control, primary 
antibodies were omitted to determine background and autofluorescence (not shown). 
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For the quantitative analysis of the co-localization of p-SYK and different tau epitopes 
(Figure 10) between 400 and 570 cortical fields (50,000 μm2-per field) from four male Tg Tau 
P301S animals (average age 47±3.1 (SEM) weeks) were analyzed for each tau epitope. To quantify 
the percentage of the immunopositive neurons a total of 2546 microscopic fields and 21800 
neurons were counted using the Zen Blue 2.1 software (Carl Zeiss AG, Germany).  
The fluorescence intensities (Figure 11-Figure 15) of 30 to 40 neurons immunopositive for 
p-SYK, p-tau or both (co-localized) were determined for each tau epitope (total of 90 neurons per 
epitope) using Zen Blue 2.1 (Carl Zeiss AG, Germany). The male Tg Tau P301S mice (n=4) used 
for quantification were on average 47±3.1 weeks old (AVG±SEM).    
In addition, the different immunostainings mentioned above were performed on paraffin-
embedded tissue sections (10μm, dorsolateral frontal cortex) from a 67-year-old, male patient with 
AD (Braak VI) and a 102-year-old, male non-demented control that were provided by Dr. Ann 
McKee (Boston University, MA, USA).  Institutional review board approval for brain donation 
was obtained through the Boston University Alzheimer’s Disease Center (BUADC, Boston, MA, 
USA).  
 
2.2.4 Cell Culture 
 
SH-SY5Y cells were purchased from American Type Culture Collection (VA, USA). SH-SY5Y 
cells were grown in DMEM/F12 medium (Thermo Fisher Scientific, MA, USA) supplemented 
with 10% fetal bovine serum (Thermo Fisher Scientific, MA, USA), GlutaMAX and 1% 
penicillin/streptomycin/fungizone.  
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2.2.5 Generation of SYK overexpressing SH-SY5Y Cells 
 
A human cDNA ORF Clone of the human SYK gene (NM_003177, transcript variant 1) was 
purchased from OriGene Technologies (MD, USA). The cDNA fragment encoding human SYK 
was amplified by PCR using PfuUltra II Fusion HS DNA polymerase (Agilent Genomics, CA, 
USA) and subcloned into the p3xFLAG-Myc-CMV™-26 Expression Vector (Sigma-Aldrich, 
MO, USA) to generate the pCMV-SYK-Flag plasmid. The entire reading frame of the plasmid 
was confirmed by DNA sequencing. SH-SY5Y cells were maintained in advanced DMEM/F-12 
medium supplemented with 10% fetal bovine serum, 1% GlutaMAX, 1% penicillin/streptomycin 
(Thermo Fisher Scientific, MA, USA) and incubated in a humidified 5% CO2 atmosphere at 37˚C. 
For stable transfection, SH-SY5Y cells were grown in 6-wells cell culture plates until reaching 70-
80% confluence and transfected with 3 μg of empty pCMV vector (control cells) or pCMV-SYK-
Flag plasmids per well using lipofectamine 2000 (Thermo Fisher Scientific, MA, USA). After 48 
hours, the medium surrounding transfected cells was replaced with fresh medium containing 
0.2mg/ml of G418 for selection. After 14 days of selection, G418 resistant cells were trypsinized 
and expanded. The expression efficiency of SYK was analyzed by Western blot using antibodies 
against SYK (4D10 SYK antibody, Santa Cruz Biotechnology, TX, USA) and the Flag tag (Sigma-
Aldrich, MO, USA).  
 
2.2.6 Immunoblotting 
 
SH-SY5Y cells were cultured in 24-well-plates for 24 hours and subsequently lysed with 
mammalian protein extraction reagent (MPER, Thermo Fisher Scientific, MA, USA) containing 
Halt protease & phosphatase single use inhibitor/EDTA (Thermo Fisher Scientific, MA, USA) and 
1 mM PMSF. Proteins of cell lysates were separated by 10% tris-glycine-SDS-PAGE using 1 mm 
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Criterion TGX gels (Bio-Rad Laboratories, CA, USA) and electro-transferred onto 0.2 μm PVDF 
membranes (Bio-Rad Laboratories, CA, USA). Membranes were blocked in TBS containing 5% 
non-fat dried milk for 1h and were hybridized with the primary antibody (α-SYK (4D10, 1:1000, 
Santa Cruz, TX, USA), α-p-tau S396/404 (PHF-1, 1:1000, Dr. Peter Davies’ Lab), α-t-au (DA9, 
1:1000, Dr. Peter Davies’ Lab), α-p-tau Y18 (9G3, 1:1000, MediMabs Inc., QC, Canada,) 
overnight at 4˚C. Subsequently, the membranes were incubated for 1h in HRP-conjugated α-
mouse secondary antibody (1:1000, Cell Signaling, MA, USA). Western blots were visualized 
using chemiluminescence (Super Signal West Femto Maxium Sensitity Substrate, Thermo 
Fisher Scientific, MA, USA). Signals were quantified using ChemiDoc XRS (Bio-Rad 
Laboratories, CA, USA) and densitometric analyses were performed using Quantity One (Bio-
Rad Laboratories, CA, USA) image analysis software.  
 
2.2.7 Statistical Analyses 
 
The data were analyzed and plotted with GraphPad Prism (GraphPad Software, Inc., CA, USA). 
The Shapiro-Wilk test for normality was used to test for Gaussian distribution. Statistical 
significance was determined by either Kruskal-Wallis followed by Dunn’s post-hoc test or the 
non-parametric Mann-Whitney test. All data are presented as mean ± the standard error of the 
mean (SEM) and p<0.05 was considered significant.  
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2.3 Results 
 
2.3.1 Cellular localization of Syk activation in brains of Tg PS1/APPsw, Tg APPsw mice 
and WT mice 
 
To investigate whether pathological SYK activation occurs in the brain of AD mouse models, we 
analyzed the brains of 116-week-old wild-type, Tg APPsw and Tg PS1/APPsw mice using high-
resolution confocal microscopy and immunofluorescence. All transgenic mice (Figure 3b-e) 
exhibit an increased Iba-1 and GFAP reactivity compared to wild-type littermates (Figure 3a). 
Moreover, some of the activated amoeboid microglia that are observed in transgenic mice are also 
strongly positive for p-SYK (Figure 3b-d). In contrast, we did not detect any p-SYK 
immunoreactivity in astrocytes (Figure 3). In addition, we observed that p-SYK immunoreactivity 
is upregulated near Aȕ plaques but neither co-localizes with microglia nor astrocytes suggesting 
that it could be of neuronal origin. (Figure 3e). We further investigated the cellular origin of these 
p-SYK accumulations by immunofluorescence staining and confocal microscopy (Figure 4). 
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2.3.2 SYK activation in dystrophic neurites of Tg PS1/APPsw and Tg APPsw mice  
 
To further characterize the cellular origin of p-SYK accumulations near Aȕ plaques, we tested 
different markers of dystrophic neurites (BACE-1 and sAPPȕ) (Sadleir et al. 2016) and found a 
strong co-localization between p-SYK and sAPPȕ (Figure 4a) around Aȕ deposits. The sAPPȕ 
staining clearly reveals dystrophic swellings of neurites (Figure 4a) which are a known hallmark 
of AD. Most of the dystrophic neurites are positive for p-SYK (Figure 4a). Additionally, we found 
a strong co-localization between sAPPȕ and BACE-1 (Figure 4b) which are often used as markers 
of dystrophic neurites. Both sAPPȕ and BACE-1 exhibit circular accumulations near Aȕ plaques 
(Figure 4b), highly reminiscent of the pattern observed for activated SYK. 
In conclusion, activated SYK is not only found in microglia but also in neurons near Aȕ 
deposits, particularly in dystrophic neurites of Tg APPsw and Tg PS1/APPsw mice supporting a 
possible role of SYK activation in the formation of dystrophic neurites. Dystrophic neurites are 
characterized by an accumulation of BACE-1 and sAPPȕ (Sadleir et al. 2016) and our previous 
work (Paris et al. 2014) has shown that SYK regulates BACE-1 expression and sAPPȕ levels 
suggesting that SYK upregulation in dystrophic neurites could contribute to the accumulation of 
BACE-1 and sAPPȕ. 
 Figure 3: p-SYK is increased in activated microglia and non-glial cells associated with Aβ-
plaques in Tg APPsw and Tg PS1/APPsw mice. 
a) Spatial distribution and cellular localization of activated/phosphorylated SYK were 
investigated in the cortex of 116 ± 13.5-week-old (avg. ± SEM) wildtype mice (n = 6) by 
triple-immunostaining of p-SYK (Y525/526, green), microglia (Iba1, red) and astrocytes 
(GFAP, purple). Nuclei were stained with DAPI (blue). b) Syk activation in wild-type 
animals was compared to age-matched Tg APPsw (n = 6) (b-c) and Tg PS1/APPsw 
littermates (n = 6) (d-e). Plaque-associated cortical areas (c, e) were compared to non-plaque-
associated areas (b, d). Qualitative image analysis of orthogonal projections and 3D-image 
analysis (not-shown) revealed an increased p-SYK burden in transgenic (b-e) compared to 
wild-type mice (a) and a co-localization of p-SYK and Iba1 but not GFAP in Aȕ-
overexpressing animals (b-d). Large, non-glial spherical accumulations of p-SYK were 
observed in plaque-associated areas (e). The scale bar represents 10 μm. 
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Figure 4: p-SYK is increased in dystrophic neurites of Aβ-overexpressing mice 
Representative confocal image depicting the cortex of 116.5 ± 13.5- 
week-old Tg PS1/APPsw mice stained for sAPPȕ (purple), p-SYK (green, 
a), BACE1 (green, b), Iba-1 (red). Nuclei were stained with DAPI (blue).     
a) p-SYK was accumulated in dystrophic neurites positive for sAPPȕ (a) and 
BACE1 (b). The scale bars represent 10 μm. 
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2.3.3 Age-dependent and amyloid deposition-dependent increase of SYK activation in Tg 
PS1/APPsw and Tg APPsw compared to WT mice 
 
We also quantified the p-SYK burden in the cortex of Tg APPsw, Tg PS1/APPsw and wild-type 
(WT) littermates (Figure 3-Figure 4). Two different age-groups were investigated: younger 
animals, 45 weeks of age and older animals 116 weeks of age in average. In 45-week-old Tg 
APPsw mice, we did not observe significant ȕ-amyloidosis (only three Aȕ plaques were found in 
the cohort of mice analyzed) (data not shown) showing that, at that age, the Aȕ plaque pathology 
is almost inexistent in these mice. We differentiated between microscopic fields containing Aȕ 
deposits and microscopic fields not containing Aȕ deposits for the quantification of the p-SYK 
burden in Tg PS1/APPsw and older Tg APPsw mice. 45-week-old Tg APPsw and Tg PS1/APPsw 
mice do not show any significant difference in p-SYK burden in fields without Aȕ deposits 
compared to WT mice. The p-SYK burden of 45-week-old Tg APPsw mice is identical to that of 
the WT mice (100±6.76% compared to 80.85±11.77%; Figure 5a). The p-SYK burden in fields 
not containing Aȕ plaques in Tg PS1/APPsw mice is not statistically significantly elevated 
(153.48±18.47%), compared to the WT littermates, although a trend for an increase was observed. 
As expected, 45-week-old Tg PS1/APPsw mice exhibited a significantly higher p-SYK burden in 
fields containing Aȕ plaques (410.19±46.46%) compared to WT and Tg APPsw mice (Figure 5).  
The analysis of the p-SYK burden in the cortex of older animals (average age: 116 weeks) 
revealed large differences between genotypes. The p-SYK burden of 116-week-old Tg APPsw 
(216.32±45.23%) mice in microscopic fields without plaques is not significantly increased 
compared to WT mice (100±7.78%) (Figure 5b). In contrast, microscopic fields of older Tg APPsw 
mice containing Aȕ deposits exhibit a strong increase in p-SYK burden (799.95±130.19%) 
compared to age-matched WT mice. 116-week-old Tg PS1/APPsw mice also exhibit a statistically 
significant increase in p-SYK burden in microscopic fields that do not contain Aȕ deposits 
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(458.1±109.68) compared to age-matched WT controls. In addition, a much greater p-SYK burden 
is found in Tg PS1/APPsw in microscopic fields containing Aȕ deposits. In these fields, the p-
SYK burden is increased by 1157.31±129.68% compared to WT littermates (Figure 5b). 
In conclusion, our data show that the p-SYK burden is highly associated with Aȕ plaques and 
increases with age in Tg PS1/APPsw and Tg APPsw mice whereas no activation of SYK is 
observed in the brain of WT littermates. The upregulation of SYK activation observed in the brains 
of Tg APPsw and Tg PS1/APPsw is mainly attributable to p-SYK accumulations in dystrophic 
neurites that are associated with Aȕ plaques and increase with age and Aȕ burden.     
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Figure 5: Cortical p-SYK burden is age-dependently increased in Aβ-overexpressing mice, 
particularly in microscopic fields containing Aβ deposits, compared to wild-type littermates 
Cortical p-SYK burden (area covered) of immunofluorescence images (Figure 3) was quantified 
in 45 ± 0.3-weekold (avg. ± SEM) (a) and 116 ± 13.5-week-old (avg. ± SEM) (b) Tg APPsw (n 
= 6) and Tg PS1/APPsw mice (n = 6), compared and normalized to wildtype littermates (n = 6). 
Microscopic fields containing Aȕ deposits were distinguished from microscopic fields not 
containing Aȕ deposits as described in the materials and methods section. Kruskal-Wallis and 
post-hoc Dunn’s multiple comparison test revealed a significant increase (p < 0.001) in p-SYK 
in fields containing Aȕ deposits in younger Tg PS1/APPsw animals compared to age-matched 
wild-type littermates (a). p-SYK burden in older Tg APPsw and Tg PS1/APPsw mice was 
statistically significantly increased in cortical microscopic fields containing Aȕ deposits 
compared to age-matched wildtype littermates (p < 0.001). Older Tg PS1/APPsw mice also 
exhibited a statistically significant p-SYK burden increase in microscopic fields not containing 
Aȕ deposits (p < 0.001), whereas the p-SYK burden in Tg APPsw in microscopic fields not 
containing Aȕ deposits was not statistically different from wild-type littermates (P > 0.05). Six 
animals per genotype were analyzed. Error bars represent SEM 
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2.3.4 Age-dependent and tau dependent SYK activation pattern in Tg Tau P301S mice  
 
Having shown that Aȕ-overexpressing mouse models of AD exhibit an increased SYK activation 
in microglia and dystrophic neurites, we investigated whether SYK activation also occurs in Tg 
Tau P301S mice (a pure model of tauopathy) using immunofluorescence and confocal microscopy. 
Hippocampal neurons of Tg Tau P301S mice exhibit a high level of tau hyperphosphorylation 
(Figure 6b) as well as an accumulation of pathogenic tau conformers (MC1, not shown) compared 
to WT littermates (Figure 6a). Most importantly, pathological tau species clearly co-localize with 
p-SYK (Y525/526) in hippocampal neurons (Figure 6b). The p-SYK burden is particularly 
prominent in hippocampal neurons of Tg Tau P301S mice (Figure 6b) whereas WT littermates do 
not exhibit any p-SYK immunoreactivity in the hippocampus (Figure 6a). 
Cortical neurons of Tg Tau P301S mice also exhibit an increased level of tau 
hyperphosphorylation (Figure 7b) compared to wild-type littermates (Figure 7a). We observed a 
co-localization between p-SYK and p-tau (S202) immunoreactivities in cortical neurons. 
Interestingly, we also observed neurons that are singly immunopositive for tau or for p-SYK. We 
addressed this observation by performing additional analyses (Figure 10-Figure 17).  
We also analyzed the temporal changes of p-SYK and tau levels in hippocampi and cortices of Tg 
Tau P301S mice between the age of 8 and 56 weeks (Figure 8-Figure 9). WT mice do not exhibit 
any detectable tau phosphorylation (Figure 8f) or tau oligomerization at any age (not shown). We 
then focused on the dentate gyrus of the hippocampus and found an age-dependent increase of tau 
phosphorylation (Figure 8, S202, left panels) in Tg Tau P301S mice. Tau phosphorylation at S202 
in the dentate gyrus was already detectable in 8-week-old Tg Tau P301S mice, however, p-SYK 
immunoreactivity was not observed. Neurons immunopositive for p-SYK (Y525/526) and p-tau 
(S202) or tau conformers (MC1, not shown) were observed in the dentate gyrus of 42-week-old 
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Tg Tau P301S mice (Figure 8d). The neuronal p-SYK burden also increases with age in Tg Tau 
P301S mice and is mainly restricted to the neuronal cell body (Figure 8). Interestingly, microglia 
and neurites did not exhibit activated SYK in the hippocampus of tau P301S mice (Figure 8). 
Abnormal SYK activation seems to follow tau hyperphosphorylation (S202) in the hippocampus 
of Tg P301S mice (Figure 8), as well as the formation of MC1-tau pathological conformers (data 
not shown here but MC1 and p-SYK co-localization were quantified below).   
Cortical neurons of Tg Tau P301S mice also show an increase in tau hyperphosphorylation 
and p-SYK with age (Figure 9). Interestingly, the onset of abnormal SYK activation occurs earlier 
(16 weeks of age) in the cortex than in the hippocampus (Figure 9b compared to Figure 8d). In 
conclusion, both p-SYK and tau pathology in Tg Tau P301S mice increase with age but the 
progression is different in the hippocampus and the cortex. Many cortical neurons exhibit a co-
localization of p-SYK and p-tau (S202) (Figure 9b-c, e) but as mentioned earlier, there are also 
neurons that are singly immunopositive for p-SYK or p-tau. 
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Figure 6: p-SYK is increased in hippocampal neurons of 
Tg Tau P301S mice compared to wild-type littermates 
Representative confocal image depicting 56 week-old 
male Tg Tau P301S and wild-type mice stained with 
antibodies against p-tau (S202, purple) and p-SYK 
(Y525/526, green). a) Wild-type mice did not exhibit 
any tau phosphorylation nor Syk activation in their 
hippocampi. b) tau-overexpressing Tg Tau P301S mice 
exhibited a prominent tau phosphorylation at S202 that 
co-localized with SYK activation in hippocampal 
neurons. The scale bars represent 200 μm. 
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Figure 7: p-SYK is increased in cortical neurons of Tg Tau P301S mice 
compared to wild-type littermates 
Representative confocal image depicting 56 week-old male Tg Tau 
P301S and wild-type mice stained with antibodies against p-tau (S202, 
purple), p-SYK (Y525/526, green). a) wild-type mice did not exhibit any 
tau phosphorylation nor Syk activation in their cortices. b) tau-
overexpressing Tg Tau P301S mice exhibited a prominent tau 
phosphorylation at S202 that co-localized with Syk activation in cortical 
neurons. The scale bars represent 100 μm 
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 Figure 8: p-SYK is increased age-dependently in hippocampal neurons 
of Tg Tau P301S mice compared to wild-type littermates 
Representative confocal image depicting Tg Tau P301S and wild-type 
mice (n = 16) stained with antibodies against p-tau (S202, purple), p-SYK 
(Y525/526, green) and Iba-1 (red). Nuclei were stained with DAPI. a-e) 
tau-overexpressing Tg Tau P301S mice exhibited a prominent tau 
phosphorylation (S202) that increased with age and co-localized with Syk 
activation in hippocampal neurons. f) Wild-type mice did not exhibit any 
tau phosphorylation nor SYK activation in their hippocampi. The scale bar 
represents 10 μm. 
 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 9: p-SYK is increased age-dependently in cortical neurons of Tg 
Tau P301S mice compared to wild-type littermates 
Representative confocal image depicting Tg Tau P301S and wild-type 
mice (n = 16) stained with antibodies against p-tau (S202, purple), p-SYK 
(Y525/526, green) and Iba-1 (red). Nuclei were stained with DAPI. a-e) 
tau-overexpressing Tg Tau P301S mice exhibited a prominent tau 
phosphorylation (S202) that increased with age and partially co-localized 
with Syk activation in cortical neurons. f) Wild-type mice did not exhibit 
any tau phosphorylation nor Syk activation in their cortices. The scale bar 
represents 10 μm. 
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2.3.5 Tau species-dependent SYK activation   
 
We further quantified the number of neurons that are singly p-SYK immunopositive, singly 
immunopositive for tau pathogenic species and neurons immunopositive for both p-SYK and tau 
pathogenic species in the cortex of 47-week-old Tg Tau P301S mice (Figure 10). We calculated 
the percentages of neurons singly immunopositive for either p-SYK, pathogenic tau species or 
neurons immunopositive for both. The sum of all cortical neurons counted was standardized to 
100% including neurons positive for p-SYK and the respective tau epitope and neurons 
immunopositive for both. For all the tau epitopes tested, we found that only a small fraction of the 
neurons is singly immunopositive for p-SYK (9.7±4.4% (p-tau, Y18); 2.5±1.2% (p-tau, S202); 
9.2±1.6% (MC1 pathogenic tau conformers); 9.6±6.3% (p-tau, S396/404); 4.8±2.0% (TOC1 (tau 
oligomers)). Interestingly, a larger percentage of neurons is immuno-reactive for both p-SYK and 
tau pathogenic species (44.7±8.6% (MC1); 39.7±12.4% p-tau Y18; 22.5±18.6% (PHF-1, p-tau 
S396/404); 12.4±8.1% (TOC1, tau oligomers) but only 5.7±2.2% for p-tau (S202)). The neurons 
singly immunopositive for tau complement these observations with relative values of 46.1±8.2% 
(MC1), 50.6±16.3% (Y18), 67.9±24.9% (S396/404), 82.8±10.1% (TOC1), and 91.8±3.2% (S202) 
(Figure 10). The differences in relative co-localization between p-SYK and specific tau pathologic 
species suggest that specific pathogenic forms of tau may have a different impact on SYK 
activation or that SYK activation may contribute to the formation of specific tau pathogenic 
species (Figure 10). We therefore subsequently measured the fluorescent intensities of p-SYK and 
of the different tau epitopes to determine whether the level of SYK activation correlates with the 
amount of specific tau pathogenic species. In general, we found that neurons that exhibit a high 
level of p-SYK immunoreactivity also demonstrate a higher level of tau pathogenic species 
whereas neurons that are weakly immunopositive for p-SYK show less tau pathology (Figure 11-
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Figure 15). In addition, neurons that are singly immunopositive for tau pathogenic species 
(including hyperphosphorylated tau and misfolded tau) show also less intense tau pathologies, as 
measured by fluorescent intensities, than neurons that are displaying both p-SYK and tau 
pathology, further supporting a role of SYK in the formation of tau pathogenic species. For 
instance, the level of pathogenic tau conformers (MC1) is significantly increased in neurons that 
are also strongly immunopositive for p-SYK compared to neurons that are singly immunopositive 
for MC1 (Figure 11d, p<0.05). Interestingly, the level of p-SYK is also significantly increased in 
neurons that display an accumulation of MC1 pathogenic conformers compared to neurons that 
are singly immunopositive for p-SYK (Figure 11e, p<0.01). These data suggest that pathogenic 
tau conformers and SYK activation may promote each other. We found that tau phosphorylation 
at Y18 is significantly increased in neurons that are also immunopositive for p-SYK (Figure 12d, 
p<0.05) which is consistent with previous data showing that in vitro SYK can phosphorylates tau 
at Y18. We have previously shown that SYK positively regulates GSK3-ȕ activity in vitro. It is 
therefore consistent with our observation that the GSK3-ȕ-dependent phospho-tau epitope 
(S396/404, PHF-1) is also increased in neurons that display SYK activation (Figure 13d, 
p<0.0001). The p-SYK level, however, is not statistically significantly increased in neurons that 
are immunopositive for both PHF-1 and p-SYK compared to neurons that are singly 
immunopositive for p-SYK suggesting that PHF-1 phosphorylated tau species do not induce SYK 
activation (Figure 13e). Similar observations were obtained for tau oligomers (Figure 14, TOC1) 
and tau species phosphorylated at S202 (Figure 15, CP13). Altogether, these data suggest that only 
certain pathogenic forms of tau (MC1, Y18) promote SYK activation, whereas SYK activation 
appears to directly induce tau phosphorylation at Y18 and to indirectly regulate tau 
phosphorylation at multiple epitopes (S396/404, S202) as well as tau misfolding (MC1, TOC1).   
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Figure 10: The degree of co-localization of p-SYK and tau differs for various tau epitopes 
Sections from Tg Tau P301S mice (n = 4, 47 ± 3.1-week-old) were stained with antibodies against 
p-tau (S202, S396/404, Y18), tau oligomers (TOC1) or tau conformers (MC1) and p-SYK 
(Y525/526, green). The cortices were divided in ROIs (each at a size of 50,000μm2) and neurons 
singly immunopositive for p-SYK, singly immuno-reactive for the respective tau epitope and the 
neurons immunopositive for both p-SYK and the respective tau epitope (co-localized) were 
counted and the percentages of each neuronal fraction calculated using Zen Blue 2.1 (Zeiss) and 
Excel (MS Office), respectively. In average, 509 cortical fields were analyzed for each epitope 
(total of 21,800 neurons counted). The percentage of neurons singly immunopositive for p-SYK 
was at a similar level for all tau epitopes investigated (p-SYK only). MC1 and p-tau Y18 show the 
highest co-localization with p-SYK whereas the incidence of neurons immunopositive for both p-
SYK and tau oligomers (TOC1) or p-tau S202 was much lower (co-localized fraction). The error 
bars represent SEM. 
 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 11: The amount of MC1 tau conformers and p-SYK (Y525/526) levels 
cross-influence each other 
Sections from Tg Tau P301S (n = 4, 47 ± 3.1-week-old) were stained with 
antibodies against tau conformers (MC1, purple) and p-SYK (Y525/526, green). 
Fluorescent intensities of MC1 and p-SYK were measured using Zen Blue 2.1 
(Zeiss). Three different neuronal fractions were differentiated: a) neurons singly 
immunopositive for MC1, (b) neurons singly immunopositive for p-SYK and (c) 
neurons immunopositive for both MC1 and p-SYK (co-localized). d) Fluorescent 
intensities of MC1 were compared between neurons singly MC1 positive 
(purple) and neurons exhibiting a co-localization of MC1 and p-SYK (purple-
green-striped). Two-tailed Mann–Whitney test revealed a significant increase (p 
< 0.05) of MC1 fluorescent intensity in neurons exhibiting a co-localization of 
MC1 and p-SYK compared to neurons singly immunopositive for MC1. e) 
Fluorescent intensities of p-SYK were compared between neurons singly 
immunopositive for p-SYK (green) and neurons that show an immunoreactivity 
for both p-SYK and MC1 (purple-green-striped). Two-tailed Mann–Whitney test 
revealed a significant increase (p < 0.01) of p-SYK fluorescent intensity in 
neurons immuno-reactive for both p-SYK and MC1 compared neurons that are 
singly immunopositive for p-SYK. The scale bar represents 10 μm. The error 
bars represent SEM. 
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 Figure 12: tau phosphorylation at Y18 and Syk activation (Y525/526) cross-
influence each other 
Sections from Tg Tau P301S (n = 4, 47 ± 3.1-weekold) were stained with 
antibodies against phosphorylated tau (Y18, purple) and p-SYK (Y525/526, 
green). Fluorescent intensities of p-tau (pY18) and p-SYK were measured 
using Zen Blue 2.1 (Zeiss). Three different neuronal fractions were 
differentiated: a) neurons singly immunopositive for pY18, (b) neurons singly 
immunopositive for p-SYK and (c) neurons immunopositive for both (co-
localized). d) Fluorescent intensities of pY18 tau were compared between 
singly pY18 immunopositive and the double immunopositive neurons (co-
localized, purple-green-striped). Two-tailed Mann–Whitney test revealed a 
significant increase (p < 0.05) of pY18 fluorescent intensity for neurons 
exhibiting a co-localization compared to the neurons singly immunopositive 
for pY18 tau. e) Fluorescent intensities of p-SYK were compared between 
singly p-SYK immunopositive neurons (green) and double immunopositive 
neurons for p-SYK and pY18 tau (purple-green-striped). Two-tailed Mann–
Whitney test revealed a significant increase (p < 0.01) of p-SYK fluorescent 
intensity in neurons double immunopositive for p-SYK and pY18 tau compared 
to singly p-SYK immunopositive neurons. The scale bar represents 10 μm. The 
error bars represent SEM. 
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 Figure 13: Syk activation (p-SYK (Y525/526) influences the level of tau 
phosphorylation at S396/404 
Sections from Tg Tau P301S (n = 4, 47 ± 3.1-week-old) were stained with 
antibodies against phosphorylated tau (S396/404, purple) and p-SYK 
(Y525/526, green). Fluorescent intensities of p-tau (pS396/404) and p-SYK 
were measured using Zen Blue 2.1 (Zeiss). Three different neuronal fractions 
were differentiated: a) neurons singly immunopositive for pS396/404 tau, (b) 
neurons singly immunopositive for p-SYK and (c) neurons immunopositive for 
both (co-localized). d) Fluorescent intensities of pS396/404 tau were compared 
between neurons singly immunopositive for pS396/404 (purple) and the 
neurons exhibiting a co-localization of pS396/404 and p-SYK (purple-green-
striped). Two-tailed Mann–Whitney test revealed a significant increase (p < 
0.0001) of pS396/404 fluorescent intensity in the neurons exhibiting a co-
localization compared to neurons singly immunopositive for pS396/404 tau. e) 
Fluorescent intensities of p-SYK were compared between singly p-SYK 
immunopositive neurons (green) and neurons exhibiting a co-localization of p-
SYK and pS396/404 tau (purple-green-striped). Two-tailed Mann–Whitney test 
revealed no significant change of p-SYK fluorescent intensity in neurons 
exhibiting a co-localization compared to singly p-SYK immunopositive 
neurons. The scale bar represents 10 μm. The error bars represent SEM. 
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 Figure 14: SYK activation (Y525/526) influences the level of tau 
oligomerization (TOC1) 
Sections from Tg Tau P301S (n = 4, 47 ± 3.1-week-old) stained with antibodies 
against tau oligomers (TOC1, purple) and p-SYK (Y525/526, green). 
Fluorescent intensities of oligomerized tau (TOC1) and p-SYK were measured 
using Zen Blue 2.1 (Zeiss). Three different neuronal fractions were 
differentiated: a) neurons singly immunopositive for TOC1, (b) neurons singly 
immunopositive for p-SYK and (c) neurons immunopositive for both (co-
localized). d) Fluorescent intensities of TOC1 were compared between 
neurons singly immunopositive for TOC1 (purple) and neurons exhibiting a 
co-localization of p-SYK and TOC1 (purple-green-striped). Two-tailed 
Mann–Whitney test revealed a significant increase (p < 0.0001) of TOC1 
fluorescent intensity in neurons exhibiting a co-localization with p-SYK 
compared to singly TOC1 immunopositive neurons. e) Fluorescent intensities 
of p-SYK were compared between neurons singly immunopositive for p-SYK 
(green) and neurons exhibiting a co-localization pf TOC1 and p-SYK (purple-
green-striped). Two-tailed Mann–Whitney test revealed no significant change 
of p-SYK fluorescent intensity in neurons exhibiting a co-localization 
compared to the singly p-SYK immunopositive neurons. The scale bar 
represents 10 μm. The error bars represent SEM. 
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 Figure 15: Syk activation (Y525/526) influences the level of tau 
phosphorylation at S202 
Sections from Tg Tau P301S (n = 4, 47 ± 3.1-week-old) stained with antibodies 
against phosphorylated tau (S202, purple) and p-SYK (Y525/526, green). 
Fluorescent intensities of p-tau (S202) and p-SYK were measured using Zen 
Blue 2.1 (Zeiss). Three different neuronal fractions were differentiated: a) 
neurons singly immunopositive for S202, (b) neurons singly immunopositive for 
p-SYK and (c) neurons immunopositive for both (co-localized). d) Fluorescent 
intensities of pS202 tau were compared between neurons singly pS202 
immunopositive (purple) and neurons exhibiting a co-localization between 
pS202 and p-SYK (purple-green-striped). Two-tailed Mann–Whitney test 
revealed a significant increase (p < 0.0001) of pS202 fluorescent intensity in 
neurons exhibiting a co-localization compared to neurons singly 
immunopositive for pS202. e) Fluorescent intensities of p-SYK were compared 
between neurons singly immunopositive for p-SYK (green) and neurons 
exhibiting a co-localization of p-SYK and pS202 tau (purple-green-striped). 
Two-tailed Mann–Whitney test revealed no significant change of p-SYK 
fluorescent intensity in neurons exhibiting a co-localization compared to singly 
p-SYK immunopositive neurons. The scale bar represents 10 μm. The error bars 
represent SEM. 
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2.3.6 SYK upregulation promotes tau accumulation in neuron-like SH-SY5Y cells 
 
To further investigate the impact of SYK on tau, we generated human neuronal-like (SH-SY5Y) 
cells overexpressing SYK (SYK-OX). SYK-OX SH-SY5Y cells show an approximate 17-fold 
increase in SYK expression compared to control SH-SY5Y cells transfected with the empty vector 
(Fig. 14b, p<0.0001). Interestingly, SYK upregulation in SH-SY5Y cells leads to a significant 
increase (1.7-fold) in phosphorylated tau at Y18 (Figure 16c, p<0.01) and at S396/404 (Figure 
16d, 3-fold, p<0.0001) compared to control cells. Total tau levels are also significantly increased 
following SYK overexpression (Figure 16e, 4.2-fold, p<0.0001). We analyzed the possible impact 
of SYK on tau mRNA levels by quantitative RT-PCR and found that SYK does not affect tau 
transcription and translation (Figure 23: SYK inhibition does not alter transcription or translation 
levels of tau in vitro) suggesting that SYK may regulate tau degradation. In summary, these results 
show that the accumulation of tau pathogenic species can trigger SYK activation, as shown in Tg 
Tau P301S mice (Figure 10-Figure 15), whereas SYK itself appears to regulate total tau levels and 
tau phosphorylation at multiple epitopes (Figure 16) therefore influencing the development of the 
tau pathology.  
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 Figure 16: Syk overexpression increases tau phosphorylation and total tau levels in 
SH-SY5Y cells 
SH-SY5Y cells were transfected with either the empty plasmid as a control or with the 
same plasmid carrying the SYK sequence for overexpression (SYK OX). Proteins 
expressed by transfected SH-SY5Y cells were analyzed by Western-blotting. Western-
blots chemiluminescent signals were quantified and results were tested for normal 
distribution using the Shapiro-Wilk test. A subsequent Mann–Whitney test was used to 
test for statistical significance. a Representative Western blots are shown. b) Level of 
Syk overexpression is in average 17.3 times higher than in control cells (p ≤ 0.0001, n 
= 18). c) Level of tau phosphorylation at Y18 is 1.7 times higher in SYK overexpressing 
compared to control cells (p ≤ 0.01, n = 11). d) Level of tau phosphorylation at 
S396/404 is 3 times higher in SYK overexpressing compared to control cells (p ≤ 
0.0001, n = 17). e) Level of total tau (DA9) is 4.1 times higher in SYK overexpressing 
compared to control cells (p ≤ 0.0001, n = 18). The error bars represent SEM. 
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2.3.7 Increased SYK activation in human AD specimen compared to non-demented 
controls 
 
We also performed different immunostainings against Aȕ, p-SYK, GFAP, Iba-1, tau pathogenic 
conformers (MC1) and phosphorylated tau at Y18 using brain sections from human AD and non-
demented controls. We found an increase in SYK activation in DNs surrounding Aȕ deposits as 
well as in neurons displaying an accumulation of phosphorylated tau at Y18 and elevated levels of 
MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for p-
SYK was observed in brain sections from a non-demented control (Figure 17-Figure 19). As 
observed in the AD mouse models, astrocytes did not exhibit SYK activation in neither the AD 
brain section nor the control. Only a subset of microglial cells exhibited a weak p-SYK signal. 
Most of the detected p-SYK signal was of neuronal origin and either localized in the somata or 
DNs. These data complement our observation in AD mouse models and reveal an association 
between SYK activation and typical AD pathological lesions in the human brain. Further studies 
will be required using a larger sample of AD pathological specimen to further clarify the role of 
SYK activation in AD brains. 
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Figure 17: p-SYK is increased in cortical neurons immunopositive for p-tau (Y18) of human AD 
compared to non-demented controls 
Representative confocal images of the dorsolateral frontal cortex sections of human AD (b) were 
stained with antibodies against p-tau (Y18) (purple), p-SYK (525/526) (green), Iba-1 (red) and 
GFAP (blue) and compared to control brain sections (a). a) The non-demented control (102-year-
old, male) does not exhibit any tau phosphorylation nor increased SYK activation in the 
dorsolateral frontal cortex. b) The AD brain (67-year-old, male) exhibits a prominent tau 
phosphorylation at Y18 that co-localizes with Syk activation (Y525/526) in cortical neurons. The 
scale bars represent 10 μm. 
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Figure 18: p-SYK is increased in cortical neurons immunopositive for MC1 pathogenic tau 
conformers in AD compared to brain sections from a non-demented control 
Representative confocal images of the dorsolateral frontal cortex sections of human AD (b) were 
stained with antibodies against conformationally altered tau species (MC1) (purple), p-SYK 
(525/526) (green), Iba-1 (red) and GFAP (blue) and compared to non-demented control brain 
sections (a). a) The non-demented control (102-year-old, male) does not exhibit any cells 
immunopositive for MC1 nor increased in SYK activation in the dorsolateral frontal cortex. b) 
The AD brain (67-year-old, male) exhibits neurons strongly immunopositive for MC1 that co-
localize with SYK activation (Y525/526) in cortical neurons. The scale bars represent 10 μm. 
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Figure 19: p-SYK is increased in dystrophic neurites associated with β-amyloid plaques of human 
AD patients compared to healthy controls 
Representative confocal images of dorsolateral frontal cortex sections of human AD (b) were
stained with antibodies against Aȕ (6E10) (purple), p-SYK (525/526) (green), Iba-1 (red) and 
compared to non-demented control brain sections (a). a) The non-demented control (102-year-
old, male) does not exhibit any Aȕ deposits nor increased Syk activation in neurons. b) The AD 
brain (67-year-old, male) exhibits neurons strongly immunopositive for p-SYK (Y525/526). c) 
The AD brain also exhibits dystrophic neurites immunopositive for p-SYK (Y525/526) 
near/within Aȕ deposits. The scale bars represent 10 μm. 
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2.4 Discussion  
 
Our previous studies have shown that tau hyperphosphorylation, Aȕ production and 
neuroinflammation are reduced following an acute inhibition of SYK (Paris et al. 2014). These 
data prompted us to investigate the level of SYK activation in different mouse models of AD and 
in brain sections from a non-demented control and AD patients. We found that SYK activation 
occurs in three different mouse models of AD, overexpressing Aȕ or tau, showing that SYK 
activation is triggered by both Aȕ deposits and tau pathological species. Most importantly, we 
made similar observations in human AD brain sections.  
Recent late phase clinical trials targeting the major pathological hallmarks of AD, mainly 
extracellular Aȕ plaques or intra-neuronal tau aggregates, have been unsuccessful so far and have 
failed to prevent cognitive decline and brain atrophy in AD patients (Siemers et al. 2016; Le 
Couteur et al. 2016; St-Amour et al. 2016; Gauthier et al. 2016). As PET scan imaging of AD 
patients reveals that Aȕ deposits and pathological tau accumulation occur during the prodromal 
phase of AD (Ossenkoppele et al. 2011), it has been suggested that therapies that are targeting Aȕ 
or pathological tau accumulation must be implemented decades before the appearance of the 
symptoms to be successful (Ossenkoppele et al. 2011). Hence, pharmacological intervention at 
downstream targets of Aȕ and tau may represent a more promising therapeutic strategy for AD 
patients. However, therapeutic targets downstream of the Aȕ and tau pathological lesions remain 
to be identified. Our work supports the view that SYK may be such a therapeutic target as it appears 
to be activated in vivo in response to ȕ-amyloidosis and the formation of pathological tau species. 
In this chapter, we report a hyperactivation of SYK in the brains of three different AD mouse 
models versus wild-type littermate controls and human AD compared to non-demented controls. 
In Tg PS1/APPsw, Tg APPsw mice, SYK activity is largely increased in activated microglia and 
 113 
in DNs around Aȕ deposits. In addition, we observed an activation of SYK in DNs around Aȕ 
deposits in an AD pathological specimen. In Tg Tau P301S mice and AD brain sections, SYK 
hyperactivation is co-localized with misfolded tau and hyperphosphorylated tau in neurons. 
The strong increase in activated SYK observed in dystrophic neurites (DNs) surrounding 
Aȕ deposits may suggest the involvement of SYK in the formation of these DNs that ultimately 
leads to the synaptic loss observed in AD (Sanchez-Varo et al. 2012). DNs are characterized by an 
accumulation of BACE-1 and sAPPȕ which implies a contribution of DNs to Aȕ production and 
accumulation (Sadleir et al. 2016). In fact, several in vivo studies have shown that BACE-1 
immunopositive dystrophic neurites precede Aȕ plaque formation in the brains of 3xTg-AD, 
2xFAD and 5xFAD mice and therefore, represent an early pathological event in AD (Cai et al. 
2012; Kandalepas et al. 2013; Zhang et al. 2009). Our previous in vitro and in vivo data have shown 
that SYK regulates Aȕ and sAPPȕ production via a modulation of BACE-1 expression (Paris et 
al. 2014) and therefore support a causative role of SYK activation in the accumulation of BACE-
1 and sAPPȕ in DNs.  
The increased activation of SYK in activated microglia of Aȕ-overexpressing mice further 
supports a role of SYK in microglial activation in vivo and suggests that Aȕ accumulation can lead 
to an activation of SYK in microglia. Previous in vitro studies have shown that Aȕ fibrils and 
oligomers can trigger a microglial inflammatory response mediated by SYK and leading to 
neurotoxicity (Combs et al. 1999; Combs et al. 2001; McDonald et al. 1997).  
Recruitment and activation of SYK has been suggested to be mediated by activation of 
triggering receptor expressed on myeloid cells 2 (TREM2) (Lanier and Bakker 2000). TREM2 is 
a type I transmembrane protein and part of the immunoglobulin (Ig) receptor superfamily. Since 
TREM2 does not have any cytoplasmic signaling motifs, an adaptor protein DNAX-activating 
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protein of 12 kDa (DAP12, also known as TYROBP) is needed for TREM2 signal transduction. 
DAP12 interacts with the transmembrane domain of TREM2. The cytoplasmic domain of DAP12 
contains an immunoreceptor tyrosine activation motif (ITAM) that provides docking sites for SYK 
activation. Interestingly, loss-of-function mutations in the DAP12 or TREM2 genes cause a rare 
autosomal recessive disorder called Nasu-Hakola disease (NHD) whereas heterozygous carriers of 
these mutations show an elevated risk to develop AD (Paloneva et al. 2002). Symptoms of NDH 
include multifocal bone cysts and presenile dementia. Interestingly, SYK activation (p-SYK, 
Y525/526) is increased in NHD neurons compared to controls  (Satoh et al. 2012) and was found 
to be also present in microglia and macrophages but not in astrocytes or oligodendrocytes (Satoh 
et al. 2012) supporting a role of SYK activation in the development of NHD dementia. 
SYK plays a key role in the activation of immune cells and the production of inflammatory 
cytokines. We have shown previously that activation of NFκB (nuclear factor kappa-light-chain-
enhancer of activated B cells) which is known to play a regulatory role in neuroinflammation, is 
prevented following either pharmacological SYK inhibition or genetic knockdown of SYK. Hence, 
this suggests a role of SYK in the regulation of neuroinflammation. In addition, SYK has been 
shown to mediate the neuroinflammation and neurotoxicity caused by Aȕ. Furthermore, the Aȕ-
induced cytokine production by microglia has been found to be mediated by SYK, suggesting that 
SYK is involved in the activation of microglia.  
The pathological analysis of Tg Tau P301S mice shows that SYK activation is associated 
with the formation of hyperphosphorylated tau and misfolded tau in the hippocampus and cortex 
while our previous work has shown that acute SYK inhibition can reduce tau phosphorylation at 
multiple AD relevant epitopes (Paris et al. 2014). Interestingly, we show here that SYK 
upregulation in human neuronal like SH-SY5Y cells induces tau accumulation and tau 
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phosphorylation further confirming a role of SYK in the formation of tau pathogenic species. 
Altogether, our data suggest that SYK activation may also promote tau hyperphosphorylation and 
misfolding in vivo as neurons that show higher levels of SYK activation also show more 
accumulation of hyperphosphorylated tau and tau pathogenic conformers. Pathological tau species 
accumulation clearly results in SYK activation in Tg Tau P301S mice while SYK activation 
appears to be a mediator of the formation of tau pathogenic species, thereby implying the existence 
of a positive feedback loop resulting in an enhanced progression of tau pathology. Given that SYK 
is also present in DNs which exhibit tau accumulation and tau phosphorylation (Schmidt et al. 
1994; Su et al. 1993), this further supports a pathological role of SYK in the formation of DNs and 
ultimately synaptical loss.  
Our previous in vivo and in vitro data show decreased tau phosphorylation at multiple 
epitopes (S396/404, S202, Y18) following SYK inhibition (Paris et al. 2014). Interestingly, we 
show here that SYK overexpression in SH-SY5Y cells increases tau phosphorylation and total tau 
levels (Y18, S396/404, DA9). The increase in total tau levels following SYK upregulation is not 
caused by an increased transcription, as SYK does not impact tau transcription (Figure 23). 
Therefore, increased SYK levels may lead to a decreased degradation of tau. However, the 
molecular mechanisms responsible for the increased tau levels following SYK overexpression or 
decreased tau following SYK inhibition are delineated in the following chapter of this thesis. 
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In this study, we also provide evidence for an aberrant SYK activation in DNs around Aȕ deposits 
and in neurons immunopositive for pathological tau species in human AD brain sections further 
validating the data obtained with different transgenic mouse models of AD. In conclusion, our data 
support a pathological role of SYK in the formation of Aȕ deposits and misfolded tau and suggest 
additionally that reduction of SYK hyperactivity through pharmacological inhibition may be a 
promising therapeutic approach for the treatment of AD.    
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3 Mechanistic assessment of the role of SYK in autophagy and the 
mTOR pathway in CNS-derived SH-SY5Y cells 
 
3.1 Introduction 
 
Protein misfolding, aggregation and accumulation constitute a pathological hallmark of 
neurodegenerative proteinopathies including AD and frontotemporal lobar degeneration (FTLD). 
Many studies have suggested that neurodegeneration is, at least partly, caused by a dysfunctional 
degradation of proteins that are prone to aggregate. In fact, an impaired autophagic clearance of 
macromolecules has been widely accepted to be a major contributor to various neurodegenerative 
diseases (Nixon 2007; Nixon and Yang 2011; Ghavami et al. 2014; Menzies et al. 2015) by 
promoting the accumulation of misfolded proteins. The mammalian target of rapamycin (mTOR) 
is known to regulate autophagy (Jung et al. 2010). The members of the mTOR pathway including 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), 3-phosphoinositide-dependent protein 
kinase 1 (PDK1), protein kinase B (Akt), Tuberous sclerosis 1/2 (TSC1/2), Ras homolog enriched 
in brain (Rheb), mTOR and ribosomal protein S6 kinase (S6K), thereby also indirectly control the 
autophagic degradation of proteins. AD and FTLD share the accumulation of tau as a common 
underlying pathology. In human AD and FTLD cases, as well as in mouse models of AD and pure 
tauopathy, autophagy has been found to be decreased (Zare-Shahabadi et al. 2015; Kragh et al. 
2012; Wang et al. 2012) and to contribute to the pathological accumulation of tau aggregates. 
Impaired autophagy has been linked to an overactive mTOR pathway which acts as a regulator of 
autophagy initiation and lysosomal degradation, thereby controlling the autophagic flux (Jung et 
al. 2010; Puertollano 2014).  
More specifically, in the frontotemporal dementia and parkinsonism linked to chromosome 
17 (FTDP-17) mouse model that overexpresses mutant tau (Tg Tau P301S), direct inhibition of 
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mTOR with either rapamycin or temsirolimus attenuated tau pathology (Ozcelik et al. 2013; Jiang 
et al. 2014b). Furthermore, stimulation of autophagy by trehalose or by the overexpression of the 
transcription factor EB (TFEB) were both shown to be efficient in reducing neurodegeneration and 
mitigating tauopathy in Tg Tau P301S mice (Schaeffer et al. 2012; Wang et al. 2016) suggesting 
that inhibiting mTOR may have therapeutic value for the treatment of tauopathies.  
SYK has also been suggested to phosphorylate microtubules in B-cells (Faruki et al. 2000), 
and furthermore, pharmacological SYK inhibition has been found to stabilize microtubules in 
paclitaxel-resistant tumor cells (Yu et al. 2015). 
SYK has been shown to mediate the activation of microglial cells induced by Aȕ oligomers 
(Combs et al. 1999; McDonald et al. 1997), while SYK inhibition has been shown to prevent Aȕ-
mediated neurotoxicity in vitro (Combs et al. 1999). A subsequent study also demonstrated that 
SYK was the mediator of the Aȕ-induced elevated cytokine production including interleukin 1 
beta (IL-1ȕ) and tumor necrosis factor alpha (TNFα) which is responsible for increased iNOS 
expression resulting in apoptosis in primary mouse neuronal cultures (Combs et al. 2001). In 
addition, it has been suggested that SYK contributes to microglial dysfunction in AD (Ghosh and 
Geahlen 2015). 
In our previous studies, we identified SYK as a novel target for the treatment of AD (Paris 
et al. 2014; Schweig et al. 2017). We found that SYK inhibition can decrease Aȕ production and 
tau hyperphosphorylation in vitro, and in vivo in mouse models of AD and tauopathy following an 
acute treatment (Paris et al. 2014), in part, by promoting the phosphorylation of GSK3-ȕ at the 
inhibitory Ser9 site and reducing BACE-1 expression (Paris et al. 2014). 
We have shown that SYK activation, as measured by p-SYK (Y525/526) levels, is largely 
increased in dystrophic neurites and microglia of Aȕ-overexpressing mouse models of AD (Tg 
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PS1/APPsw, Tg APPsw) and in neurons of a mouse model of tauopathy (Tg Tau P301S) displaying 
pathological tau species while neurons of wild-type animals showed no activation of SYK 
(Schweig et al. 2017), suggesting that SYK plays a key role in the formation of AD pathological 
lesions (see previous chapter). Similarly, we observed  an increased SYK activation in dystrophic 
neurites and in neurons affected by the tau pathology in human AD specimens (Schweig et al. 
2017). Interestingly, we have shown that SYK activation promotes tau accumulation but does not 
affect tau expression suggesting that SYK may affect tau clearance (Schweig et al. 2017). In the 
present study, we further investigated the SYK molecular mechanisms which drive tau 
accumulation in vitro. We show that SYK is a key regulator of the mTOR pathway and that SYK 
inhibition, as well as suppression of SYK expression, lead to an inhibition of the mTOR pathway, 
resulting in increased autophagic tau degradation. These data not only provide further evidence for 
an important role of SYK in the pathological impairment of protein degradation observed in AD 
and tauopathies but also illustrate that pharmacological SYK inhibition may represent a promising 
therapeutic strategy for the treatment of AD and other neurodegenerative proteinopathies 
associated with a defective autophagic clearance of misfolded proteins.  
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3.2 Methods 
 
3.2.1 Cell Culture 
 
SH-SY5Y cells were purchased from American Type Culture Collection (VA, USA). SH-SY5Y 
cells were grown in DMEM/F12 medium (Thermo Fisher Scientific, MA, USA) supplemented 
with 10% fetal bovine serum (Thermo Fisher Scientific, MA, USA), GlutaMAX and 1% 
penicillin/streptomycin/fungizone. 
 
3.2.2 Cell Culture Treatments 
 
SH-SY5Y cells were treated in 500μl medium for 24h using 24-well cell culture plates. The cells 
were treated with the following inhibitors/activators: SYK inhibitor BAY61-3606 (5-10μM, 
Sigma, MO, USA), Akt activator SC79 (20μM, Sigma, MO, USA), mTOR activator MHY1485 
(4-12μM, Sigma, MO, USA), mTOR inhibitor KU0063794 (1-2μM, Sigma, MO, USA), S6K 
inhibitor PF4708671 (5-10μM, Tocris, MN, USA), lysosomal inhibitor chloroquine (CQ, 100-
200μM, Tocris, MN, USA).  
 
3.2.3 Puromycin Incorporation Assay 
 
To investigate the possible impact of SYK inhibition on protein synthesis, we used the SUrface 
SEnsing of Translation (SUnSET) technique (Schmidt et al. 2009). This technique involves the 
use of the antibiotic puromycin (a structural analog of tyrosyl-tRNA), and anti-puromycin 
antibodies to detect the amount of puromycin incorporation into nascent peptide chains. 
Incorporation of puromycin into nascent polypeptides causes termination. Although a high 
concentration of puromycin is toxic because it can inactivate translation, at low concentrations it 
provides an accurate snapshot of protein synthesis without causing lethality. Confluent SH-SY5Y 
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cells were treated with BAY61-3606 and PF4708671 for 24 hours and with cycloheximide for 5 
hours. Cells were then treated for 1 hour with 10 μg/ml of puromycin and lysed in ice-cold M-PER 
(Thermo Fisher Scientific, MA, USA) containing Halt protease & phosphatase single use 
inhibitor/EDTA (Thermo Fisher Scientific, MA, USA) and 1 mM PMSF. Levels of newly 
synthesized proteins containing puromycin were then detected by Western blot using an anti-
puromycin antibody (1/1000 dilution, Millipore Sigma, MA, USA). 
 
3.2.4 Immunoprecipitation (IP) 
 
Following the SUnSET technique, cell lysates were centrifuged at 16,000g for 15 min at 4°C to 
remove the insoluble fractions. The resulting supernatants were subjected to IP with 2μg/ml anti-
puromycin (Millipore Sigma, MA, USA) overnight at 4°C. Then 20μl protein A-magnetic beads 
(Thermo Fisher Scientific, MA, USA) were added for 2 hours at 4°C. The beads were carefully 
washed, and the proteins were eluted with reducing 2x Laemmli sample buffer (Bio-Rad 
Laboratories, CA, USA) at 95°C for 5min. The samples were then analyzed by Western blotting. 
 
3.2.5 Quantitative RT-PCR 
 
Total RNA was extracted from SH-SY5Y cells treated with DMSO or BAY61-3606 using the 
Trizol reagent (Invitrogen, CA, USA). RNA was reverse-transcribed into first-strand cDNA using 
the superScript™ III First-Strand Synthesis System (Invitrogen, CA, USA). Quantitative real-time 
PCR (qPCR) was performed with ssoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad 
Laboratories, CA, USA) and analyzed on a CFX96 Touch™ Real-Time PCR Detection System 
(Bio-Rad Laboratories, CA, USA) as per the manufacturer’s instructions. The mRNA levels in 
each sample were analyzed by normalizing the threshold cycle (Ct) value to that of internal loading 
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control, ȕ-actin employing the primer sets used for human total and 3R tau detection that have 
been described previously (Fernández-Nogales et al. 2014). 
 
3.2.6 Generation of SYK knockdown SH-SY5Y Cells 
 
Short hairpin RNAs (shRNAs) were used to stably knockdown SYK gene expression in SH-SY5Y 
cells. GIPZ lentiviral vectors expressing SYK specific shRNAs (Paris et al. 2014) or nonsense 
control shRNAs were purchased from Origene. For stable transfection, SH-SY5Y cells were 
grown on 6-well plates until reaching 70-80% confluence and transfected with shRNAs plasmids 
using lipofectamine 2000 (Invitrogen, CA, USA). After 48 hours, transfected cells were placed 
into fresh medium in the presence of 1μg/ml puromycin for selection. After 14 days, the resistant 
cells were trypsinized and expanded. The knockdown efficiency of SYK was confirmed by 
western blot using antibodies against SYK (4D10, Santa Cruz, TX, USA). 
 
3.2.7 Immunoblotting 
 
Western blots were performed as previously described (Paris et al. 2014; Schweig et al. 2017). 
Briefly, SH-SY5Y cells were cultured in 24-well-plates, treated for 24 hours and subsequently 
lysed with mammalian protein extraction reagent (MPER, Thermo Fisher Scientific, MA, USA) 
containing Halt protease & phosphatase single use inhibitor/EDTA (Thermo Fisher Scientific, 
MA, USA) and 1 mM PMSF. Proteins of cell lysates were separated by 10% tris-glycine-SDS-
PAGE using 1 mm Criterion TGX gels (Bio-Rad Laboratories, CA, USA) and electro-transferred 
onto 0.2 μm PVDF membranes (Bio-Rad Laboratories, CA, USA). Membranes were blocked in 
TBS containing 5% non-fat dried milk for 1h and were hybridized with the primary antibody (anti-
SYK (4D10, 1:1000, Santa Cruz, TX, USA), anti-p-tau S396/404 (PHF-1, 1:1000, Dr. Peter 
Davies’ Lab), anti-t-tau (DA9, 1:1000, Dr. Peter Davies’ Lab), anti-p-tau S202 (CP13, 1:1000, Dr. 
 123 
Peter Davies’ Lab), anti-p-tau T231 (RZ3, 1:1000, Dr. Peter Davies’ Lab), anti-conformer-tau 
(MC1, 1:1000, Dr. Peter Davies’ Lab), anti-oligomeric-tau (TOC1, 1:1000, Dr. Lester Binder’s 
Lab) anti-p-SYK (Y525/526), anti-p-mTOR (S2448), anti-p-S6K (T389/T412), anti-p-Akt (S473), 
anti-LC3b, anti-Actin, anti-NeuN, anti-LAMP-1, anti-iNOS (all 1:1000, Cell Signaling, MA, 
USA), anti-GFAP (1:5000, DAKO, USA), anti-Iba1 (1:1000, Abcam, MA, USA), anti-beta-
tubulin (1:1000, BD Biosciences, CA, USA) overnight at 4˚C. Subsequently, the membranes were 
incubated for 1h in HRP-conjugated anti-mouse or anti-rabbit secondary antibody (1:1000, Cell 
Signaling, MA, USA). Western blots and Dot Blots were visualized using chemiluminescence 
(Super Signal West Femto Maxium Sensitity Substrate, Thermo Fisher Scientific, MA, USA). 
Signals were quantified using ChemiDoc XRS (Bio-Rad Laboratories, CA, USA) and 
densitometric analyses were performed using Quantity One (Bio-Rad Laboratories, CA, USA) 
image analysis software. 
 
3.2.8 Statistical Analyses 
 
The data were analyzed and plotted with GraphPad Prism (GraphPad Software, Inc., CA, USA). 
The Shapiro-Wilk test for normality was used to test for Gaussian distribution. Statistical 
significance was determined by either ANOVA (for comparisons of three or more groups) or t-
tests (SYK knockdown). All data are presented as mean ± the standard error of the mean (SEM) 
and p<0.05 was considered significant (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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3.3 Results 
 
Our previous data suggest that SYK may regulate tau clearance since we have observed that SYK 
upregulation promotes tau accumulation without affecting tau expression (Schweig et al. 2017). 
As tau clearance is known to be regulated via autophagy, we therefore investigated the possible 
impact of SYK inhibition on the mTOR pathway and autophagic degradation of tau in SH-SY5Y 
cells.  
 
3.3.1 SYK inhibition decreases p-tau, as well as total tau levels and reverses the effects of 
the Akt activator SC79 on the mTOR pathway  
 
We show that SYK inhibition using the selective SYK inhibitor BAY61-3606 (Yamamoto et al. 
2003) decreases p-tau (S396/404) levels significantly (Figure 20A) in SH-SY5Y cells and reduces 
total tau levels (Figure 20A).  
In parallel with the reduction of total tau levels induced by SYK inactivation with BAY61-
3606, an inhibition of several members of the mTOR pathway was observed (Figure 20B). 
Compared to untreated control cells, p-Akt (S473) and p-S6K (T389, T412) levels were 
significantly lower following SYK inhibition (Figure 20B, p<0.01). As expected, the Akt activator 
SC79 stimulated the mTOR pathway, as it increases the phosphorylation levels of p-S6K (T389, 
T412) and p-mTOR (S2448) significantly (Figure 20B, p<0.01). We show that SYK inhibition 
reverses the effects of the Akt activator and decreases the phosphorylation levels of p-Akt (S473), 
p-S6K (T389, T412), p-mTOR (S2448) induced by SC79 (Figure 20B, p<0.001). Interestingly, 
baseline levels of mTOR phosphorylation remained unchanged following SYK inhibition but 
elevated mTOR phosphorylation following SC79 activation were brought back to baseline levels 
following SYK inhibition, suggesting that SYK inhibition can antagonize dysregulated mTOR 
phosphorylation (Figure 20B).   
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 Figure 20: SYK inhibition decreases p-tau, as well as total tau levels and reverses the effects of 
the Akt activator SC79 on the mTOR pathway 
A) Representative Western blots depicting p-tau (S396/404) and total tau are shown. Western blots 
chemiluminescent signals were quantified by densitometry and normalized to actin. The histogram 
represents the quantification of p-tau (S396/404) and t-tau following a 24h treatment of SH-SY5Y cells 
with 5μM or 10μM of the SYK inhibitor BAY61-3606. ANOVA with post-hoc Bonferroni test revealed 
significantly decreased tau phosphorylation at S396/404 (p<0.001) and total tau (p<0.05) levels following 
SYK inhibition (n=4 for each treatment condition).  
B) Representative Western blots depicting p-mTOR (S2448), p-S6K (T389, T412) and p-Akt (S473) are 
shown. Western blots chemiluminescent signals were quantified by densitometry and normalized to actin. 
The histogram represents the quantification of p-mTOR (S2448), p-S6K (T389, T412) and p-Akt (S473) 
following a 24h treatment of SH-SY5Y cells with 5μM of the SYK inhibitor BAY61-3606 and 20μM of 
the Akt activator SC79 and a combination thereof. ANOVA with post-hoc Bonferroni test revealed 
significantly decreased p-Akt (S473) (p<0.01) and p-S6K (T389, T412) (p<0.01, p<0.001) levels 
following SYK inhibition (n=3) and also significantly increased p-mTOR (S2448) (p<0.01) and p-S6K 
(T389, T412) (p<0.01) levels following Akt activation. SYK inhibition reverses these effects 
significantly in the double treatment (n=3 for each treatment condition).  
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3.3.2 SYK inhibition reverses the effects of the mTOR activator MHY1485 and mimics the 
effects of the mTOR inhibitor KU0063794  
 
We further investigated the effects of SYK inhibition on the mTOR pathway and determined 
whether SYK inhibition can overcome the impact of the mTOR activator MHY1485. We also 
tested the effects of the mTOR inhibitor KU0063794 on phosphorylated and total tau levels in SH-
SY5Y cells to determine whether direct mTOR inactivation can mimic the effects of SYK 
inhibition. mTOR activation with MHY1485 significantly increased p-mTOR (S2448), p-S6K 
(T389, T412), and p-tau (S396/404) levels while mTOR inhibition with KU0063794 significantly 
decreased p-Akt (S473), p-S6K (T389, T412) and p-mTOR (S2448) levels compared to the 
untreated control cells (Figure 21A-B). The levels of t-tau, p-tau (S396/404) were also significantly 
lower in cells that were treated with the mTOR inhibitor than in cells that were treated with the 
mTOR activator (Figure 21A-B). In fact, mTOR inhibition appears to be mimicking the effects of 
SYK inhibition on the mTOR pathway (Figure 20-Figure 21). Interestingly, SYK inhibition was 
able to antagonize the increased p-tau (S396/404), p-S6K (T389, T412), p-mTOR (S2448) and p-
Akt (S473) levels induced by MHY1485 (Figure 21C-D). A trend for an increase in total tau levels 
was observed following 24 hours of treatment with the mTOR activator MHY1485 which was also 
prevented by SYK inhibition (Figure 21C-D) showing that SYK inhibition can overcome the 
effects of a stimulation of the mTOR pathway. In summary, these results show that SYK inhibition 
and direct mTOR inhibition have similar effects on the mTOR pathway and tau levels. 
Furthermore, SYK inhibition can reverse the effects of mTOR activation on members of the mTOR 
pathway and tau, thereby underlining a role of SYK as an upstream modulator of the mTOR 
pathway and regulator of autophagic tau degradation.     
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 Figure 21: SYK inhibition reverses the effects of the mTOR activator 
MHY1485 and mimics the effects of the mTOR inhibitor KU0063794 
SH-SY5Y cells were treated for 24h with A-B) 4μM of the mTOR activator 
MHY1485 or 1-2μM of the mTOR inhibitor KU0063794 or C-D) a combination of 
6-12μM of the mTOR activator MHY1485 and 5μM of the SYK inhibitor BAY61-
3606.  
A) Representative Western blots depicting p-mTOR (S2448), p-S6K (T389, T412), 
p-Akt (S473), p-tau (S396/404) and t-tau are shown.  
B) Western blots chemiluminescent signals were quantified by densitometry, 
normalized to actin and presented as histograms. ANOVA with post-hoc Bonferroni 
test revealed significantly increased p-mTOR (S2448) (p<0.05), p-S6K (T389, T412) 
(p<0.01, p<0.0001) and p-tau (S396/404) (p<0.05) levels compared to untreated 
control cells following mTOR activation by MHY1485, whereas mTOR inhibition by 
KU0063794 decreased p-S6K (T389, T412) (p<0.0001, p<0.01) and p-Akt (S473) 
(p<0.01) levels significantly compared to control (n=3 for each treatment condition). 
C) Representative Western blots depicting p-mTOR (S2448), p-S6K (T389, T412), 
p-Akt (S473), p-tau (S396/404) and t-tau are shown.  
D) Western blots chemiluminescent signals were quantified by densitometry, 
normalized to actin and presented as histograms. ANOVA with post-hoc Bonferroni 
test revealed that the combination of the mTOR activator and the SYK inhibitor 
results in significantly decreased p-mTOR (S2448) (p<0.01), p-S6K (T389, T412) 
(p<0.01), p-Akt (S473) (p<0.01) and p-tau (S396/404) (p<0.01) levels compared to 
untreated control cells (n=3 for each treatment condition). 
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3.3.3 SYK inhibition increases the autophagic flux and decreases tau levels in the presence 
of the lysosomal inhibitor chloroquine 
 
Having shown that SYK acts upstream of mTOR and thereby influences the autophagic 
degradation of tau, we investigated whether SYK inhibition could impact the autophagic flux by 
quantifying the amount of the microtubule-associated protein 1A/1B-light chain (LC3). During 
autophagy initiation, soluble cytosolic LC3-I gets lipidated and the resulting LC3-II becomes 
associated with the inside and outside of autophagosomal membranes (Kabeya et al. 2000). After 
the fusion of autophagosomes with lysosomes, LC3-II is degraded. Hence, the ratio of unlipidated 
LC-I to lipidated LC3-II can be used to measure the autophagic flux, the rate of autophagy 
initiation and lysosomal degradation (Mizushima and Yoshimori 2007; Pugsley 2017). Since an 
increased in LC3-II levels following a drug treatment could be indicative of either an increased in 
autophagy initiation or a decreased in lysosomal degradation, we employed a lysosome inhibitor 
(chloroquine (CQ)) to determine the rate of autophagy initiation, as previously described 
(Mizushima and Yoshimori 2007; Tanida et al. 2008). CQ accumulates in the lysosomes and raises 
their pH. Thereby, CQ decreases the functionality of lysosomal proteases and inhibits the fusion 
of lysosomes and autophagosomes. Therefore, CQ allows the observation of the conversion rate 
of LC3-I to LC3-II (autophagy initiation) by limiting the degradation of LC3-II. We treated SH-
SY5Y cells for 24h with two different doses of CQ (100μM and 200μM) alone or in combination 
with 5μM of the SYK inhibitor BAY61-3606. CQ treatment significantly increased, p-S6K (T389), 
p-mTOR (S2448) and t-tau levels (Fig. 3A-B) showing an inhibition of lysosomal t-tau 
degradation. As expected, CQ treatment also increased the ratio of LC3-II/I by decreasing the 
degradation of LC3-II (Figure 22C). Importantly, the increased levels of p-S6K (T389), p-mTOR 
(S2448) and t-tau levels induced by CQ were significantly reduced following SYK inhibition 
(Figure 22A-B). The ratio of LC3II/I was further increased after a double treatment with CQ and 
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BAY61-3606 compared to CQ alone (Figure 22C). Since the degradation of LC3-II is inhibited by 
CQ, the additional increase of LC3-II observed in cells treated with CQ and the SYK inhibitor 
suggests that SYK inhibition accelerates the conversion of LC3-I into LC3-II and therefore 
stimulates the autophagic flux. The increased degradation of t-tau following the co-treatment with 
CQ and the SYK inhibitor compared to CQ alone (Figure 22) suggests that SYK inhibition not 
only increases autophagy initiation but may also increase the lysosomal degradation of tau which 
was antagonized by CQ. 
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 Figure 22: SYK inhibition increases the autophagic flux and decreases tau levels in the presence 
of the lysosomal inhibitor chloroquine 
SH-SY5Y cells were treated for 24h with 100-200μM of the lysosomal inhibitor chloroquine (CQ) or a 
combination of 100-200μM of CQ and 5μM of the SYK inhibitor BAY61-3606.  
A) Representative Western blots depicting p-mTOR (S2448), p-S6K (T389, T412), p-tau (S396/404), t-
tau, and LC3-I/II are shown. 
B-C) Western blots chemiluminescent signals were quantified by densitometry, normalized to actin and 
presented as histograms.  
B) ANOVA with post-hoc Bonferroni test revealed significantly increased p-mTOR (S2448) (p<0.001), 
p-S6K (T389) (p<0.001) and t-tau (p<0.05) levels compared to untreated control cells following 
lysosomal inhibition by CQ, whereas a combination of CQ and the SYK inhibitor reverses the effects of 
CQ, leading to significantly decreased p-mTOR (S2448) (p<0.01), p-S6K (T389, T412) (p<0.0001, 
p<0.05) and t-tau (p<0.01) levels compared to CQ alone (n=4 for each treatment condition).  
C) ANOVA with post-hoc Bonferroni test revealed that the combination of the lysosomal and the SYK 
inhibitor results in significantly increased autophagic flux compared to CQ alone (CQ [100μM]+BAY61-
3606, p<0.05, CQ [200μM]+BAY61-3606, p<0.0001), as measured by LC3II/I while LC3-I levels are 
not altered significantly (n=4 for each treatment condition). 
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3.3.4 SYK inhibition does not affect tau translation or transcription 
 
Since SYK acts upstream of the mTOR pathway and the downstream kinase S6K is known to be 
involved in translation, we investigated whether SYK inhibition and S6K inhibition could impact 
tau translation (Figure 23). We show that the reduction in t-tau protein level following SYK 
inhibition is not caused by a reduction of t-tau transcription as measured by RT-PCR (mRNA) 
(Figure 23). We then assessed protein translation in SH-SY5Y cells that were treated for 24h with 
either 5μM or 10μM of the SYK inhibitor BAY61-3606 or 5μM, 10μM of the S6K inhibitor 
PF4708671 or 20μM cycloheximide (inhibitor of protein translation used as a positive control) 
(Figure 23A). Protein translation was quantified using the SUrface SEnsing of Translation 
(SUnSET) techniques (Schmidt et al. 2009) by monitoring puromycin incorporation in newly 
synthesized proteins. Both SYK inhibition and S6K inhibition significantly decreased puromycin 
incorporation, particularly in proteins of higher molecular weight (Figure 23A). This may suggest 
a general effect of SYK inhibition on translation that is possibly mediated by S6K inhibition, since 
SYK inhibition completely prevents S6K phosphorylation and since a direct S6K inhibition 
mimics the impact of SYK inhibition on protein translation (Figure 23A-B). However, isolation of 
newly synthesized proteins by immunoprecipitation using an anti-puromycin antibody followed 
by Western-blot analysis using a total tau antibody (DA9) to quantify the amount of nascent tau, 
reveals no impact of SYK inhibition (Figure 23C-D) on tau protein translation. In addition, t-tau 
and 3R mRNA levels in SH-SY5Y cells are not impacted by SYK inhibition with 5μM BAY61-
3606 for 4h, 8h, 12h and 24h (Figure 23E-F) showing that SYK inhibition does not affect tau 
expression at the mRNA level. These data further demonstrate that the decrease in t-tau level, 
observed following SYK inhibition, is mainly caused by an increase in autophagic tau degradation, 
rather than a decreased level of tau translation or transcription. 
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In a subsequent experiment, we tested the effects of S6K inhibition by PF4708671 on the mTOR 
pathway and tau degradation. S6K inhibition using 10μM of PF4708671 leads to a significant 
reduction in p-mTOR (S2448) and p-S6K (T389, T412) levels (Figure 24A-B). p-Akt (S473) levels 
remain unchanged following S6K inhibition. This could imply the existence of a feedback 
mechanism following S6K inhibition on the mTOR pathway, as S6K is a downstream kinase of 
mTOR. In fact, S6K has been shown to phosphorylate mTOR (S2448) (Chiang and Abraham 
2005) and the reduction in mTOR phosphorylation that we observed with PF4708671 are 
consistent with that observation. A non-significant trend for a decrease in p-tau (S396/404) and t-
tau levels was observed in SH-SY5Y cells (Figure 24A, C) following 24 hours of treatment with 
the S6K inhibitor, suggesting that the S6K inhibition observed following SYK inactivation does 
not play a major role in the increased tau clearance induced by SYK inhibition.      
In summary, these in vitro data show an upstream modulatory role of SYK on the mTOR pathway 
in SH-SY5Y cells and suggest that SYK is a major kinase that regulates the autophagic degradation 
of tau. Our data suggest that SYK inhibition increases tau degradation in SH-SY5Y cells by 
inhibiting the mTOR pathway and increasing the autophagic flux.   
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 Figure 23: SYK inhibition does not alter transcription or translation levels of tau in vitro 
A-B) The SUrface SEnsing of Translation (SUnSET) technique (Schmidt et al., 2009) was used to assess 
the impact of SYK inhibition on protein translation. SH-SY5Y cells were treated with 5-10μM of the 
SYK inhibitor BAY61-3606 or 5-10μM of the S6K inhibitor PF4708671 for 24 hours or with 
cycloheximide for 5 hours. Cells were then treated for 1 hour with 10 μg/ml of puromycin. Levels of 
newly synthesized proteins containing puromycin were then detected by Western blot using an anti-
puromycin antibody.  
A) Representative Western blots depicting puromycin and actin are shown. B) Western blots 
chemiluminescent signals were quantified by densitometry, normalized to actin and presented as 
histograms. ANOVA with post-hoc Bonferroni test revealed total levels of translation are significantly 
reduced following SYK inhibition (5μM p<0.05; 10μM p<0.01) or S6K inhibition (10μM p<0.01) or 
following cycloheximide treatment (20μM p<0.0001) (n=4 for each treatment condition).  
C-D) Anti-puromycin antibodies and protein A-magnetic beads were used for immunoprecipitation of 
the cell lysate following treatment with 5μM of BAY61-3606. Western blot analysis with anti-puromycin 
and anti-t-tau antibodies, quantification (as in A-B) and subsequent unpaired t-test (D) revealed no 
significant difference in total tau translation levels following SYK inhibition while puromycin levels 
were significantly decreased (p<0.05) (n=3 for each treatment condition).  
E-F) mRNA levels of total tau and 3R tau were measured by RT-PCR following different durations of 
treatment with 5μM of the SYK inhibitor BAY61-3606. ANOVA with post-hoc Bonferroni test revealed 
no significant difference of tau mRNA levels treated with BAY61-3606 for 4, 8, 12 or 24h versus 
untreated control (n=4 for each treatment condition).   
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 Figure 24: S6K inhibition by PF4708671 has similar effects as SYK inhibition on the mTOR 
pathway and tau levels 
SH-SY5Y cells were treated for 24h with 5-10μM of the S6K inhibitor PF4708671. Western blots were 
quantified, normalized to actin and expressed relative to the untreated control cells.  
A) Representative Western blots depicting p-mTOR (S2448), p-S6K (T389, T412), p-Akt (S473), p-tau 
(S396/404), and t-tau are shown. B-C) Western blots chemiluminescent signals were quantified by 
densitometry, normalized to actin and presented as histograms. B) ANOVA and post-hoc Bonferroni test 
revealed that p-mTOR (S2448) (p<0.001) and p-S6K (T389, T412) (p<0.001, p<0.01) levels were 
reduced significantly compared to control following S6K inhibition. P-Akt levels remained unchanged. 
C) Total tau and p-tau (S396/404) were slightly reduced at the highest dose of PF4708671 (n=4 for each 
treatment condition). 
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3.3.5 Suppression of SYK expression mimics pharmacological inhibition of SYK and 
decreases total tau levels 
 
To validate the data obtained following pharmacological inhibition of SYK with BAY61-3606 and 
ensure that the effects observed were mediated by SYK inhibition, we knocked down SYK by 
stably overexpressing a SYK shRNA in SH-SY5Y cells. As expected, a significant decrease in 
total SYK (t-SYK) (Figure 25) was observed in the SYK knockdown SH-SY5Y cells compared to 
control SH-SY5Y cells that were stably transfected with a non-sense shRNA using the same 
vector. We show that SYK knockdown significantly decreases p-mTOR (S2248), p-S6K (T389), 
p-Akt (S473), p-tau (S396/404) and t-tau levels (Figure 25A-B) mimicking the effects of the SYK 
inhibitor BAY61-3606 in SH-SY5Y cells. Interestingly, LC3-I and LC3-II were both significantly 
decreased in the SYK knockdown cells while their ratio remained unchanged (Fig. 6A). These data 
suggest that genetic suppression of SYK expression leads to an increased autophagy initiation 
(LC3-I conversion to LC3-II) and an enhancement of lysosomal LC3-II degradation. To further 
test this hypothesis, we treated both control and SYK knockdown cells for 24h with 200μM of the 
lysosomal inhibitor chloroquine (CQ). In presence of CQ, the SYK knockdown cells exhibited a 
significantly increased ratio of LC3-II/I as observed in SH-SY5Y cells treated with CQ and 
BAY61-3606, implying an increased autophagic flux and suggesting that SYK may impact both 
the autophagy initiation and lysosomal degradation (Figure 25C).    
Overall our data show that the knockdown of SYK mimics the data obtained following 
pharmacological inhibition of SYK in SH-SY5Y cells resulting in an inhibition of key members 
of the mTOR pathway and further establishes a key role of SYK as an upstream modulator of the 
mTOR pathway. 
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 Figure 25: SYK knockdown mimics pharmacological inhibition of SYK and decreases total tau 
levels 
Lentiviral vectors expressing SYK specific shRNAs or nonsense control shRNAs were used to stably 
knockdown SYK gene expression in SH-SY5Y cells.  
A-B) Representative Western blots depicting p-mTOR (S2448), p-S6K (T389, T412), t-SYK, and LC3-
I/II, as well as p-Akt (S473), p-tau (S396/404), and t-tau are shown. Western blots chemiluminescent 
signals were quantified by densitometry, normalized to actin and presented as histograms. Unpaired t-
tests revealed that in SYK knockdown cells in which t-SYK was decreased significantly (p<0.0001), p-
mTOR (S2448) (p<0.05), p-S6K (T389) (p<0.05), p-Akt (S473) (p<0.0001), t-tau (p<0.0001) and p-tau 
(S396/404) (p<0.0001) levels were also significantly decreased (n=6). LC3-I and LC3-II levels were 
significantly decreased in SYK knockdown cells compared to control (p<0.0001) but the ratio of both 
remains unchanged.  
C) Both SYK knockdown and control cells were treated for 24h with 200μM of the lysosomal inhibitor 
chloroquine (CQ). Representative Western blots depicting t-SYK, and LC3-I/II are shown. Western blots 
chemiluminescent signals were quantified by densitometry, normalized to actin and presented as 
histograms. Unpaired t-tests revealed that in SYK knockdown cells in which t-SYK was decreased 
significantly (p<0.0001), the ratio of LC3-II/I was significantly increased (p<0.001) (n=6 for each 
treatment condition).    
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3.4 Discussion 
 
Our previous data have shown that SYK is upregulated in the brain of AD patients and in mouse 
models of AD (Schweig et al. 2017). In particular, we have shown that SYK is overactivated in 
neurons affected by the tau pathology and that SYK upregulation promotes tau accumulation 
without affecting tau expression (Schweig et al. 2017). In the present study, we show that SYK 
inhibition as well as genetic suppression of SYK expression lower total tau levels in SH-SY5Y 
cells without impacting tau expression at the mRNA level or tau protein translation, suggesting 
that other mechanisms are responsible for the increased tau clearance observed following SYK 
inhibition. Therefore, we investigated the possible effects of SYK inhibition on the mTOR 
pathway and autophagic degradation of tau in SH-SY5Y cells as autophagy plays a pivotal role in 
tau degradation (Chesser et al. 2013).   
We show for the first time that SYK can regulate the mTOR pathway in neuronal like SH-
SY5Y cells and promote the autophagic clearance of tau. These data are consistent with previous 
studies that have highlighted the role of SYK on the mTOR pathway in immune and cancerous 
cells (Bartaula-Brevik et al. 2018; Carnevale et al. 2013; Choi et al. 2015; Fruchon et al. 2012; 
Gao et al. 2017; Krisenko et al. 2015; Leseux et al. 2006). Autophagy is crucial for maintaining 
the intracellular homeostasis by regulating the turnover of misfolded or damaged proteins, 
organelles and eliminating dysfunctional components. A decreased functionality of the autophagic 
degradation system has therefore been linked to aging and neurodegenerative diseases (Cuervo 
2008; Eskelinen and Saftig 2009; Funderburk et al. 2010; Ghavami et al. 2014; Lee et al. 2010; 
Menzies et al. 2015; Nixon 2007; Nixon and Yang 2011).  Many studies have now demonstrated 
the beneficial effects of mTOR inhibition in mouse models of AD and tauopathy, resulting in 
increased autophagy and in an amelioration of tau pathologies (Jiang et al. 2014b; Ozcelik et al. 
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2013; Schaeffer et al. 2012; Wang et al. 2016), suggesting that manipulating the mTOR pathway 
may represent an attractive therapeutic strategy for the treatment of neurodegenerative 
proteinopathies. 
In this study, we demonstrate that SYK inhibition leads to an increased total tau 
degradation via the mTOR-dependent autophagy pathway while transcription and translation 
levels of tau remain unchanged. By examining the effects of SYK inhibition on members of the 
mTOR pathway, using selective inhibitors and activators of the mTOR pathway in combination 
with the SYK inhibitor BAY61-3606, we confirmed that SYK acts upstream of the mTOR pathway 
and thereby modulates autophagy in a neuron-like cell line (SH-SY5Y). We show, for example, 
that the dysregulation of the mTOR pathway, as well as the tau accumulation induced by the AKT 
stimulator SC79 or by MHY1485 (a direct activator of mTOR) can be reversed by SYK inhibition. 
We also confirm that inhibition of mTOR with KU0063794 can mimic the effects of SYK 
inhibition and increase the clearance of tau in SH-SY5Y cells. In addition, the treatment with CQ 
in combination with the SYK inhibitor revealed an increased autophagic flux following SYK 
inhibition, as measured by an increase in the LC3II/I ratio, as well as mTOR and S6K inhibition 
and increased tau degradation. To validate the data obtained with the SYK inhibitor BAY61-3606, 
we also generated an SH-SY5Y cell line in which SYK has been stably knocked down. We confirm 
that tau degradation is stimulated and that the mTOR pathway is also inhibited in this SYK 
knockdown cell line, showing that the effects of BAY61-3606 on tau clearance are recapitulated 
by genetic suppression of SYK expression and are therefore attributable to an inhibition of SYK.  
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The data presented in this chapter illustrate that SYK acts as a regulator of autophagy in cells 
derived from the CNS. The observations made in this study not only provide further evidence for 
an important role of SYK in the pathogenesis of AD and the development of tau pathologies but 
also demonstrate that pharmacological SYK inhibition may represent a promising therapeutic 
strategy for the treatment of AD and other neurodegenerative proteinopathies. 
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 Figure 26: Schematic depiction of the role of SYK in the mTOR pathway and autophagy 
The schematic describes the role of SYK in the mTOR pathway and autophagic tau degradation and 
highlights the findings presented in this chapter. The mTOR pathway including PI3K, PDK1, Akt, 
TSC1/2, Rheb, mTOR and S6K and their role in regulation of autophagy have been well described in the 
literature (for review see (Sarkar, 2013). Our previous studies revealed SYK as an upstream regulator of 
PKA, GSK3-ȕ, and PI3K (Paris et al., 2014). PI3K is recognized as an upstream member of the mTOR 
pathway and GSK3-ȕ is known to regulate raptor which is known to form a complex with mTOR (C1) 
and enhance its downstream signaling. In this present study, we used different activators and inhibitors 
of members of the mTOR pathway (see legend) to elucidate the effect of SYK inhibition on the mTOR 
pathway. Our mechanistic experiments lead to the conclusion that SYK acts upstream of the mTOR 
pathway and thereby influences the activity levels of different members of that pathway and the 
autophagic degradation of tau. mTOR itself is known to inhibit autophagy. mTOR prevents the 
transcription factor EB (TFEB) from entering the nucleus, thereby preventing the transcription of 
autophagy related genes (ATGs), leading to a decreased autophagy initiation. Furthermore, the kinase 
S6K downstream of mTOR is involved in translation. Our results show that SYK inhibition leads to a 
decreased activation of the mTOR pathway and results in an increased autophagic flux (LC3-I to LC3-II 
conversion), leading to an increased lysosomal degradation of tau.      
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4 Effects of chronic SYK inhibition in Tg Tau P301S mice 
 
4.1 Introduction 
 
In the previous chapter we delineated the role of SYK in the autophagic degradation of tau in a 
neuroblastoma cell line (SH-SY5Y). Our mechanistic in vitro studies identified SYK as an 
upstream regulator of the mTOR pathway and autophagic tau degradation and showed that an 
inhibition of SYK may be beneficial for the treatment of tauopathies. Therefore, we investigated 
the effects of pharmacological SYK inhibition in a chronic treatment paradigm over twelve weeks 
in a mouse model with established tauopathy (30-week-old Tg Tau P301S) and age-matched wild-
type littermates (Figure 27). We assessed the effects of SYK inhibition on key members of the 
mTOR pathway, tau pathology, behavior (motor and learning), and neuroinflammation.  
As mentioned in the previous chapter, the neurodegeneration observed in proteinopathies 
is, at least partly, caused by a dysfunctional degradation of proteins that are prone to aggregate and 
an impaired autophagic clearance of macromolecules has been widely accepted to be a major 
contributor to various neurodegenerative diseases by promoting the accumulation of misfolded 
proteins (Nixon 2007; Nixon and Yang 2011; Ghavami et al. 2014; Menzies et al. 2015). mTOR 
is known to regulate autophagy (Jung et al. 2010). AD and FTLD share the accumulation of tau as 
a common underlying pathology. In human AD and FTLD cases, as well as in mouse models of 
AD and pure tauopathy, autophagy has been found to be decreased (Zare-Shahabadi et al. 2015; 
Kragh et al. 2012; Wang et al. 2012) and to contribute to the pathological accumulation of tau 
aggregates. Impaired autophagy has been linked to an overactive mTOR pathway which acts as a 
regulator of autophagy initiation and lysosomal degradation, thereby controlling the autophagic 
flux (Jung et al. 2010; Puertollano 2014).  
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Previous studies of other research groups have investigated the effects of autophagy activation 
(pharmacological mTOR inhibition or autophagy initiation by trehalose or TFEB) in tau mouse 
models. More precisely, in Tg Tau P301S mice direct inhibition of mTOR with either rapamycin 
or temsirolimus attenuated tau pathology (Ozcelik et al. 2013; Jiang et al. 2014b). Furthermore, 
stimulation of autophagy by trehalose or by the overexpression of the transcription factor EB 
(TFEB) were both shown to be efficient in reducing neurodegeneration and mitigating tauopathy 
in Tg Tau P301S mice (Schaeffer et al. 2012; Wang et al. 2016) suggesting that inhibiting mTOR 
may have therapeutic value for the treatment of tauopathies.  
The involvement of SYK in microglial activation and cytokine production has been 
investigated in previous in vitro studies by other groups. For example, SYK has been shown to 
mediate the activation of microglial cells induced by Aȕ oligomers (Combs et al. 1999; McDonald 
et al. 1997), while SYK inhibition has been shown to prevent Aȕ-mediated neurotoxicity in vitro 
(Combs et al. 1999). A subsequent study also demonstrated that SYK was the mediator of the Aȕ-
induced elevated cytokine production including interleukin 1 beta (IL-1ȕ) and tumor necrosis 
factor alpha (TNFα) which is responsible for increased iNOS expression resulting in apoptosis in 
primary mouse neuronal cultures (Combs et al. 2001). In addition, it has been suggested that SYK 
contributes to microglial dysfunction in AD (Ghosh and Geahlen 2015). Therefore, we also aimed 
to investigate the effects of chronic SYK inhibition in vivo on neuroinflammation, including 
microglial and astroglial markers, as well as cytokine levels in brain and plasma. 
In our previous studies, we found that SYK inhibition can decrease tau 
hyperphosphorylation in vitro, and in vivo in mouse models of tauopathy following an acute 
treatment (Paris et al. 2014), in part, by promoting the phosphorylation of GSK3-ȕ at the inhibitory 
Ser9 site (Paris et al. 2014). In addition, we have shown that SYK activation, as measured by p-
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SYK (Y525/526) levels, is largely increased subsets of activated microglia of Aȕ-overexpressing 
mouse models of AD (Tg PS1/APPsw, Tg APPsw) and in neurons of a mouse model of tauopathy 
(Tg Tau P301S) displaying pathological tau species while neurons of wild-type animals showed 
no activation of SYK (Schweig et al. 2017), suggesting that SYK plays a key role in the formation 
of AD pathological lesions. Similarly, we observed  an increased SYK activation in dystrophic 
neurites and in neurons affected by the tau pathology in human AD specimens (Schweig et al. 
2017).  
In the previous chapter we have shown that key members of the autophagic pathway 
including Akt, mTOR and S6K can be largely influenced by SYK, thereby implying an indirect 
control of SYK over the autophagic degradation of proteins and providing an explanation for the 
decreased total tau levels observed following SYK inhibition. Therefore, we wanted to investigate 
the long-term effects of a chronic SYK inhibition in vivo on mTOR and S6K, as well as on tau 
pathological species.   
In this chapter, we show that chronic SYK inhibition lowers pathological tau accumulation 
in Tg Tau P301S mice by inhibiting hyperactive mTOR. Furthermore, chronic SYK inhibition 
reduces the levels of pro-inflammatory cytokines, neuronal and synaptic loss and improves 
locomotor deficits in Tg Tau P301S mice.  
These data not only provide further evidence for an important role of SYK in the 
pathogenesis of AD and the development of tauopathies but also illustrate that pharmacological 
SYK inhibition may represent a promising therapeutic strategy for the treatment of AD and other 
neurodegenerative proteinopathies associated with a defective autophagic clearance of misfolded 
proteins.  
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4.1.1 Study design  
 
 
30-week-old Tg Tau P301S mice and wild-type (WT) littermates were injected 
intraperitoneally with either PBS (vehicle) or 20mg/kg of the SYK inhibitor BAY61-3606 five 
consecutive days per week for a total of 12 weeks. 45 animals were treated in total (WT-PBS 
(n=11), WT-BAY61-3606 (n=11), Tg Tau P301S-PBS (n=11), Tg Tau P301S-BAY61-3606 
(n=12)). The motor performance was assessed with the rotarod every 14 days and the spatial 
memory was assessed on five consecutive days starting in week 8 and an additional probe day 14 
days after the last test day. After 12 weeks of treatment, brain homogenates were used to assess 
target engagement (t-SYK and p-SYK levels), as well as pathological tau species (soluble and 
insoluble), neuroinflammation (Iba-1, GFAP, iNOS, cytokines), neurodegeneration (NeuN, PSD-
95), and effects on autophagic and lysosomal markers (mTOR, S6K, LAMP-1).  
  
 
 
 
 
 
 
 
 
 
 
Figure 27: Study design for 12-week chronic SYK inhibition   
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4.2 Methods 
 
4.2.1 Animals 
 
All mice were maintained under specific pathogen free conditions in ventilated racks in the 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC) accredited vivarium of the Roskamp Institute. All experiments involving mice were 
reviewed and approved by the Institutional Animal Care and Use Committee of the Roskamp 
Institute before implementation and were conducted in compliance with the National Institutes of 
Health Guidelines for the Care and Use of Laboratory Animals. Tg Tau P301S (Yoshiyama et al. 
2007) mice were obtained from the Jackson Laboratories (ME, USA) and bred with C57BL/6J 
mice to produce the Tg Tau P301S and wild-type littermates used in this study.  
 
4.2.2 In vivo treatment 
 
30-week-old Tg Tau P301S mice and wild-type (WT) littermates were injected with either PBS 
(vehicle) or 20mg/kg of the SYK inhibitor BAY61-3606 five consecutive days per week for a total 
of 12 weeks. 45 animals were treated in total (WT-PBS (n=11), WT-BAY61-3606 (n=11), Tg Tau 
P301S-PBS (n=11), Tg Tau P301S-BAY61-3606 (n=12)). 2-(7-(3,4-dimethoxyphenyl) 
imidazo[1,2-c] pyrimidin-5-ylamino) nicotinamide hydrochloride hydrate (BAY61-3606) was 
synthetized as previously described (Takeshi Yura, Arnel B. Concepcion, Gyoonhee Han, Makiko 
Marumo, Hiroko Katsumata, Norihiro Kawamura, Toshio Kokubo, Hiroshi Komura, Yingfu Li, 
Timothy B. Lowinger, Muneto Mogi, Noriyuki Yamamoto, Nagahiro Yoshida, Scott Miller, 
Margaret A. Popp, Aniko M. Redmann, Martha E. Rodriguez, William J. Scott, Ming Wang 2001). 
The identity and purity of the compound obtained was analyzed by tandem mass spectroscopy 
(MS (ESI, pos. ion) m/z: 391.1 (M+1)). The activity of the synthesized BAY61-3606 was further 
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compared against a batch of BAY61-3606 obtained by a commercial vendor (Sigma-Aldrich, MO, 
USA) by assessing its potency for inhibiting p65-NFκB and STAT3 phosphorylation induced by 
TNFα in SH-SY5Y cells as previously described (Paris et al. 2014) (data not shown). 
 
4.2.3 Behavioral Analysis 
 
The spatial memory of the mice was assessed after 8 weeks of treatment with either PBS or 
20mg/kg of the SYK inhibitor BAY61-3606 using the radial arm water maze (RAWM). The mice 
underwent 9 trials per day for a total of five consecutive days plus an additional probe day two 
weeks after the fifth day of testing (day 20). The RAWM consists of six arms that are 
distinguishable by unique visual cues. The mice were placed into one of the five arms and had to 
find the hidden platform in the sixth arm. Each trial ended after one minute and errors were 
calculated after tracking the movements using the EthoVision software (Noldus, VA, USA). Motor 
performance was assessed using a Rotarod apparatus every 14 days. The mice were placed onto a 
horizontally oriented, rotating cylinder. The baseline level was set to 5 rpm. The speed of the 
rotation of the cylinder was set up to increase to 50 rpm within 1 minute. The latency to fall was 
measured in seconds. Each mouse underwent 3 trials per day and the average latency to fall was 
calculated. Mice showing signs of partial paralysis of the hind limbs were excluded from the 
behavioral assessments.      
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4.2.4 Tissue Processing 
 
All mice were humanely euthanatized and their brains were collected, snap-frozen in liquid 
nitrogen and stored at -80˚C until processing. The method of euthanasia used follows the AVMA 
(American Veterinary Medical Association) guidelines for the euthanasia of animals. Briefly, mice 
were rendered unconscious through inhalation of 5% isoflurane in oxygen using a vaporizer and a 
gas chamber. While under anesthesia, after verifying the absence of reflexes, mice were 
euthanatized by exsanguination (blood was withdrawn from cardiac puncture). 
Subsequently, the brains were homogenized in Mammalian Protein Extraction Reagent (M-
PER™, Thermo Fisher Scientific, MA, USA) containing Halt protease & phosphatase single use 
inhibitor/EDTA (Thermo Fisher Scientific, MA, USA) and 1 mM PMSF. Brain homogenates were 
centrifuged at 4˚C, 21,817xG for 30 minutes. The supernatant (detergent soluble fraction) was 
collected and stored at -80˚C until being assayed for total tau and phosphorylated tau as described 
below. The pellet (detergent insoluble fraction) was re-suspended by sonication in M-PER (1v:1v). 
A portion of this detergent insoluble fraction was treated with an equal volume of 5M guanidine 
isothiocyanate to dissociate and re-solubilize tau aggregates and quantify the amount of detergent 
insoluble total tau and phosphorylated tau at multiple epitopes as described below.  The remaining 
portion of the detergent insoluble fraction was used to assess the levels of tau oligomers and tau 
pathogenic conformers under native conditions as described below.   
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4.2.5 Immunoblotting 
 
For dot blots, 3μl of each sample were pipetted onto a nitrocellulose membrane (pore size 45μm, 
Bio-Rad Laboratories, CA, USA). Membranes were blocked in TBS containing 5% non-fat dried 
milk for 1h and were hybridized with the primary antibody (anti-SYK (4D10, 1:1000, Santa Cruz, 
TX, USA), anti-p-tau S396/404 (PHF-1, 1:1000, Dr. Peter Davies’ Lab), anti-t-tau (DA9, 1:1000, 
Dr. Peter Davies’ Lab), anti-p-tau S202 (CP13, 1:1000, Dr. Peter Davies’ Lab), anti-p-tau T231 
(RZ3, 1:1000, Dr. Peter Davies’ Lab), anti-conformer-tau (MC1, 1:1000, Dr. Peter Davies’ Lab), 
anti-oligomeric-tau (TOC1, 1:1000, Dr. Lester Binder’s Lab), anti-p-SYK (Y525/526), anti-p-
mTOR (S2448), anti-p-S6K (T389/T412), anti-NeuN, anti-LAMP-1, anti-iNOS (all 1:1000, Cell 
Signaling, MA, USA), anti-GFAP (1:5000, DAKO, USA), anti-Iba1 (1:1000, Abcam, MA, USA), 
anti-beta-tubulin (1:1000, BD Biosciences, CA, USA) overnight at 4˚C. Subsequently, the 
membranes were incubated for 1h in HRP-conjugated anti-mouse or anti-rabbit secondary 
antibody (1:1000, Cell Signaling, MA, USA). Western blots and Dot Blots were visualized 
using chemiluminescence (Super Signal West Femto Maxium Sensitity Substrate, Thermo 
Fisher Scientific, MA, USA). Signals were quantified using ChemiDoc XRS (Bio-Rad 
Laboratories, CA, USA) and densitometric analyses were performed using Quantity One (Bio-
Rad Laboratories, CA, USA) image analysis software. All quantifications were normalized to 
beta-tubulin levels.  
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4.2.6 Total protein concentration (BCA) 
 
Total protein levels of in vivo samples were determined using the Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific, MA, USA). The samples were prepared and measured as directed by 
the manufacturer’s handbook. 
 
4.2.7 ELISA for PSD-95 and cytokine levels 
 
For quantification of in vivo PSD-95 and cytokine levels the MESO QuickPlex SQ 120 and the 
appropriate ELISA kits were used (Meso Scale Diagnostics, MD, USA). The samples were 
prepared and measured as directed by the manufacturer’s instructions. 16 wells were used for the 
standard. 10 samples (brain homogenates) from each treatment group were randomly selected. The 
values for all brain samples were normalized to total protein level as determined by the BCA 
method.  
 
4.2.8 Statistical Analyses 
 
The data were analyzed and plotted with GraphPad Prism (GraphPad Software, Inc., CA, USA). 
The Shapiro-Wilk test for normality was used to test for Gaussian distribution. Statistical 
significance was determined by either ANOVA (for comparisons of three or more groups), 2-way 
ANOVA (behavioral test) or t-tests (SYK knockdown) or the non-parametric Kruskal-Wallis 
(Cytokine ELISA), where appropriate for data that were not normally distributed. The ROUT test 
(Q=1%) was used for the identification or rejection of statistical outliers. All data are presented as 
mean ± the standard error of the mean (SEM) and p<0.05 was considered significant (*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001). 
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4.3 Results  
 
4.3.1 Chronic SYK inhibition reduces p-SYK and t-SYK levels in Tg Tau P301S mice, 
rescues neuronal and synaptical loss and decreases mTOR activity 
 
Following the in vitro studies presented in the previous chapter, we investigated the effects of 
chronic SYK inhibition on tau levels, neurodegeneration, inflammation and behavior in vivo using 
a tauopathy mouse model. 30-week-old Tg Tau P301S mice and age-matched wild-type (WT) 
littermates were treated for 12 weeks with 20 mg/kg of the SYK inhibitor BAY61-3606 or PBS as 
a vehicle control (Figure 28). As we previously demonstrated (Schweig et al. 2017) SYK 
activation, as measured by p-SYK (Y525/526) levels, is significantly higher in Tg Tau P301S-PBS 
mice compared to WT controls (Figure 28). 
Importantly, the chronic treatment with the SYK inhibitor significantly reduced the 
elevated levels of p-SYK (Y525/526) (Figure 28) confirming target engagement following 
treatment with BAY61-3606. t-SYK levels were also increased in Tg Tau P301S-PBS mice 
compared to WT littermates and were significantly decreased following chronic SYK inhibition 
(Figure 28).  
The neuron-specific protein NeuN (Mullen et al. 1992) has been used previously as a 
marker for neurodegeneration or neuronal loss (Wolf et al. 1996; Maximova et al. 2010). Neuronal 
loss revealed by a reduction in NeuN has been described previously in Tg Tau P301S mice 
(Schaeffer et al. 2012; Wang et al. 2012). Post-synaptic density-95 (PSD-95) has been shown to 
promote the stabilization of synapses and to regulate synaptic transmission (Béïque and Andrade 
2003; Chen et al. 2011; Taft and Turrigiano 2014). In addition, it has been established that levels 
of PSD-95 are significantly reduced in Tg Tau P301S mice and reflect synaptic loss (Yoshiyama 
et al. 2007; Leyns et al. 2017). We therefore investigated whether chronic inhibition of SYK with 
BAY61-3606 was able to affect NeuN and PSD-95 levels in Tg Tau P301S mice. Our data show 
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that PSD-95 and NeuN levels were reduced in Tg Tau P301S-PBS mice compared to WT 
littermates (Figure 28) confirming previous observations (Yoshiyama et al. 2007; Leyns et al. 
2017). Interestingly, the chronic treatment with the SYK inhibitor, was able to considerably 
increase PSD-95 and NeuN levels in Tg Tau P301S mice (Figure 28), suggesting that SYK 
inhibition prevents neuronal and synaptic loss in Tg Tau P301S mice.  
P-mTOR (S2448) levels were significantly increased in Tg Tau P301S-PBS mice 
compared to WT littermates (Figure 28), suggesting there might be an associated reduction in 
autophagy. As observed in our in vitro experiments, SYK inhibition was able to significantly 
decrease the abnormally high p-mTOR (S2448) levels observed in Tg Tau P301S brains bringing 
them back to the levels observed in WT littermates (Figure 28). P-S6K (T389) levels were slightly 
elevated in Tg Tau P301S-PBS mice compared to WT littermates and chronic SYK inhibition was 
able to significantly decrease p-S6K (T389) levels in the brain of Tg Tau P301S mice (Figure 28), 
confirming an inhibition of the mTOR pathway. Interestingly, the lysosomal-membrane associated 
protein 1 (LAMP-1) was also significantly increased in Tg Tau P301S-PBS mice compared to WT 
littermates while chronic SYK inhibition was able to significantly reduce LAMP-1 levels in the 
brains of Tg Tau P301S mice (Figure 28).   
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Figure 28: Chronic SYK inhibition reduces p-SYK and t-SYK levels in Tg Tau P301S mice, rescues 
neuronal and synaptic loss and decreases mTOR activity 
PSD-95 levels were measured by ELISA. Levels of p-SYK, t-SYK, NeuN, p-mTOR (S2448), p-S6K 
(T389) and LAMP-1 were obtained by dot blots whose chemiluminescent signals were quantified and 
normalized to ȕ-tubulin levels. All values are presented relative to WT-PBS (control).  
Upper panel: ANOVA with post-hoc Bonferroni test revealed that SYK activation, as measured by p-SYK 
(Y525/526) levels, was significantly increased in Tg Tau P301S-PBS mice compared to WT controls 
(p<0.0001). Chronic treatment with 20mg/kg of the SYK inhibitor BAY61-3606 reduced these levels 
significantly (p<0.0001). T-SYK levels were also significantly reduced following treatment in Tg Tau 
P301S mice (p<0.01). PSD-95 and NeuN levels were significantly increased (p<0.05) following treatment 
with BAY61-3606 in Tg Tau P301S mice compared to untreated (PBS) controls.  
Lower panel: ANOVA with post-hoc Bonferroni test revealed that mTOR activation, as measured by p-
mTOR (S2248) levels, was significantly increased in Tg Tau P301S-PBS mice compared to WT controls 
(p<0.001). Chronic treatment with 20mg/kg of the SYK inhibitor BAY61-3606 reduced these levels 
significantly (p<0.01). LAMP-1 levels were also significantly increased in Tg Tau P301S-PBS mice 
compared to WT controls (p<0.0001). Chronic treatment with 20mg/kg of the SYK inhibitor BAY61-3606 
reduced these levels significantly (p<0.001). The treatment also reduced p-S6K (T389) levels significantly 
in Tg Tau P301S mice (p<0.01). 
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4.3.2 Chronic SYK inhibition reduces tau accumulation and improves motor performance 
in Tg Tau P301S mice 
 
Following the assessment of target engagement, we investigated the effects of chronic SYK 
inhibition on detergent soluble and insoluble tau levels in the brains of Tg Tau P301S mice. We 
found that chronic SYK inhibition over a 12-week period significantly reduced the levels of t-tau, 
p-tau (S396/404 and S202) and tau oligomers (TOC1) in the detergent insoluble fraction of brain 
homogenates compared to PBS-treated Tg Tau P301S mice. A trend for a reduction in detergent 
insoluble p-tau (S231) and tau conformers (MC1) was also observed following chronic SYK 
inhibition (Figure 29A). Detergent soluble total tau levels were also reduced following SYK 
inhibition compared to PBS-treated Tg Tau P301S mice, however, only soluble p-tau (S231) was 
significantly impacted by SYK inhibition (Figure 29B).  
In addition to the reduced tau burden, a significant improvement in locomotor coordination, 
measured by a decreased latency to fall in the rotarod apparatus, was observed in Tg Tau P301S 
mice following chronic inhibition of SYK (Figure 29C). Furthermore, Tg Tau P301S mice 
receiving the Syk inhibitor, performed better after four days of training in the radial arm water 
maze (RAWM) compared to PBS-treated controls (Figure 29D). After 20 days, following the last 
training trial in the RAWM, the performance of the mice was reevaluated to determine whether 
the mice were able to remember the position of the hidden platform. On day 20, Tg Tau P301S 
mice treated with BAY61-3606 were making less errors to find the hidden platform than placebo 
treated Tg Tau P301S. 
 
 
 
 
 
 
 161 
 
 162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 29: Chronic SYK inhibition reduces insoluble and soluble tau levels and improves motor 
performance in Tg Tau P301S mice 
30-week-old Tg Tau P301S mice and wild-type (WT) littermates were treated for 12 weeks with either 
PBS (control) or 20mg/kg of the SYK inhibitor BAY61-3606 (administered IP) Tg Tau P301S-PBS 
(n=11), Tg Tau P301S-BAY61-3606 (n=12).   
A) Detergent (M-PER) insoluble, as well as B) detergent (M-PER) soluble tau levels were obtained by 
dot blots whose chemiluminescent signals were quantified, normalized to ȕ-tubulin levels and expressed 
as a fold change of the average tau values quantified in placebo treated Tg Tau P301S mice. A) Unpaired 
t-tests revealed that insoluble total tau levels (p<0.05), as well as p-tau (S396/404 (p<0.05), S202 
(p<0.001)) and tau oligomers (TOC1) (p<0.01) were significantly reduced following chronic SYK 
inhibition. B) Soluble p-tau (S231) levels were reduced significantly following treatment with BAY61-
3606.  
C) The animals’ motor performance was tested using the rotarod every 14 days following the initiation 
of the BAY61-3606 treatment. Two-way ANOVA with post-hoc Bonferroni revealed a significant 
difference in motor performance for the last day (R6) between the control (Tg Tau P301S-PBS) mice and 
the mice treated with the SYK inhibitor. Motor performance of Tg Tau P301S-BAY61-3606 mice 
improved significantly between the first and last day (R1-R6) of assessment but not in control.  
D) There was no statistically significant difference between Tg Tau P301S mice treated with PBS and 
BAY61-3606 in percentage of errors made as measured by two-way ANOVA with post-hoc Bonferroni. 
However, the mice that received the treatment with the Syk inhibitor performed better on days 4 and 20.   
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4.3.3 Chronic SYK inhibition decreases neuroinflammation in Tg Tau P301S mice 
 
Since SYK is known to be involved in the activation of microglia (McDonald et al. 1997; Combs 
et al. 1999), we investigated the effects of chronic SYK inhibition on neuroinflammation in Tg 
Tau P301S mice. As expected, the microglial marker Iba-1 was significantly increased in Tg Tau 
P301S-PBS mice compared to WT littermates (Figure 30A). Chronic SYK inhibition was able to 
decrease Iba-1 levels significantly in Tg Tau P301S mice (Figure 30A). We also investigated the 
levels of inducible nitric oxide synthase (iNOS) which is known to be elevated in activated 
microglia (Cherry et al. 2014). iNOS levels were found to be significantly increased in Tg Tau 
P301S-PBS mice compared to WT littermates (Figure 30A). Chronic SYK inhibition appeared to 
significantly lower iNOS levels in Tg Tau P301S mice (Figure 30A). Levels of the astrocytic 
marker, glial fibrillary acidic protein (GFAP) were similar with or without BAY61-3606 treatment 
in wild-type and Tg Tau P301S mice (Figure 30A). We also quantified by ELISA the amount of 
various pro-inflammatory cytokines in the brain and plasma. Overall, pro-inflammatory cytokine 
levels for most of the cytokines analyzed were higher in Tg Tau P301S-PBS mice compared to 
WT littermates and decreased in the Tg Tau P301S-BAY61-3606 treatment group (Figure 30B).  
In summary, these data show that chronic SYK inhibition over a course of twelve weeks, leads to 
significant reduction in neuronal and synaptic loss, inhibition of hyperactive mTOR, decreased tau 
burden, improved motor performance and suppression of neuroinflammation in Tg Tau P301S 
mice. Importantly, the decreased t-tau and p-mTOR levels observed suggest that in vivo, SYK 
inhibition also triggers the degradation of tau via an autophagy-dependent mechanism similar to 
the one observed in vitro.   
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 Figure 30: Chronic SYK inhibition decreases microgliosis and reduces pro-inflammatory 
cytokines in Tg Tau P301S mice 
30-week-old Tg Tau P301S mice and wild-type (WT) littermates were treated for 12 weeks with either 
PBS (control) or 20mg/kg of the SYK inhibitor BAY61-3606 (administered IP) WT-PBS (n=11), WT-
BAY61-3606 (n=11), Tg Tau P301S-PBS (n=11), Tg Tau P301S-BAY61-3606 (n=12).  
A) Iba-1, GFAP and iNOS levels were obtained by dot blots whose chemiluminescent signals were 
quantified, normalized to ȕ-tubulin levels and expressed as a fold change of the average tau values 
quantified in placebo treated Tg Tau P301S mice. ANOVA with Bonferroni tests revealed that Iba-1 
(p<0.05) and iNOS (p<0.0001) levels were significantly increased in Tg Tau P301S-PBS mice compared 
to WT-PBS mice suggesting that microglia are activated in Tg Tau P301S mice. Chronic SYK inhibition 
significantly reduced Iba-1 (p<0.01) and iNOS (p<0.0001) levels in Tg Tau P301S mice. GFAP levels 
did not differ significantly between the groups. 
B-E) Brain and plasma cytokine levels were quantified by ELISA. Brain cytokine levels were normalized 
to total protein levels. B-C) Kruskal-Wallis test revealed that the elevated brain cytokine levels observed 
in Tg Tau P301S-PBS (control) mice were significantly reduced following chronic SYK inhibition (Tg 
Tau P301S-BAY61-3606) for IFNȖ (p<0.05), IL-2 (p<0.05), IL-5 (p<0.05) and IL12p70, KC/GRO levels 
were significantly increased (p<0.05) in Tg Tau P301S-PBS mice compared to WT controls. 
D-E) Kruskal-Wallis test revealed that the elevated plasma cytokine levels observed in Tg Tau P301S-
PBS (control) mice were significantly reduced following chronic SYK inhibition (Tg Tau P301S-
BAY61-3606) for IFNȖ (p<0.01), IL-12p70 (p<0.001) and IFNȖ levels were significantly increased 
(p<0.05) in Tg Tau P301S-PBS mice compared to WT controls. 
 166 
 
4.4 Discussion 
 
Our previous data have shown that SYK is upregulated in the brain of AD patients and in mouse 
models of AD (Schweig et al. 2017). In particular, we have shown that SYK is overactivated in 
neurons affected by the tau pathology and that SYK upregulation promotes tau accumulation 
without affecting tau expression (Schweig et al. 2017). Furthermore, in the previous chapter we 
have shown in vitro that SYK acts upstream of the mTOR pathway, thereby indirectly influencing 
the autophagic degradation of tau. SYK inhibition as well as genetic suppression of SYK 
expression lowered total tau levels in SH-SY5Y cells without impacting tau expression at the 
mRNA level or tau protein translation suggesting that other mechanisms are responsible for the 
increased tau clearance observed following SYK inhibition. Therefore, we investigated the 
possible effects of SYK inhibition on the mTOR pathway and autophagic degradation of tau in Tg 
Tau P301S following a chronic treatment with the SYK inhibitor BAY61-3606. 
Autophagy is a crucial mechanism for maintaining the intracellular homeostasis by 
regulating the turnover of misfolded or damaged proteins, organelles and eliminating 
dysfunctional components. Therefore, a decreased autophagic degradation has been linked to aging 
and neurodegenerative diseases (Cuervo 2008; Eskelinen and Saftig 2009; Funderburk et al. 2010; 
Ghavami et al. 2014; Lee et al. 2010; Menzies et al. 2015; Nixon 2007; Nixon and Yang 2011).  
Many studies have now demonstrated the beneficial effects of mTOR inhibition in mouse models 
of AD and tauopathy, resulting in increased autophagy and in an amelioration of tau pathologies 
(Jiang et al. 2014b; Ozcelik et al. 2013; Schaeffer et al. 2012; Wang et al. 2016), suggesting that 
manipulating the mTOR pathway may represent an attractive therapeutic strategy for the treatment 
of neurodegenerative proteinopathies. 
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In this chapter, we demonstrate that chronic SYK inhibition in a mouse model of pure tauopathy 
leads to an increased total tau degradation via the mTOR-dependent autophagy pathway, thereby 
recapitulating the results obtained from in vitro experiments, presented in the previous chapter.  
SYK inhibition was initiated in 30-week-old Tg Tau P301S mice. By that age, Tg Tau 
P301S already show significant tau accumulation and hyperphosphorylation as well as 
neuroinflammation and synaptic loss (Yoshiyama et al. 2007). We treated Tg Tau P301S mice for 
12 weeks with BAY61-3606 and observed that the treatment was well tolerated. Behavioral 
analyses revealed that locomotor performances of the Tg Tau P301S mice were improved 
following SYK inhibition in the rotarod apparatus. Our biochemical characterizations of the brain 
of these mice, confirmed our previous findings that SYK activation is increased in Tg Tau P301S 
mice (Schweig et al. 2017), and revealed target engagement following BAY61-3606 treatment, as 
the phosphorylation of SYK in the activation loop of the kinase (Y525/526) was significantly 
reduced in Tg Tau P301S mice treated with BAY61-3606. We found that mTOR activation was 
increased in Tg Tau P301S mice compared to WT littermates, suggesting that autophagy could be 
decreased and contribute to pathological tau accumulation in Tg Tau P301S mice. Tg Tau P301S 
mice treated with the SYK inhibitor showed a reduction of mTOR activation confirming the in 
vitro data showing the impact of SYK on the regulation of the mTOR pathway.  
We analyzed the impact of SYK inhibition on the accumulation of tau pathogenic species 
in the soluble and insoluble detergent fractions of Tg Tau P301S brain homogenates. Detergent 
insoluble tau species have been shown to generally contain tau aggregates that contribute to 
neurodegeneration (Fatouros et al. 2012; Yanamandra et al. 2015) while hyperphosphorylated tau 
in the detergent soluble fraction has previously been associated with synaptic loss (Kimura et al. 
2010). We found that t-tau levels, as well as p-tau (S396/404, S202) levels and tau oligomers 
 168 
(TOC1) were significantly decreased in the detergent insoluble fraction, following SYK inhibition 
in Tg Tau P301S mice. Given that mTOR phosphorylation was reduced following SYK inhibition 
in Tg Tau P301S mice, these data further suggest that the decreased accumulation of pathological 
tau species observed, results in part, from an increased tau degradation via the restored mTOR-
autophagy pathway.      
It is well known that tauopathies including AD and frontotemporal dementia with 
parkinsonism-17 (FTDP-17) lead to neurodegeneration. In mouse models of tauopathy including 
the Tg Tau P301S mice, reduced levels of the neuronal marker NeuN have been found and 
interpreted as evidence of neurodegeneration (Schaeffer et al. 2012; Wang et al. 2016). 
Interestingly, it has been shown (Schaeffer et al. 2012; Wang et al. 2016) that NeuN levels were 
restored in Tg Tau P301S mice following stimulation of autophagy. In addition, it was found that 
stimulation of autophagy in Tg Tau P301S mice can decrease insoluble tau, as well as p-tau 
(AT100 and PHF-1) levels (Schaeffer et al. 2012; Wang et al. 2016). The results of our study are 
in line with these findings. We also observed decreased levels of synaptic and neuronal markers 
PSD-95 and NeuN in Tg Tau P301S mice which were considerably increased following chronic 
SYK inhibition, suggesting that SYK inhibition can prevent neurodegeneration and synaptic loss 
induced by tau pathogenic species in Tg Tau P301S mice.  
Neuroinflammation has been shown previously to be increased in Tg Tau P301S mice 
(Bellucci et al. 2004; Yoshiyama et al. 2007) and is likely to exacerbate the neurodegeneration and 
tau pathology (Bellucci et al. 2004). We carefully investigated the impact of chronic SYK 
inhibition on neuroinflammation in Tg Tau P301S mice by analyzing the levels of various pro-
inflammatory cytokines and by quantifying Iba-1 and iNOS levels as markers of microgliosis 
(Korzhevskii and Kirik 2016; Xu et al. 2017), as well as GFAP to measure astrogliosis (Sofroniew 
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and Vinters 2010). We found that Iba-1, iNOS and various pro-inflammatory cytokine levels were 
markedly increased in Tg Tau P301S mice compared to WT littermates, while GFAP levels were 
unchanged. Chronic SYK inhibition appeared to significantly reduce Iba-1, iNOS and pro-
inflammatory cytokine levels in Tg Tau P301S mice suggesting that SYK plays a key role in the 
induction of neuroinflammation by tau pathogenic species. Pro-inflammatory cytokines produced 
by activated microglia have been shown to promote tau hyperphosphorylation (Bernhardi et al. 
2010; Wang et al. 2015a) and therefore SYK inhibition by directly targeting the activation of 
microglia could also contribute to the decreased tau hyperphosphorylation observed. 
Several studies have linked neuroinflammation and a deficit of autophagy in the context of 
neurodegenerative diseases. It has been shown, for example, that mTOR or S6K inhibition by 
rapamycin or PF4708671, respectively, prevents neuroinflammation in a mouse model of cerebral 
palsy (Srivastava et al. 2016). In that mouse model, the mice were subjected to hypoxia-ischemia 
and LPS-induced inflammation on day 6 after birth. Zheng et al. (2013) showed that 5 mg/kg LPS 
injected intraperitoneally into C57BL/6J mice at 3 and 16 months of age not only leads to increased 
neuroinflammation but also to an autophagic impairment. Zhou et al.  (2011) demonstrated that 
GSK3-ȕ inhibition suppressed neuroinflammation in the cortices of rats subjected to ischemic 
brain injury by activating autophagy. In another study, it was observed that neuroinflammation can 
block the autophagic flux in rats subjected to stress-induced hypertension (Du et al. 2017).  It has 
also been suggested that glial cells play a major role in the development of autophagy deficits 
observed in HIV-associated dementia (Alirezaei et al. 2008). In conclusion, these studies suggest 
that a pathological disruption of autophagy can cause an initiation or exacerbation of 
neuroinflammation and conversely, neuroinflammation can induce an autophagic deficit further 
contributing to neurodegeneration. Our data show that SYK is involved in both the regulation of 
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autophagy, as well as neuroinflammation and suggest that SYK may represent an important 
therapeutic target for the treatment of neurodegenerative proteinopathies.  
We found increased LAMP-1 levels in Tg Tau P301S compared to wild-type littermates 
which could be indicative of a lysosomal defect in Tg Tau P301S. Interestingly, LAMP-1 levels 
were reduced in Tg Tau P301S mice following SYK inhibition which could suggest that lysosomal 
functions were also improved by the treatment. Bain et al. (2018) found that in some cases the 
pathological mechanism in FTLD-tau may be attributed to lysosomal deficiencies and impaired 
transport, as LAMP-1 levels were increased suggesting the presence of more lysosomes. They 
concluded that FTLD cases with an underlying GRN (granulin) mutation show TAR DNA-binding 
protein (TDP-43) aggregates because of a lysosomal dysfunction (impaired degradation) rather 
than a lysosomal deficiency (lack of lysosomes). In our study, we show that Tg Tau P301S mice 
exhibit elevated levels of LAMP-1, along with increased tau levels compared to WT littermates. 
Since LAMP-1 levels are increased and suggest higher numbers of lysosomes or increased 
lysosomal surface area, a lysosomal defect or a dysfunctional transport, as suggested by Bain et 
al. (2018), could also contribute to the accumulation of tau in Tg Tau P301S mice. It is possible 
that the increased LAMP-1 levels observed in Tg Tau P301S mice represents a compensatory 
mechanism, initiated to counteract the lysosomal dysfunction. Interestingly, the treatment with the 
SYK inhibitor decreased tau, as well as LAMP-1 levels significantly, suggesting an improvement 
of lysosomal functions. The analysis of the ratio of LC3-II/I in stable SYK knockdown cells alone 
and in the presence of the lysosome inhibitor CQ also indicate a possible role of SYK in lysosomal 
degradation (previous chapter). The role of SYK in lysosomal functions will need to be further 
delineated in future experiments. 
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The data presented in this chapter illustrate the dual role of SYK as a regulator of 
neuroinflammation and autophagy in the CNS. The observations made in this study not only 
provide further evidence for an important role of SYK in the pathogenesis of AD and the 
development of tau pathologies but also demonstrate that pharmacological SYK inhibition may 
represent a promising therapeutic strategy for the treatment of AD and other neurodegenerative 
proteinopathies. 
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4.4.1 Excursion: Tg Tau P301S organotypic vibrosections: brain cytokine levels following 
ex-vivo SYK inhibition 
 
 
4.4.1.1 Introduction 
As stated previously, SYK is known as a modulator of the immune response in the 
periphery. More specifically, SYK has been shown to be involved in B-cell receptor (BCR) and 
T-cell receptor (TCR) signaling (Kurosaki et al. 1994; Latour et al. 1997). 
Our previous studies have revealed that SYK does not only play a major role in the 
periphery but is also present in CNS. More precisely, we have shown that SYK activation, is 
largely increased in subsets of microglia and in dystrophic neurites in AD mouse models, as well 
as in neurons of Tg Tau P301S mice, compared to wild-type (WT) animals that did not exhibit 
activation SYK activation (Schweig et al. 2017). We observed a similar increase in SYK activation 
in dystrophic neurites and neurons in human AD specimens. 
This means that SYK activity is increased in neurons displaying the tau pathology but not 
in microglia of Tg Tau P301S. However, Tg Tau P301S mice are known to exhibit microgliosis 
(see previous chapter (Iba-1) and (Yoshiyama et al. 2007)) which implies that neuronal tau 
pathology can promote the activation of microglia but the mechanism remains elusive and implies 
a cross-talk between neurons and microglia. Given that SYK is upregulated in neurons in these 
mice, and since SYK has been shown to regulate inflammatory pathways in microglia in vitro 
(Combs et al. 1999; Combs et al. 2001; Lovering et al. 2012; McDonald et al. 1997), we were 
prompted to investigate whether blocking SYK activity could influence tau-induced 
neuroinflammation using organotypic vibrosections from Tg Tau P301S brains. By studying the 
effects of SYK inhibition on cytokine production ex vivo in organotypic vibrosections, we were 
able to directly assess the impact of SYK inhibition on the CNS and avoid peripheral effects of 
SYK inhibition on immune cells.  
 173 
To our knowledge, no other studies have examined the immediate effects of SYK inhibition on 
neuroinflammation in the CNS. Therefore, we investigated the effect of SYK inhibition on 
cytokine production under normal conditions and in presence of LPS in culture media ex vivo, in 
organotypic brain vibrosections of a mouse model of tauopathy (Tg Tau P301S) and WT 
littermates. 
 
4.4.1.2 Materials and Methods 
 
4.4.1.2.1 Animals 
 
All mice were maintained under specific pathogen free conditions in ventilated racks in the 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC) accredited vivarium of the Roskamp Institute. All experiments involving mice were 
reviewed and approved by the Institutional Animal Care and Use Committee of the Roskamp 
Institute before implementation and were conducted in compliance with the National Institutes of 
Health Guidelines for the Care and Use of Laboratory Animals. Tg Tau P301S (Yoshiyama et al. 
2007) mice were obtained from the Jackson Laboratories (ME, USA) and bred with C57BL/6J 
mice to produce the Tg Tau P301S and wild-type littermates used in this study.  
 
4.4.1.2.2 Treatment of organotypic vibrosections 
 
Adult Tg Tau P301S mice and age-matched WT littermates were rapidly sacrificed after 3 minutes 
of 3% isoflurane anesthesia and their brains dissected in pre-cooled (4˚C) HBSS. Coronal, 250μm 
thick brain sections were cut at a speed of 0.3mm/s in pre-cooled (4˚C) HBSS using the Leica VT 
1200S (Leica Inc., IL, USA) vibratome attached to the Julabo FL300 (Julabo Inc., PA, USA) 
recirculating cooler. Each brain section was immediately transferred into a well of a 24-well plate 
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with 500μl of DMEM/F12 media containing 10% FBS (Thermo Fisher Scientific, MA, USA), 1% 
GlutaMAX and 1% penicillin/streptomycin/fungizone.  
The sections were incubated at 37˚C in a humidified 5% CO2 atmosphere. The organotypic 
coronal vibrosections of 43-week-old Tg Tau P301S mice and age-matched WT littermates were 
treated with 5μM BAY61-3606 or 500ng/ml LPS or a combination of both for 24 hours. After 24h 
the supernatant was collected and stored at -80˚C for subsequent analysis of cytokine levels. The 
brain sections were lysed in 100μl MPER containing Halt protease inhibitors and also stored at -
80˚C for subsequent analysis of total protein levels. Two animals for each genotype and five to ten 
organotypic vibrosections per treatment were analyzed and compared to untreated control slices 
using the MSD ELISA for multiple cytokines.    
 
4.4.1.2.3 ELISA for cytokine levels 
 
For quantification of ex vivo cytokine levels, the MESO QuickPlex SQ 120 and the appropriate 
ELISA kits were used (Meso Scale Diagnostics, MD, USA). The samples were prepared and 
measured as directed by the manufacturer’s instructions. The values for all brain samples were 
normalized to total protein level as determined by the BCA method.  
 
4.4.1.2.4 Total protein concentration (BCA) 
 
Total protein levels of ex vivo samples were determined using the Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific, MA, USA). The samples were prepared and measured as directed by 
the manufacturer’s handbook. 
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4.4.1.2.5 Statistical Analyses 
 
The data were analyzed and plotted with GraphPad Prism (GraphPad Software, Inc., CA, USA). 
The Shapiro-Wilk test for normality was used to test for Gaussian distribution. Statistical 
significance was determined by ANOVA and post-hoc Bonferroni test. All data are presented as 
mean ± the standard error of the mean (SEM) and p<0.05 was considered significant (*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001). 
 
4.4.1.3 Results 
 
In our previous studies we revealed that SYK is hyperactivated in neurons and microglia of AD 
brains and AD mouse models. Having established a possible role of SYK in the CNS and given 
that SYK is a well-known modulator of the peripheral immune response, we investigated the role 
of SYK in neuroinflammation directly in the CNS. We measured the release of pro-inflammatory 
and anti-inflammatory cytokines in the media of 250μm thick organotypic brain vibrosections of 
43-week-old Tg Tau P301S mice and age-matched WT littermates following a 24h treatment with 
either 5μM of the SYK inhibitor BAY61-3606 or 500ng/ml LPS or a combination of both.  
The baseline levels of TNFα were more than 2.5 times higher in Tg Tau P301S (227.71 
pg/mg) compared to WT (85.86 pg/mg) vibrosections (Ctl) (Figure 31). The TNFα release was 
significantly increased in Tg Tau P301S following LPS treatment compared to untreated control 
(Ctl) (p<0.0001). In the double treatment, SYK inhibition significantly reduced the elevated TNFα 
levels (p<0.001). The LPS-induced TNFα release was significantly higher in organotypic 
vibrosections of Tg Tau P301S (1125.12 pg/mg) brains compared to WT littermates (316.15 
pg/mg) (p<0.001). This means that the LPS-induced TNFα level was approximately 5 times higher 
in Tg Tau P301S vibrosections compared to baseline, while WT vibrosections exhibited less than 
 176 
a 4-fold increase in TNFα following LPS treatment. Both WT and Tg Tau P301S vibrosections 
showed a decrease in TNFα following SYK inhibition with BAY61-3606 alone and in presence of 
LPS. 
Similar to the TNFα data, the baseline levels of IL-1ȕ were nearly 3 times higher in Tg Tau 
P301S (3.41 pg/mg) compared to WT (1.15 pg/mg) vibrosections (Ctl) (Figure 31). The IL-1ȕ 
release was significantly increased in Tg Tau P301S following LPS treatment compared to 
untreated control (Ctl) (p<0.001). In the double treatment, SYK inhibition significantly reduced 
the elevated IL-1ȕ levels (p<0.001). The LPS-induced IL-1ȕ release was significantly higher in 
organotypic vibrosections of Tg Tau P301S brains (9.38 pg/mg) compared to WT littermates (1.88 
pg/mg) (p<0.0001). This means that the LPS treatment lead to a 2.75-fold increased IL-1ȕ release 
in Tg Tau P301S vibrosections compared to baseline, while WT vibrosections exhibited a 1.6-fold 
increase in IL-1ȕ following LPS treatment. Both WT and Tg Tau P301S vibrosections showed a 
decrease in IL-1ȕ following SYK inhibition with BAY61-3606 alone and in presence of LPS. 
Interestingly, the anti-inflammatory IL-4 release was different to the pro-inflammatory 
TNFα and IL-1ȕ release. The baseline levels of IL-4 were similar in Tg Tau P301S (0.065 pg/mg) 
and WT (0.056 pg/mg) vibrosections (Ctl) (Figure 31). ANOVA with post-hoc Bonferroni test 
revealed a significant increase in IL-4 release following LPS treatment compared to untreated 
control (Ctl) vibrosections in WT (p<0.001), however, not in the Tg Tau P301S mice. The increase 
in IL-4 release in the presence of LPS suggests the initiation of anti-inflammatory feedback loop 
following the induction of the pro-inflammatory response. The LPS-induced IL-4 release was also 
significantly lower in organotypic vibrosections of Tg Tau P301S brains compared to WT 
littermates (p<0.05). In fact, we observed a 6.76-fold increase in LPS-induced IL-4 levels in WT 
vibrosections compared to untreated control, while in Tg Tau P301S we only observed a 2.45-fold 
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increase in IL-4 release (Figure 31). This suggests a decreased anti-inflammatory response in Tg 
Tau P301S compared to WT mice. Both WT and Tg Tau P301S vibrosections showed a decrease 
in IL-4 following SYK inhibition with BAY61-3606 alone and in presence of LPS. This suggests 
that the initiation of the anti-inflammatory feedback loop mediated by IL-4 is suppressed following 
SYK inhibition because of a decreased pro-inflammatory response.  
ANOVA with post-hoc Bonferroni test did not reveal any significant difference in IL-5 
levels between transgenic and WT mice or following any treatment. This suggests that IL-5 does 
not play a role in LPS-induced inflammation or in the neuroinflammation observed in Tg Tau 
P301S mice. 
The baseline release of IL-6 from Tg Tau P301S vibrosections (Ctl, 6171.53 pg/mg) was 
approximately 1.5-fold higher compared to WT vibrosections (Ctl, 4025.04 pg/mg). The release 
of IL-6 was not impacted by LPS. However, the IL-6 release was significantly lower in 
vibrosections of Tg Tau P301S mice double-treated with LPS and BAY61-3606 compared to LPS 
alone (p<0.05). Both WT and Tg Tau P301S vibrosections showed a decrease in IL-6 following 
SYK inhibition with BAY61-3606 alone and in presence of LPS (Figure 31). 
The baseline levels of IL-10 were 2.6 times higher in Tg Tau P301S (2.31 pg/mg) compared 
to WT (0.87 pg/mg) vibrosections (Ctl) (Fig. 1). The IL-10 release was significantly increased in 
Tg Tau P301S double-treated with LPS and BAY61-3606 compared to LPS alone (p<0.05). 
Although the LPS-induced IL-10 release was significantly higher in organotypic vibrosections of 
Tg Tau P301S brains (3.88 pg/mg) compared to WT littermates (1.74 pg/mg) (p<0.05), the relative 
increase was lower in Tg Tau P301S compared to WT vibrosections (Figure 31). In fact, the LPS 
treatment lead to a 1.7-fold increased IL-10 release in Tg Tau P301S vibrosections compared to 
baseline, while WT vibrosections exhibited a 2-fold increase in IL-10 following LPS treatment. 
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Both WT and Tg Tau P301S vibrosections showed a decrease in IL-10 following SYK inhibition 
with BAY61-3606 alone and in presence of LPS. 
The baseline levels of KC-GRO were 1.86 times higher in Tg Tau P301S (712.98 pg/mg) 
compared to WT (382.7 pg/mg) vibrosections (Ctl) (Figure 31). The KC-GRO release was 
significantly decreased in Tg Tau P301S vibrosections treated with BAY61-3606 compared to the 
untreated control (p<0.05). The KC-GRO release was not significantly altered following treatment 
with LPS in WT vibrosections (402.48 pg/mg). However, LPS decreased the KC-GRO release in 
Tg Tau P301S vibrosections (520.4 pg/mg). Both WT and Tg Tau P301S vibrosections showed a 
decrease in KC-GRO following SYK inhibition with BAY61-3606 alone and in presence of LPS. 
Tg Tau P301S IL-12p70 baseline levels (41.34 pg/mg) are slightly higher than WT vibrosections 
(29.04 pg/mg) IL-12p70 baseline levels. Although ANOVA with post-hoc Bonferroni test did not 
reveal a significant difference in IL-12p70 levels, both LPS and BAY61-3606 seem to reduce the 
release of IL-12p70 (Figure 31).   
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 Figure 31: Cytokine production in organotypic vibrosections of Tg Tau P301S mice and WT 
littermates following LPS exposure and SYK inhibition 
250μm thick brain sections of 43-week-old Tg Tau P301S mice and age-matched WT littermates 
were treated in 24-well plates for 24h with either 5μM of the SYK inhibitor BAY61-3606 or 
500ng/ml LPS or a combination of both. Cytokine levels of the culture media were analyzed by 
ELISA.  
ANOVA with post-hoc Bonferroni test revealed a significant increase in TNFα release in Tg 
Tau P301S following LPS treatment compared to untreated control (Ctl) (p<0.0001). In the 
double treatment, SYK inhibition significantly reduced the elevated TNFα levels (p<0.001). The 
LPS-induced TNFα release was significantly higher in organotypic vibrosections of Tg Tau 
P301S brains compared to WT littermates (p<0.001).   
ANOVA with post-hoc Bonferroni test revealed a significant increase in IL-1ȕ release in Tg Tau 
P301S following LPS treatment compared to untreated control (Ctl) vibrosections (p<0.001). In 
the double treatment, SYK inhibition significantly reduced the elevated IL-1ȕ levels (p<0.001). 
The LPS-induced IL-1ȕ release was significantly higher in organotypic vibrosections of Tg Tau 
P301S brains compared to WT littermates (p<0.0001).   
ANOVA with post-hoc Bonferroni test revealed a significant increase in IL-4 release in WT 
following LPS treatment compared to untreated control (Ctl) vibrosections (p<0.001). The LPS-
induced IL-4 release was significantly lower in organotypic vibrosections of Tg Tau P301S 
brains compared to WT littermates (p<0.05).   
ANOVA with post-hoc Bonferroni test did not reveal a significant difference in IL-5 levels. 
ANOVA with post-hoc Bonferroni test revealed a significant decrease in IL-6 release in 
vibrosections of Tg Tau P301S mice double-treated with LPS and BAY61-3606 compared to 
LPS alone (p<0.05). 
ANOVA with post-hoc Bonferroni test revealed a significant decrease in IL-10 release in 
vibrosections of Tg Tau P301S mice double-treated with LPS and BAY61-3606 compared to 
LPS alone (p<0.05). The LPS-induced IL-10 release was significantly higher in organotypic 
vibrosections of Tg Tau P301S brains compared to WT littermates (p<0.05).  
ANOVA with post-hoc Bonferroni test revealed a significant decrease in KC-GRO release in 
vibrosections of Tg Tau P301S mice treated with BAY61-3606 compared to the untreated 
control (p<0.05). 
ANOVA with post-hoc Bonferroni test did not reveal a significant difference in IL-12p70 levels. 
All cytokine levels were normalized to total protein measured. All data are presented as mean ± 
SEM. For all graphs WT and Tg Tau P301S Ctl, LPS; n=10, WT and Tg Tau P301S BAY61-
3606, BAY61-3606+LPS; n=5 vibrosections were analyzed. 
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4.4.1.4 Discussion 
 
Although SYK is a known regulator of the peripheral immune response, here we report, for the 
first time, a SYK-dependent release of various pro-inflammatory and anti-inflammatory cytokines 
in the CNS of WT and Tg Tau P301S mice. Since our previous studies suggested that SYK can 
regulate NFκB which is known to regulate neuroinflammation and cytokine production (Paris et 
al. 2014), we investigated the cytokine release in ex vivo experiments using brain organotypic 
vibrosections in addition to the in vivo experiments described in the previous chapter, in order to 
avoid possible confounding effects arising from SYK inhibition in the periphery and therefore 
enabling us to directly assess SYK inhibition in the CNS.   
More precisely, we show that the baseline levels of pro-inflammatory cytokines including 
TNFα and IL-1ȕ largely differ between WT and Tg Tau P301S mice, providing further evidence 
for the known cerebral neuroinflammation observed in Tg Tau P301S mice. Tg Tau P301S also 
exhibited a much stronger release of TNFα and IL-1ȕ following LPS stimulation, suggesting that 
the neuroinflammation in Tg Tau P301S mice triggers a stronger pro-inflammatory response in 
those mice compared to WT littermates. Since LPS has been shown to induce the release of pro-
inflammatory cytokines by stimulating (TLR4) (Lu et al. 2008), this could also suggest that TLR4 
signaling is enhanced in Tg Tau P301S mice. Both TNFα and IL-1ȕ baseline levels, as well as 
LPS-induced increases, were largely reduced following SYK inhibition in Tg Tau P301S mice, 
suggesting a SYK-dependent release of these pro-inflammatory cytokines. The roles of the pro-
inflammatory cytokines TNFα and IL-1ȕ, along with IL-6 in the brain have been extensively 
studied and elevated levels of those pro-inflammatory cytokines are often related to sickness, 
depression, and neurodegenerative disorders like AD (Griffin et al. 1989; Hull et al. 1996; Dantzer 
et al. 2008). IL-1ȕ has been found to be increased in the hippocampus in 12-months-old Tg Tau 
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P301S mice compared to non-transgenic mice (Yoshiyama et al. 2007). The authors argue that 
neuroinflammation, and microgliosis in particular, may be the one of the earliest pathological 
changes observed in neurodegenerative tauopathies and that an inhibition of the 
neuroinflammatory response to tau could delay the progression of the tau pathology (Yoshiyama 
et al. 2007). 
Interestingly, baseline levels of the anti-inflammatory cytokine IL-4 were similar in Tg Tau 
P301S mice compared to WT littermates but LPS stimulation induced a significantly smaller anti-
inflammatory feedback response in Tg Tau P301S mice compared to WT littermates, suggesting 
an impaired anti-inflammatory response in Tg Tau P301S mice. This can be explained by the 
predominant neuroinflammation in Tg Tau P301S mice and could suggest that an increased pro-
inflammatory baseline caused by the tau overexpression results in a decreased LPS-induced anti-
inflammatory response. The effects of overexpression of IL-4 in amyloid overexpressing animal 
models remains controversial, as it has been shown to either attenuate or exacerbate the amyloid 
pathology, suggesting that more research needs to be done to assess the effects of IL-4 on the AD 
pathology (Kiyota et al. 2010; Chakrabarty et al. 2012). Significantly increased plasma IL-4 and 
IL-10 levels have been associated with a faster cognitive decline (ADA-cog.) in human AD 
patients, suggesting a correlation of anti-inflammatory cytokines and disease severity (Leung et 
al. 2013). However, a more recent study showed the exact opposite and stated that decreased IL-4 
plasma levels were associated with increased disease severity in human AD patients (King et al. 
2018), also suggesting that more research needs to be done to clarify the role of IL-4 in AD.   
Some cytokines, including IL-5, did neither show a major difference between WT and Tg 
Tau P301S mice, nor a LPS-induced release, implying that IL-5 does not play a major role in the 
mediation of neuroinflammation in WT or Tg Tau P301S mice. The amount of released IL-12p70 
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was also similar in WT and Tg Tau P301S mice. Both LPS and the SYK inhibitor BAY61-3606 
seemed to reduce the IL-12p70 release. Plasma IL-12 levels have been found to be vary at different 
stages of AD. Patients with mild AD exhibited the highest IL-12 levels, whereas patients with 
severe AD did not exhibit higher IL-12 levels compared to non-demented controls (Motta et al. 
2007).    
The release of IL-6 was also not altered by LPS, neither in WT nor in Tg Tau P301S mice. 
Only the baseline levels of IL-6 were slightly higher in Tg Tau P301S mice compared to WT 
littermates. In AD patients the levels of IL-6 in the serum has been found to significantly higher 
than in the control group (Cojocaru et al. 2011), whereas another study showed that CSF levels of 
IL-6 were decreased in dementia with Lewy bodies compared to AD and controls and that IL-6 
levels negatively correlated with MMSE scores (Wennström et al. 2015).  
The release of KC-GRO following LPS treatment was only slightly reduced compared to 
the untreated control in the Tg Tau P301S mice but did not differ for the WT littermates. KC-GRO 
is a ligand of the CXCR2 receptor and has been shown to be involved in triggering ERK1/2 and 
PI3K pathways resulting in tau hyperphosphorylation (Xia and Hyman 2002). The increase KC-
GRO baseline levels that we observed in Tg Tau P301S compared to WT mice could therefore 
also contribute to the tau pathology. 
  The baseline level, as well as the LPS-induced release of IL-10 was also increased in Tg 
Tau P301S mice compared to WT littermates and Syk inhibition decreased IL-10 levels both in 
WT and Tg Tau P301S mice. IL-10 deficiency has been shown to mitigate AD pathology in 
APP/PS1 mice and was elevated in AD patient brains (Guillot-Sestier et al. 2015). It has therefore 
been suggested that IL-10 suppression may be a therapeutic approach to treat AD (Guillot-Sestier 
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et al. 2015). However, other studies have argued that increasing IL-10 could be a potential 
treatment strategy for AD, as IL-10 reduced pro-inflammatory cytokines (Magalhaes et al. 2017).  
Various pro-inflammatory and anti-inflammatory cytokines were reduced following SYK 
inhibition with BAY61-3606, even in the presence of LPS, including TNFα, IL-1ȕ, IL-4, IL-6, IL-
10, KC-GRO and IL-12p70. This suggests that SYK plays a regulatory role in the release of pro-
inflammatory and anti-inflammatory cytokines in the CNS. Our findings also imply that the 
neuroinflammation observed in Tg Tau P301S mice, as well as LPS induced inflammation, can be 
controlled and brought back to baseline levels by inhibiting SYK. 
Our studies presented in the previous three chapters found increased levels of SYK 
activation in subsets of activated microglia in Aȕ-overexpressing animal models of AD, as well as 
in neurons of tau-overexpressing Tg Tau P301S mice. However, so far we found no evidence for 
increased SYK activation in microglia of Tg Tau P301S mice, although we confirmed the well-
known microgliosis in this chapter. Therefore, we hypothesize that SYK could be a key kinase 
controlling the cross-talk between neurons carrying tau pathological species and microglia 
responding with a release of cytokines in Tg Tau P301S mice. Although glial cells are known to 
be the main source of cytokines (Hanisch 2002; Wang et al. 2015a), there is evidence that supports 
a cytokine release by neurons (Acarin et al. 2000; Bartfai and Schultzberg 1993; Sei et al. 1995). 
In fact, increased IL-1ȕ levels have been observed in pyramidal neurons of the hippocampus in Tg 
Tau P301S mice while it was nearly absent in non-transgenic control mice (Yoshiyama et al. 2007). 
This means that, potentially, the cytokines could, at least partially, originate from neurons and 
SYK inhibition could prevent this neuronal release. Furthermore, even though we did not directly 
detect an elevated SYK activation in microglia of Tg Tau P301S mice, this does not mean that 
SYK inhibition could not directly influence the microglial cytokine release, as SYK may still be 
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present and activated to a lesser degree in those microglia. However, future studies have to 
determine the exact origin of the cytokines detected in this study and elucidate the exact 
mechanism by which SYK represses the tau- and LPS-induced cytokine release.      
  In conclusion, our data show a definite and direct involvement of SYK in the regulation 
of cytokine release in the CNS. This means that our previously observed hyperactivation of SYK 
in microglia and neurons in AD brains and AD mouse models is likely to contribute to the known 
neuroinflammation in AD. Hence, a pharmacological intervention targeting SYK may represent a 
promising approach to reduce neuroinflammation in AD and other diseases of the CNS with an 
underlying neuroinflammatory component.    
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5 Conclusion 
 
Earlier work by our Roskamp Institute team had identified SYK as a target of the L-type calcium 
channel blocker and known anti-hypertensive drug nilvadipine (Paris et al. 2014). Nilvadipine is a 
racemic compound and was found to not only lower blood pressure but also to be a potential 
treatment for AD (see below for more information) (Paris et al. 2004; Paris et al. 2011; Bachmeier 
et al. 2011; Paris et al. 2014; Hanyu et al. 2007). Our team found in a previous study that treatment 
with nilvadipine resulted in a reduction of tau hyperphosphorylation, Aȕ production and 
neuroinflammation (Paris et al. 2014; Paris et al. 2011). Interestingly, the (-)-enantiomer of 
nilvadipine does not exhibit anti-hypertensive activities, but still has comparable effects on AD 
pathologies compared to the racemic mixture and was found to inhibit SYK (Paris et al. 2014), 
suggesting that the positive impact of nilvadipine on AD pathologies was not mediated by its anti-
hypertensive or L-type calcium channel blocker activities. Therefore, our team hypothesized that 
SYK inhibition with a selective Syk inhibitor should mimic the effects of nilvadipine and reduce 
the known AD pathologies. In fact, treatment with a specific SYK inhibitor BAY61-3606 resulted 
in reduction of tau hyperphosphorylation, Aȕ production and neuroinflammation in vitro and in 
acute in vivo treatment paradigms (Paris et al. 2014), mimicking the effects of nilvadipine. 
Previous mechanistic studies in our lab have shown that SYK inhibition results in an inactivation 
of GSK3-ȕ leading to a decreased tau phosphorylation at GSK3-ȕ-dependent epitopes in addition 
to a partial reduction of tau phosphorylation at Tyr18 directly mediated by SYK. Furthermore, 
SYK was shown to regulate BACE-1 transcription and BACE-1 protein levels, by preventing p65-
NFκB activation, resulting in a decreased Aȕ and sAPPȕ production (Paris et al. 2014). Altogether, 
these findings suggested an involvement of SYK in the formation of tau and ȕ-amyloid pathologies 
in AD (Paris et al. 2014).  
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In this thesis, we report a hyperactivation of SYK in the brains of three different AD mouse models 
compared to age-matched wild type littermates. In Tg PS1/APPsw and Tg APPsw mice, SYK 
activity was largely increased in activated microglia and in dystrophic neurites around ȕ-amyloid 
deposits. In Tg Tau P301S mice, SYK hyperactivation was co-localized with pathological tau 
species in hippocampal and cortical neurons. Similarly, human AD specimens exhibited increased 
SYK activation in neurons immunopositive for pathological tau species and dystrophic neurites.   
The increased activation of SYK in activated microglia of Aȕ-overexpressing mice 
supports a possible role of SYK in microglial activation in vivo and suggests that Aȕ accumulation 
can lead to an activation of SYK in vivo in microglia and in dystrophic neurites around ȕ-amyloid 
deposits. In this regard, previous in vitro studies have shown that Aȕ oligomers can trigger a 
microglial inflammatory response mediated by SYK and leading to neurotoxicity (Combs et al. 
1999; Combs et al. 2001; McDonald et al. 1997; Sondag et al. 2009).  
The strong increase in activated SYK in dystrophic neurites (DNs) may suggest the 
involvement of SYK in the formation of these DNs that ultimately lead to the synaptic loss 
observed in AD (Sanchez-Varo et al. 2012). The DNs are characterized by an accumulation of 
BACE-1 and sAPPȕ which implies a contribution of DNs to Aȕ production and accumulation. In 
fact, several in vivo studies have shown that BACE-1 immunopositive dystrophic neurites precede 
Aȕ plaque formation in the brains of 3xTg-AD, 2xFAD and 5xFAD mice and therefore, represent 
an early pathological event in AD (Cai et al. 2012; Kandalepas et al. 2013; Zhang et al. 2009). Our 
previous in vitro and in vivo data showing that SYK regulates Aȕ production via a modulation of 
BACE-1 expression (Paris et al. 2014) support the contribution of SYK upregulation to BACE-1/ 
sAPPȕ accumulation in DNs.  
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The impaired autophagy observed in AD is suggested to be at least partially caused by an impaired 
axonal transport that contributes to the formation of DNs. Accumulations of autophagic vesicles 
(AVs) contribute to the axonal swellings. AVs accumulate in DNs, at least in part, because of an 
impaired transport along the axon. The axonal transport may be impaired because of decreased 
levels of kinesin-1 and dynein motor proteins (Sanchez-Varo et al. 2012) resulting in a decreased 
lysosomal degradation of AVs. It has been shown that Aȕ oligomers could associate with AVs and 
interact with dynein motor proteins, thereby impairing dynein recruitment to amphisomes and 
finally leading to an impaired retrograde transport (Tammineni et al. 2017). The impairment of the 
axonal transport along the microtubule network could also be caused by SYK hyperactivity since 
it has been shown that pharmacological SYK inhibition stabilizes microtubules through decreased 
phosphorylation of microtubules and microtubule-associated proteins (MAPs) (Yu et al. 2015).  
The induction of autophagy, as well as the lysosomal degradation are strongly dependent 
on the key regulator mTOR. The mTOR pathway, including downstream targets like p70-S6K and 
4EBP1 are upregulated in brains of AD patients (Tramutola et al. 2015). This upregulation has 
also been associated with increased cytosolic tau and increased tau secretion (Tang et al. 2015). 
Tau-induced neuronal loss, as well as Aȕ-induced synaptotoxicity have been shown to be 
prevented by pharmacological inhibition of mTOR in vivo (Ramirez et al. 2014; Siman et al. 2015). 
Interestingly, the data presented in this thesis show that SYK inhibition has pronounced effects on 
the mTOR pathway and autophagic tau degradation in vitro, as well as in vivo. SYK inhibition 
lowers pharmacologically induced mTOR and Akt activity placing SYK as an upstream regulator 
of the mTOR pathway and ultimately as a regulator of autophagy and lysosomal degradation in 
neuron-like cells. Importantly, we confirmed these findings in vivo using a mouse model of 
tauopathy. Chronic SYK inhibition over 12 weeks significantly lowered pathological tau species 
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via mTOR inhibition, improved motor performance and decreased neuroinflammation in Tg Tau 
P301S mice, suggesting that targeting SYK could have a major impact on several key pathologies 
observed in AD patients. 
Furthermore, the involvement of SYK in autophagy additionally supports the role of SYK 
in the formation of DNs, as it has been reported that pharmacological inhibition of mTOR can 
prevent neuritic dystrophy in PC12 cells and superior cervical ganglion neurons (Yang et al. 2014).  
The pathological analysis of Tg Tau P301S mice shows that SYK activation occurs concomitantly 
with the formation of hyperphosphorylated tau oligomers/aggregates in the cortex. This may 
suggest a possible involvement of SYK activation in tau oligomerization and aggregation in vivo. 
Pathological tau conformers may induce SYK activation but SYK activation could also be required 
for the establishment of tau pathologies, thereby inducing a positive feedback loop resulting in an 
enhanced progression of tau pathology. This is supported by our data showing that SYK 
upregulation in SH-SY5Y cells promotes tau accumulation in vitro.  
Given that SYK is also present in DNs which exhibit tau accumulation and tau 
phosphorylation (Schmidt et al. 1994; Su et al. 1993), this further supports a pathological role of 
SYK in the formation of DNs and ultimately synaptical loss. Our in vivo study showed that chronic 
inhibition of SYK results in increased NeuN and PSD-95 levels in Tg Tau P301S mice compared 
to vehicle treated controls, suggesting a decreased neuronal and synaptic loss in treated Tg Tau 
P301S mice. This means that SYK inhibition could potentially counteract the neurodegeneration 
induced by pathological tau species and therefore represents a promising treatment strategy for 
AD.  
Our previous findings show that SYK regulates GSK3-ȕ activity which is a known tau-
kinase (Paris et al. 2014; Hooper et al. 2008). In addition, mTOR and its downstream kinase S6K 
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can also directly phosphorylate tau (Pei et al. 2006; Sonoda et al. 2016; Tang et al. 2013). Both 
mTOR and S6K activation were decreased following pharmacological SYK inhibition in vitro and 
in vivo. Hence, mTOR and S6K represent additional targets of SYK inhibition that possibly 
contribute to the reduction of tau phosphorylation. Our previous and present data show decreased 
tau phosphorylation at multiple epitopes including S396/404, Ser202, T231, and Y18, as well as 
decreased tau oligomers (TOC1) and pathological tau conformers (MC1) following SYK 
inhibition (Paris et al. 2014) (and chapter 4).   
In summary, SYK inhibition targets and reduces the activity of multiple tau-kinases and 
could therefore ameliorate tau pathology. Additionally, stimulation of tau degradation via 
increased autophagy may also contribute to the amelioration of the tau pathology following SYK 
inhibition which may explain why SYK inhibition has such a drastic impact on tau.  
The results of this thesis show increased SYK activation in neurons of tau overexpressing 
mice and in dystrophic neurites and in microglia of Aȕ overexpressing mice, indicating that both 
Aȕ and tau can elicit a downstream activation of SYK. In addition, SYK overexpression increased 
tau phosphorylation and total tau levels implying a positive feedback loop between SYK and tau. 
SYK does not only exacerbate the tau pathology by directly phosphorylating tau at Y18 and 
indirectly by activating other downstream kinases (e.g. GSK3-ȕ, S6K, Akt), thereby contributing 
to tau hyperphosphorylation but also by regulating the autophagic degradation of tau (Figure 32). 
Taken together, the results of the three main chapters, as well as the results from previous studies 
(Paris et al. 2014), suggest that both the tau and Aȕ pathologies could exacerbate each other via 
the activation of SYK since SYK regulates tau hyperphosphorylation, tau degradation, Aȕ 
production and neuroinflammation through downstream pathways, thereby creating positive 
feedback loops between Aȕ, tau and SYK (as described in Figure 32).  
 191 
     
Figure 32: Relationships between SYK and the main AD pathologies 
In the first chapter of this thesis, we have shown that SYK is activated in AD mouse models 
overexpressing Aȕ, as well as mouse models overexpressing P301S tau. Therefore, SYK activation 
occurs downstream of Aȕ and tau pathologies. Our present and previous studies (Paris et al. 2014) 
have shown that SYK activation causes activation of downstream kinases and conversely, SYK 
inhibition causes inhibition of certain kinases that are known to phosphorylate tau including 
GSK3-ȕ, Akt, S6K and SYK itself (yellow star, P = phosphorylation of tau), thereby possibly 
exacerbating tau hyperphosphorylation. In addition, the second and third chapter of this thesis 
show that SYK acts upstream of the mTOR pathway and thereby influences the tau degradation, 
creating another and possibly stronger positive feedback loop between the tau pathology and SYK. 
Furthermore, our previous studies have shown that SYK impacts the expression of BACE1, the 
rate-limiting enzyme in Aȕ production, via NFκB thereby closing the positive feedback loop 
between Aȕ and SYK. NFκB is known to be involved in neuroinflammation and since we have
shown SYK activation occurs in microglia, SYK is likely to contribute to neuroinflammation. 
Taken together our findings indicate that SYK activation is a downstream event of the Aȕ and tau 
pathologies but also exacerbates these known AD pathologies and could therefore represent a 
promising target for the treatment of AD. 
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As described in detail in the introduction (1.3), to date, there is no cure available to AD 
patients, as none of the drugs approved by the FDA halts the cognitive decline but are just 
considered symptomatic cognitive enhancers. While symptomatic cognitive enhancers may help 
patients in the short term by boosting their cognitive performance, they do not alter the advance of 
the disease in the long term. Therefore, FDA approved disease modifying therapies (DMTs) are 
needed to successfully treat AD.  
The findings mentioned in chapter 1.3, underline the importance of investigating and 
advancing new potential DMTs to the clinic and because of the data presented in this thesis, the 
development of specific SYK inhibitors represents a new and promising treatment strategy for AD. 
To this date, there have been only oral SYK inhibitors in clinical trials or FDA approved that aim 
to treat conditions like cancer and autoimmune diseases. Only a small number of teams have been 
working on SYK as a target for the treatment of CNS diseases, thereby mainly focusing on AD. In 
the near future, however, the scientific field around SYK inhibitors may expand to CNS-related 
disorders, as the role of SYK in several important processes within the nervous system becomes 
more apparent to the scientific community.    
In conclusion, our previous data, as well as the data presented in this thesis support a 
pathological role of SYK in the formation of Aȕ deposits, tau aggregates, and neuroinflammation 
and furthermore, suggest that prevention of SYK hyperactivity through pharmacological inhibition 
may be a promising therapeutic approach for Alzheimer’s disease, pure tauopathies and potentially 
other neurodegenerative diseases with an underlying autophagic impairment or 
neuroinflammatory component.    
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6 Future Directions 
 
In the first chapter of this thesis we focused on describing the activation of SYK in different cell 
types of the CNS and compared human AD specimens to non-demented controls, as well as AD 
mouse models overexpressing tau and Aȕ to wild-type littermates. The second and third chapters 
mainly focused on the relationship between SYK and the tau pathology in vitro and in a chronic 
in vivo treatment paradigm.  
However, we already performed experiments that investigated the effects of chronic SYK 
inhibition on AD mouse models overexpressing Aȕ (Tg APPsw and Tg PS1/APPsw). We 
investigated two different age-groups that were treated with 20mg/kg BAY61-3606 or placebo; 
70-week-old and 90-week-old transgenic mice were each compared to age-matched wild-type 
littermates. The two chronic treatments lasted for 14 weeks (70-week-old cohort) and 7 weeks (90-
week-old cohort). The studies aimed to investigate the behavior (spatial memory, learning, anxiety, 
and social memory), as well as AD-related pathological changes on a molecular level, including 
Aȕ burden, neuroinflammation, neurodegeneration, and synaptical changes using different 
techniques like ELISA, immunoblotting, and immunofluorescence microscopy. The analyses of 
these studies are still ongoing as of 2018 and will further elucidate the impact of chronic SYK 
inhibition on the Aȕ pathology in two different mouse models of AD and additionally give valuable 
information about the best time point of intervention with a SYK inhibitor.  
In addition to the two studies mentioned above, it will be interesting to add another, younger, age-
group and treat 45-week-old Aȕ-overexpressing mice chronically with the SYK inhibitor BAY61-
3606. This study will provide us with more detailed information about the time of intervention 
with a SYK inhibitor.  
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As mentioned in the previous chapter (5) and the introduction (1.3), there are already a few SYK 
inhibitors in clinical trials and they generally have a good safety profile, but none of them has been 
designed for the treatment of neurological disorders. Therefore, the next crucial step on the way to 
successful SYK-based therapies for neurological disorders is the development of novel specific 
SYK inhibitors that are designed to cross the BBB well and achieve an optimal target engagement 
in the CNS.    
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Alzheimer’s disease pathological lesions
activate the spleen tyrosine kinase
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Abstract
The pathology of Alzheimer’s disease (AD) is characterized by dystrophic neurites (DNs) surrounding extracellular
Aβ-plaques, microgliosis, astrogliosis, intraneuronal tau hyperphosphorylation and aggregation. We have previously
shown that inhibition of the spleen tyrosine kinase (Syk) lowers Aβ production and tau hyperphosphorylation in vitro
and in vivo. Here, we demonstrate that Aβ-overexpressing Tg PS1/APPsw, Tg APPsw mice, and tau overexpressing Tg
Tau P301S mice exhibit a pathological activation of Syk compared to wild-type littermates. Syk activation is occurring in
a subset of microglia and is age-dependently increased in Aβ-plaque-associated dystrophic neurites of Tg PS1/APPsw
and Tg APPsw mice. In Tg Tau P301S mice, a pure model of tauopathy, activated Syk occurs in neurons that
show an accumulation of misfolded and hyperphosphorylated tau in the cortex and hippocampus. Interestingly,
the tau pathology is exacerbated in neurons that display high levels of Syk activation supporting a role of Syk in
the formation of tau pathological species in vivo. Importantly, human AD brain sections show both pathological
Syk activation in DNs around Aβ deposits and in neurons immunopositive for pathological tau species recapitulating
the data obtained in transgenic mouse models of AD. Additionally, we show that Syk overexpression leads to increased
tau accumulation and promotes tau hyperphosphorylation at multiple epitopes in human neuron-like SH-SY5Y
cells, further supporting a role of Syk in the formation of tau pathogenic species. Collectively, our data show that
Syk activation occurs following Aβ deposition and the formation of tau pathological species. Given that we have
previously shown that Syk activation also promotes Aβ formation and tau hyperphosphorylation, our data suggest that
AD pathological lesions may be self-propagating via a Syk dependent mechanism highlighting Syk as an attractive
therapeutic target for the treatment of AD.
Keywords: Alzheimer’s disease, Spleen tyrosine Kinase, Dystrophic neurite, Aβ, sAPPβ, BACE1,
Tau hyperphosphorylation, Tau oligomers, Tg PS1/APPsw, Tg APPsw, Tg Tau P301S
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease
that accounts for the majority of all cases of dementia.
AD pathological hallmarks include extracellular aggre-
gates of Aβ, intracellular tau hyperphosphorylation and
aggregation, as well as neuroinflammation. Tau is a
microtubule-associated protein (MAP) involved in many
essential cellular processes including stabilization of the
microtubule network, thereby providing a functional
basis for intracellular transport [10]. Misfolding and
pathological post-translational modifications including tau
hyperphosphorylation contribute to its oligomerization
and accumulation that ultimately leads to neuronal death
[10]. In addition, tau mutations that cause familial forms
of dementia associated with the formation of tau aggre-
gates have been identified suggesting that pathological tau
species may play a key role in AD.
Tau and Aβ have been proposed to synergistically
contribute to the pathobiology of AD [25]. Through
cleavage of the amyloid precursor protein (APP) by α, β
and γ-secretases different variants of Aβ and soluble
APP forms (α, β) are generated [41]. A variety of post-
translational modifications and the nature of the Aβ
variants define their susceptibility to aggregation and
neurotoxicity [41, 42]. Several mutations in the APP and
presenilin (PSEN1/2) genes (members of the γ-secretase
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complex) have been identified and cause familial forms
of AD (FAD) [36]. These mutations either render APP
more susceptible to cleavage by the β-secretase (BACE-1)
or the γ-secretase resulting in increased Aβ production or
lead to the production of longer forms of Aβ that are
more prone to aggregation and accumulation resulting in
early onset AD (EOAD). In contrast, the etiology of spor-
adic or late onset AD (LOAD) accounts for more than
99% of all AD cases and remains unknown [24].
Many studies have suggested the importance of neuro-
inflammation caused by Aβ in AD and that a therapeutic
strategy can only be successful if it counteracts the
neurotoxicity caused by inflammation [24, 29]. Aβ fibrils
have been shown to trigger an inflammatory response in
primary microglial and monocytic cells via an activation
of the tyrosine kinases Lyn (Lck/Yes novel tyrosine
kinase) and Syk (spleen tyrosine kinase) [3, 23]. Import-
antly, Syk inhibition appears to prevent Aβ-mediated
neurotoxicity in vitro [3]. A subsequent study also
showed that Syk is the mediator of the Aβ-induced cyto-
kine production including tumor necrosis factor alpha
(TNFα) and interleukin 1 beta (IL-1β) by activated
microglia [4] suggesting that Syk is a key kinase respon-
sible for the proinflammatory activity of Aβ.
Many different sites of tau hyperphosphorylation have
been identified in AD and various kinases have been the
subject of investigations regarding their possible involve-
ment in tau pathogenesis. Syk and Src family kinases
have been shown to phosphorylate tau directly at Y18
[20, 25]. Tau tyrosine phosphorylation is considered an
early pathological change in AD [5, 20]. Syk has also
been shown to phosphorylate microtubules which could
have an effect on microtubule polymerization or the
interaction of signaling molecules with the microtubule
network [6]. Moreover, pharmacological Syk inhibition
has been found to stabilize microtubules through dephos-
phorylation of microtubules and microtubule associated
proteins (MAPs) [44].
We have previously shown that Syk regulates the
activation of the glycogen synthase kinase-3β (GSK3β),
one of the main tau kinase that phosphorylates tau at
multiple sites present in neurofibrillary tangles [28]. In
addition, we have shown that Syk also regulates Aβ
production and proposed that Syk could be an im-
portant therapeutic target for the treatment of AD as
pharmacological inhibition of Syk appears to reduce
tau hyperphosphorylation and Aβ production both in
vitro and in vivo [28].
Syk is a non-receptor protein-tyrosine kinase (PTK)
that mediates inflammatory responses [8]. PTKs like Syk
are part of receptor-mediated signal transduction
cascades that require their intracellular association with
integral membrane receptors including toll-like recep-
tors (TLRs [11]) and Fc receptors (FcγR [14], FcεRI
[21]). Recruitment and activation of Syk is also mediated
by activation of triggering receptor expressed on myeloid
cells 2 (TREM2) [18]. Interestingly, several variants of
TREM2 are associated with an increased risk to develop
AD and have been shown to alter AD pathology includ-
ing Aβ deposition, tau hyperphosphorylation, neuroin-
flammation and synaptic loss in AD mouse models [17].
Syk becomes active through autophosphorylation and
several Syk autophosphorylation sites have been identi-
fied in vitro: Y130, Y290, Y317, Y346, Y358, and Y525/
526. The Y525/526 phosphorylation site is the main site
involved in receptor-mediated Syk activation and signal
propagation [30]. Although our previous work suggests
that Syk could represent a therapeutic target for AD, the
cellular localization and the activity pattern of Syk in the
brains of transgenic mouse models of AD and AD
pathological specimens remains to be determined. We
therefore investigated in this study whether Syk activa-
tion occurs in the brains of different mouse models of
AD and in human AD brain by monitoring the Y525/
526 Syk autophosphorylation site and analyzing its asso-
ciation with AD pathological hallmarks.
We investigated two different AD mouse models that
overexpress APP and one mouse model of pure tauopathy
that overexpresses human tau with the P301S mutation.
In our study, we employed transgenic APPsw (Tg 2576)
mice overexpressing the Swedish mutation (KM670/
671NL) of APP695 under the control of the hamster prion
protein promoter [13]. These mice have elevated levels of
Aβ and typically develop Aβ plaques at the age of
11 months [15]. We also analyzed transgenic PS1/APPsw
mice which carry the APP KM670/671NL (Swedish) and
the PSEN1 M146L mutations. In these mice, the human
PSEN1 M146 L transgene is driven by the PDGF-β pro-
moter. These double transgenic mice develop cortical and
hippocampal amyloid deposits at 6 months of age; much
earlier than the single transgenic APPsw (Tg2576).
Additionally, the total Aβ burden is increased in these
double transgenic mice compared to the single Tg 2576
transgenic mice [12]. Aβ deposits are associated with dys-
trophic neurites that occur at 12 months of age in Tg PS1/
APPsw mice [9]. Furthermore, these mice display an
increase in Aβ plaque-associated microglia and astrocytes
at 6 months of age. However, increased microglial activity
has been found to occur at 12 months [9]. In addition, we
analyzed whether Syk activation occurs in the brain of
transgenic Tau P301S PS19 mice that overexpress human
tau with the P301S mutation. The P301S mutation in the
tau gene on chromosome 17 has been associated with
autosomal dominantly inherited frontotemporal dementia
and parkinsonism (FTDP-17) [1, 22, 38]. The expression
of the P301S mutated tau is fivefold higher in Tg Tau
P301S mice than the endogenous mouse protein and
is driven by the mouse prion protein promoter [43].
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Interestingly, these mice progressively develop neurode-
generation and display intraneuronal tau hyperphosphory-
lation and aggregation that closely mimic neurofibrillary
tangles.
In this study, we show by high-resolution confocal mi-
croscopy that Syk activation is increased in a subset of
activated microglia and in dystrophic neurites around
Aβ plaques of Tg APPsw and Tg PS1/APPsw mice.
Interestingly, pSyk is also age-dependently increased in
neurons of Tg Tau P301S mice. The degree of colocaliza-
tion between Syk and tau is largely dependent on the tau
epitope investigated and differs between various phospho-
tau epitopes and tau oligomers/conformers. The level of
Syk activation, as measured by fluorescence intensity,
correlates with the amount of pathological tau species
detected. In addition, we show that Syk overexpression in
human neuronal like cells (SH-SY5Y) results in increased
total tau and tau phosphorylation levels at multiple epi-
topes. Taken together, our results show that β-amyloid
and tau pathological species both activate Syk in vivo and
conversely, that Syk is involved in microglial activation,
plays a role in the pathogenesis of dystrophic neurites
(DNs) and contributes to the formation of pathological
tau species therefore exacerbating AD pathological lesions.
Interestingly, human AD brain sections exhibit the same
pattern of Syk activation as the mouse models of β-
amyloidosis and tauopathy combined. Human AD brain
sections show an increase in pSyk (phosphorylated Syk at
Y525/526) levels in DNs around β − amyloid plaques and
in neurons immunopositive for hyperphosphorylated tau
(Y18) and pathological tau conformers (MC1), whereas
brain sections from non-demented controls do not show
any pSyk increase. Altogether, these data suggest a crucial
role of Syk in the pathobiology of AD and highlight Syk as
a promising therapeutic target in AD.
Materials and methods
Animals
Tg PS1/APPsw, Tg APPsw, Tg Tau P301S and wild-type
mice were generated and maintained in a C57BL/6 genetic
background as previously described [28]. All mice were
maintained under specific pathogen free conditions in venti-
lated racks in the Association for Assessment and Accredit-
ation of Laboratory Animal Care International (AAALAC)
accredited vivarium of the Roskamp Institute. All experi-
ments involving mice were reviewed and approved by the
Institutional Animal Care and Use Committee of the
Roskamp Institute before implementation and were con-
ducted in compliance with the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals.
Tissue processing
All mice were humanely euthanatized and their brains
were collected and fixed in 4% paraformaldehyde (PFA)
for 48 h. The method of euthanasia used follow the
AVMA (American Veterinary Medical Association) guide-
lines for the euthanasia of animals. Briefly, mice were
rendered unconscious through inhalation of 5% isoflurane
in oxygen using a vaporizer and a gas chamber. While
under anesthesia, after verifying the absence of reflexes,
mice were euthanatized by exsanguination (blood was
withdrawn from cardiac puncture).
Subsequently, the hemispheres were processed in a
Sakura Tissue-Tek VIP (Leica Biosystems Inc., IL, USA)
vacuum infiltration processor. Brains were then embed-
ded in paraffin with the Sakura Tissue-Tek (Leica Biosys-
tems Inc., IL, USA) and stored at 4 °C for 2 days for
subsequent cutting with a Leica RM2235 microtome
(Leica Biosystems Inc., IL, USA). All brains were cut at a
thickness of 12 μm. Sagittal slices were mounted on
glass slides and dried for 48 h at 37 °C for subsequent
immunofluorescence staining and confocal imaging.
Immunofluorescence
Paraffin sections were washed in two baths of histoclear
(National Diagnostics, USA) and progressively rehy-
drated with ethanol gradients and phosphate buffered
saline (PBS, Sigma Aldrich, MO, USA). Brain sections
were subjected to antigen retrieval for 7 min in citric
acid buffer (pH 6) at 100 °C. All sections were treated
with 0.05% Sudan Black in 70% ethanol to quench
autofluorescence. Sections were then blocked in PBS
containing 10% donkey serum (Abcam, MA, USA) for
1 h. Sections were incubated in PBS containing 1%
donkey serum and the respective panel of primary anti-
bodies overnight at 4 °C. The following antibodies were
used: CP13 (anti(α)-phospho-tau (pTau) S202, 1:200, Dr.
Peter Davies’ Lab), MC1 (α-conformational tau, 1:200,
Dr. Peter Davies’ Lab), TOC1 (1:200, Dr. Lester Binder’s
Lab), PHF-1 (α-pTau S396/404, 1:200, Dr. Peter Davies’
Lab), 9G3 (α-pTau Y18, 1:200, MediMabs Inc., QC,
Canada), DA9 (α-total-tau (tTau), 1:200, Dr. Peter
Davies’ Lab), α-BACE1 (1:200 Cell Signaling, MA, USA),
α-sAPPβ with Swedish mutation (1:100 Immuno-
Biological Laboratories Co, Ltd., Japan), α-Iba1 (1:300,
Abcam, MA, USA), α-GFAP (1:5000, Aves Labs, OR,
USA), α-pSyk (Y525/526, 1:200, Cell Signaling, MA,
USA). In addition to the α-pSyk (Y525/526, 1:200, Cell
Signaling, MA, USA), we used the α-pSyk (Y525/526,
1:100, Abgent, CA, USA) and obtained similar results.
After three washing steps in PBS for 5 min, sections
were incubated in a solution containing PBS, 1% donkey
serum and the respective panel of secondary antibodies
for 1 h in the dark at room temperature in a humidified
chamber. The following secondary antibodies were used:
donkey α-rabbit, α-goat, α-mouse conjugated to Alexa
488, 568 and 647, respectively (1:500, Life technologies).
After three washing steps in PBS for 5 min, sections
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were mounted in Fluoroshield with or without DAPI
(Sigma Aldrich, MO, USA). All images were acquired
using the confocal microscope LSM 800 (Carl Zeiss AG,
Germany), the ZEN Blue 2.1 (Carl Zeiss AG, Germany)
software and a 20× or 63× objective. The acquisition set-
tings were kept the same for all genotypes within the same
experiment.
For qualitative analysis of the pSyk burden in Tg PS1/
APPsw and Tg APPsw mice compared to age-matched
WT littermates (n = 6 for each genotype, equal amount of
male and female), 116 ± 13.5 (avg. ± SEM) weeks of age
were stained and analyzed as described above (Fig. 1).
For qualitative analysis of the pSyk burden in Tg Tau
P301S mice compared to WT littermates, hippocampi
and cortices of 16 male and female mice ranging from 8
to 56 weeks of age were stained and analyzed as
described above.
For the quantitative analysis of the pSyk burden
(Fig. 3), 140 randomly-selected microscopic fields of four
non-consecutive brain slices (containing the hippocam-
pus) from six animals per genotype (equal number of
male and female) were acquired. The area covered with
the pSyk immunopositive staining was quantified with
Fiji [34] in microscopic fields containing Aβ plaques as
well as in microscopic fields not containing Aβ deposits.
The PS1/APPsw, APPsw and WT mice of the younger
cohort were on average 45 ± 0.3 (avg. ± SEM) weeks old.
The average age of the mice of the older cohort was 116
± 13.5 weeks (±SEM). The pSyk burden of the transgenic
mice was normalized to the level of pSyk burden quanti-
fied in wild-type littermates of the respective age-group.
As a negative control, primary antibodies were omitted
to determine background and autofluorescence (not
shown).
For the quantitative analysis of the colocalization of
pSyk and different tau epitopes (Fig. 8) between 400 and
570 cortical fields (50,000 μm2 per field) from four male
Tg Tau P301S animals (average age 47 ± 3.1 (SEM) weeks)
were analyzed for each tau epitope. To quantify the per-
centage of the immunopositive neurons a total of 2546
microscopic fields and 21,800 neurons were counted using
the Zen Blue 2.1 software (Carl Zeiss AG, Germany).
The fluorescence intensities (Figs. 9, 10, 11, 12 and 13)
of 30 to 40 neurons immunopositive for pSyk, pTau or
both (colocalized) were determined for each tau epitope
(total of 90 neurons per epitope) using Zen Blue 2.1
(Carl Zeiss AG, Germany). The male Tg Tau P301S mice
(n = 4) used for quantification were on average 47 ±
3.1 weeks old (avg. ± SEM).
In addition, the different immunostainings mentioned
above were performed on paraffin-embedded tissue
sections (10 μm, dorsolateral frontal cortex) from a 67-
year-old, male patient with AD (Braak VI) and a 102-
year-old, male non-demented control that were provided
by Dr. Ann McKee (Boston University, MA, USA).
Institutional review board approval for brain donation
was obtained through the Boston University Alzheimer’s
Disease Center (BUADC, Boston, MA, USA).
Cell culture
SH-SY5Y cells were purchased from American Type
Culture Collection (VA, USA). SH-SY5Y cells were
grown in DMEM/F12 medium (Thermo Fisher Scientific,
MA, USA) supplemented with 10% fetal bovine serum
(Thermo Fisher Scientific, MA, USA), GlutaMAX and 1%
penicillin/streptomycin/fungizone.
Generation of Syk overexpressing SH-SY5Y cells
A human cDNA ORF Clone of the human SYK gene
(NM_003177, transcript variant 1) was purchased from
OriGene Technologies (MD, USA). The cDNA fragment
encoding human SYK was amplified by PCR using
PfuUltra II Fusion HS DNA polymerase (Agilent
Genomics, CA, USA) and subcloned into the p3xFLAG-
Myc-CMV™-26 Expression Vector (Sigma-Aldrich, MO,
USA) to generate the pCMV-SYK-Flag plasmid. The
entire reading frame of the plasmid was confirmed by
DNA sequencing. SH-SY5Y cells were maintained in
advanced DMEM/F-12 medium supplemented with 10%
fetal bovine serum, 1% GlutaMAX, 1% penicillin/strepto-
mycin (Thermo Fisher Scientific, MA, USA) and incu-
bated in a humidified 5% CO2 atmosphere at 37 °C. For
stable transfection, SH-SY5Y cells were grown in 6-wells
cell culture plates until reaching 70-80% confluence and
transfected with 3 μg of empty pCMV vector (control
cells) or pCMV-SYK-Flag plasmids per well using lipo-
fectamine 2000 (Thermo Fisher Scientific, MA, USA).
After 48 h, the medium surrounding transfected cells
was replaced with fresh medium containing 0.2 mg/ml
of G418 for selection. After 14 days of selection, G418
resistant cells were trypsinized and expanded. The ex-
pression efficiency of SYK was analyzed by Western blot
using antibodies against SYK (4D10 Syk antibody,
Santa Cruz Biotechnology, TX, USA) and the Flag tag
(Sigma-Aldrich, MO, USA).
Immunoblotting
SH-SY5Y cells were cultured in 24-well-plates for 24 h
and subsequently lysed with mammalian protein extrac-
tion reagent (MPER, Thermo Fisher Scientific, MA,
USA) containing Halt protease & phosphatase single use
inhibitor/EDTA (Thermo Fisher Scientific, MA, USA)
and 1 mM PMSF. Proteins of cell lysates were separated
by 10% tris-glycine-SDS-PAGE using 1 mm Criterion
TGX gels (Bio-Rad Laboratories, CA, USA) and electro-
transferred onto 0.2 μm PVDF membranes (Bio-Rad
Laboratories, CA, USA). Membranes were blocked in
TBS containing 5% non-fat dried milk for 1 h and were
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hybridized with the primary antibody (αSyk (4D10,
1:1000, Santa Cruz, TX, USA), αpTau S396/404 (PHF-1,
1:1000, Dr. Peter Davies’ Lab), αtTau (DA9, 1:1000, Dr.
Peter Davies’ Lab), αpTau Y18 (9G3, 1:1000, MediMabs
Inc., QC, Canada,) overnight at 4 °C. Subsequently, the
membranes were incubated for 1 h in HRP-conjugated
αmouse secondary antibody (1:1000, Cell Signaling, MA,
USA). Western blots were visualized using chemilumin-
escence (Super Signal West Femto Maxium Sensitity
Substrate, Thermo Fisher Scientific, MA, USA). Sig-
nals were quantified using ChemiDoc XRS (Bio-Rad
Laboratories, CA, USA) and densitometric analyses
were performed using Quantity One (Bio-Rad Laboratories,
CA, USA) image analysis software.
Statistical analyses
The data were analyzed and plotted with GraphPad Prism
(GraphPad Software, Inc., CA, USA). The Shapiro-Wilk
test for normality was used to test for Gaussian distribu-
tion. Statistical significance was determined by either
Kruskal-Wallis followed by Dunn’s post-hoc test or the
non-parametric Mann–Whitney test. All data are pre-
sented as mean ± the standard error of the mean (SEM)
and p < 0.05 was considered significant.
Results
Syk activation in activated microglia and non-glial cells
associated with Aβ-plaques in Tg APPsw and Tg PS1/
APPsw mice
To investigate whether pathological Syk activation oc-
curs in the brain of AD mouse models, we analyzed the
brains of 116-week-old wild-type, Tg APPsw and Tg
PS1/APPsw mice using high-resolution confocal micros-
copy and immunofluorescence. All transgenic mice
(Fig. 1b-e) exhibit an increased Iba-1 and GFAP reactiv-
ity compared to wild-type littermates (Fig. 1a). Moreo-
ver,wild-type some of the activated amoeboid microglia
that are observed in transgenic mice are also strongly
positive for pSyk (Fig. 1b-d). By contrast, we did not
detect any pSyk immunoreactivity in astrocytes (Fig. 1).
In addition, we observed that pSyk immunoreactivity is
upregulated near Aβ plaques but neither colocalizes with
microglia nor astrocytes suggesting that it could be of
neuronal origin. (Fig. 1e). We further investigated the
cellular origin of these pSyk accumulations by immuno-
fluorescence staining and confocal microscopy (Fig. 2).
pSyk is increased in dystrophic neurites of Aβ-
overexpressing mice
To further characterize the cellular origin of pSyk accu-
mulations near Aβ plaques, we tested different markers
of dystrophic neurites (BACE-1 and sAPPβ) [31] and
found a strong colocalization between pSyk and sAPPβ
(Fig. 2a) associated with Aβ deposits. The sAPPβ stain-
ing clearly reveals dystrophic swellings of neurites
(Fig. 2a) which are a known hallmark of AD. Most of the
dystrophic neurites are positive for pSyk (Fig. 2a). Add-
itionally, we found a strong colocalization between sAPPβ
and BACE-1 (Fig. 2b) which are often used as markers of
dystrophic neurites. Both sAPPβ and BACE-1 exhibit
circular accumulations near Aβ plaques (Fig. 2b), highly
reminiscent of the pattern observed for activated Syk.
In conclusion, activated Syk is not only found in
microglia but also in neurons near Aβ deposits, par-
ticularly in dystrophic neurites of Tg APPsw and Tg
PS1/APPsw mice supporting a possible role of Syk
activation in the formation of dystrophic neurites.
Dystrophic neurites are characterized by an accumula-
tion of BACE-1 and sAPPβ [31] and our previous
work [28] has shown that Syk regulates BACE-1
expression and sAPPβ levels suggesting that Syk
upregulation in dystrophic neurites could contribute
to the accumulation of BACE-1 and sAPPβ.
Cortical pSyk burden is age-dependently increased in
Aβ-overexpressing mice, particularly in microscopic fields
containing Aβ-plaques, compared to wild-type littermates
We also quantified the pSyk burden observed in the
cortex of Tg APPsw, Tg PS1/APPsw and wild-type (WT)
littermates (Figs. 1 and 2). Two different age-groups
were investigated: younger animals, 45 weeks of age and
older animals 116 weeks of age in average. In 45-week-
old Tg APPsw mice, we did not observe significant β-
amyloidosis (only three Aβ plaques were found in the
cohort of mice analyzed) (data not shown) showing that,
at that age, the Aβ pathology is almost inexistent in
these mice. We differentiated between microscopic fields
containing Aβ deposits and microscopic fields not
(See figure on previous page.)
Fig. 1 pSyk is increased in activated microglia and non-glial cells associated with Aβ-plaques in Tg APPsw and Tg PS1/APPsw mice. a Spatial
distribution and cellular localization of activated/phosphorylated Syk were investigated in the cortex of 116 ± 13.5-week-old (avg. ± SEM) wild-
type mice (n = 6) by triple-immunostaining of pSyk (Y525/526, green), microglia (Iba1, red) and astrocytes (GFAP, purple). Nuclei were stained
with DAPI (blue). b Syk activation in wild-type animals was compared to age-matched Tg APPsw (n = 6) (b-c) and Tg PS1/APPsw littermates
(n = 6) (d-e). Plaque-associated cortical areas (c, e) were compared to non-plaque-associated areas (b, d). Qualitative image analysis of orthogonal
projections and 3D-image analysis (not-shown) revealed an increased pSyk burden in transgenic (b-e) compared to wild-type mice (a) and a
colocalization of pSyk and Iba1 but not GFAP in Aβ-overexpressing animals (b-d). Large, non-glial spherical accumulations of pSyk were observed
in plaque-associated areas (e). The scale bar represents 10 μm
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containing Aβ deposits for the quantification of the pSyk
burden in Tg PS1/APPsw and older Tg APPsw mice. 45-
week-old Tg APPsw and Tg PS1/APPsw mice do not
show any significant difference in pSyk burden in fields
without Aβ deposits compared to WT mice. The pSyk
burden of 45-week-old Tg APPsw mice is identical to
that of the WT mice (100 ± 6.76% compared to 80.85 ±
11.77%; Fig. 3a). The pSyk burden in fields not contain-
ing Aβ plaques in Tg PS1/APPsw mice is not statistically
significantly elevated (153.48 ± 18.47%), compared to the
WT littermates. As expected, 45-week-old Tg PS1/APPsw
mice exhibited a significantly higher pSyk burden in fields
containing Aβ plaques (410.19 ± 46.46%) compared to
WTand Tg APPsw mice.
The analysis of the pSyk burden in the cortex of older
animals (average age: 116 weeks) revealed large differ-
ences between genotypes. The pSyk burden of Tg APPsw
(216.32 ± 45.23%) mice in microscopic fields without
Fig. 2 pSyk is increased in dystrophic neurites of Aβ-overexpressing mice. Representative confocal image of depicting the cortex of 116.5 ± 13.5-
week-old Tg PS1/APPsw mice stained for sAPPβ (purple), pSyk (green, a), BACE1 (green, b), Iba-1 (red). Nuclei were stained with DAPI (blue). a pSyk
was accumulated in dystrophic neurites positive for sAPPβ (a) and BACE1 (b). The scale bars represent 10 μm
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plaques is not significantly increased compared to WT
mice (100 ± 7.78%) (Fig. 3b). In contrast, microscopic fields
of older Tg APPsw mice containing Aβ deposits exhibit a
strong increase in pSyk burden (799.95 ± 130.19%) com-
pared to age-matched WT mice. Tg PS1/APPsw mice also
exhibit a statistically significant increase in pSyk burden in
microscopic fields that do not contain Aβ deposits (458.1
± 109.68) compared to age-matched WT controls. In
addition, a much greater pSyk burden is found in Tg
PS1/APPsw in microscopic fields containing Aβ de-
posits. In these fields, the pSyk burden is increased by
1157.31 ± 129.68% compared to WT littermates (Fig. 3b).
In conclusion, our data show that the pSyk burden is
highly associated with Aβ plaques and increases with age
in Tg PS1/APPsw and Tg APPsw mice whereas no activa-
tion of Syk is observed in the brain of WT littermates. The
upregulation of Syk activation observed in the brains of Tg
APPsw and Tg PS1/APPsw is mainly attributable to pSyk
accumulations in dystrophic neurites that are associated
with Aβ plaques and increase with age and Aβ burden.
Syk activity is increased in hippocampal and cortical
neurons of Tg Tau P301S mice
Having shown that Aβ-overexpressing mouse models of
AD exhibit an increased Syk activation in microglia and
dystrophic neurites, we investigated whether Syk activa-
tion also occurs in Tg Tau P301S mice (a pure model of
tauopathy) using immunofluorescence and confocal mi-
croscopy. Hippocampal neurons of Tg Tau P301S mice
exhibit a high level of tau hyperphosphorylation (Fig. 4b)
as well as an accumulation of pathogenic tau conformers
(MC1, not shown) compared to WT littermates (Fig. 4a).
Most importantly, pathological tau species clearly colo-
calize with pSyk (Y525/526) in hippocampal neurons
(Fig. 4b). The pSyk burden is particularly prominent in
hippocampal neurons of Tg Tau P301S mice (Fig. 4b)
whereas WT littermates do not exhibit any pSyk immu-
noreactivity in the hippocampus (Fig. 4a).
Cortical neurons of Tg Tau P301S mice also exhibit an
increased level of tau hyperphosphorylation (Fig. 5b)
compared to wild-type littermates (Fig. 5a). We observed
a colocalization between pSyk and pTau (S202) immuno-
reactivities in cortical neurons. Interestingly, we also
observed neurons that are singly immunopositive for tau
or for pSyk. We addressed this observation by performing
additional analyses (Figs. 8, 9, 10, 11, 12, 13, 14 and 15).
We also analyzed the temporal changes of pSyk and tau
levels in hippocampi and cortices of Tg Tau P301S mice
between the age of 8 and 56 weeks (Figs. 6 and 7). WT
mice do not exhibit any detectable tau phosphorylation
Fig. 3 Cortical pSyk burden is age-dependently increased in Aβ-overexpressing mice, particularly in microscopic fields containing Aβ deposits,
compared to wild-type littermates. Cortical pSyk burden (area covered) of immunofluorescence images (Fig. 1) was quantified in 45 ± 0.3-week-
old (avg. ± SEM) (a) and 116 ± 13.5-week-old (avg. ± SEM) (b) Tg APPsw (n = 6) and Tg PS1/APPsw mice (n = 6), compared and normalized to wild-
type littermates (n = 6). Microscopic fields containing Aβ deposits were distinguished from microscopic fields not containing Aβ deposits as described
in the materials and methods section. Kruskal-Wallis and post-hoc Dunn’s multiple comparison test revealed a significant increase (p < 0.001) in pSyk in
fields containing Aβ deposits in younger Tg PS1/APPsw animals compared to age-matched wild-type littermates (a). pSyk burden in older Tg APPsw
and Tg PS1/APPsw mice was statistically significantly increased in cortical microscopic fields containing Aβ deposits compared to age-matched wild-
type littermates (p < 0.001). Older Tg PS1/APPsw mice also exhibited a statistically significant pSyk burden increase in microscopic fields not containing
Aβ deposits (p < 0.001), whereas the pSyk burden in Tg APPsw in microscopic fields not containing Aβ deposits was not statistically different from
wild-type littermates (P > 0.05). Six animals per genotype were analyzed. Error bars represent SEM
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(Fig. 6f) or tau oligomerization at any age (not shown).
We then focused on the dentate gyrus of the hippocampus
and found an age-dependent increase of tau phosphoryl-
ation (Fig. 6, S202, left panels) in Tg Tau P301S mice. Tau
phosphorylation at S202 in the dentate gyrus was already
detectable in 8-week-old Tg Tau P301S mice, however,
pSyk immunoreactivity was not observed. Neurons immu-
nopositive for pSyk (Y525/526) and pTau (S202) or tau
conformers (MC1, not shown) were observed in the
dentate gyrus of 42-week-old Tg Tau P301S mice (Fig. 6d).
The neuronal pSyk burden also increases with age in Tg
Tau P301S mice and is mainly restricted to the neuronal
cell body (Fig. 6). Interestingly, microglia and neurites did
not exhibit activated Syk in the hippocampus of Tau
P301S mice (Fig. 6). Abnormal Syk activation seems to fol-
low tau hyperphosphorylation (S202) in the hippocampus
of Tg P301S mice (Fig. 6), as well as the formation of
MC1-tau pathological conformers (data not shown here
but MC1 and pSyk colocalization were quantified below).
Cortical neurons of Tg Tau P301S mice also show an in-
crease in tau hyperphosphorylation and pSyk with age
(Fig. 7). Interestingly, the onset of abnormal Syk activation
occurs earlier (16 weeks of age) in the cortex than in the
hippocampus (Fig. 7b compared to Fig. 6d). In conclusion,
both pSyk and tau pathology in Tg Tau P301S mice
increase with age but the progression is different in the
hippocampus and the cortex. Many cortical neurons ex-
hibit a colocalization of pSyk and pTau (S202) (Fig. 7b-c, e)
but as mentioned earlier, there are also neurons that are
singly immunopositive for pSyk or pTau.
We further quantified the number of neurons that are
singly pSyk immunopositive, singly immunopositive for
tau pathogenic species and neurons immunopositive for
both pSyk and tau pathogenic species in the cortex of
47-week-old Tg Tau P301S mice (Fig. 8). We calculated
the percentages of neurons singly immunopositive for
either pSyk, pathogenic tau species or neurons immuno-
positive for both. The sum of all cortical neurons
counted was considered 100% including neurons positive
for pSyk and the respective tau epitope and neurons
immunopositive for both. For all the tau epitopes tested,
we found that only a small fraction of the neurons is sin-
gly immunopositive for pSyk (9.7 ± 4.4% (pTau, Y18);
2.5 ± 1.2% (pTau, S202); 9.2 ± 1.6% (MC1 pathogenic tau
conformers); 9.6 ± 6.3% (pTau, S396/404); 4.8 ± 2.0%
(TOC1 (tau oligomers)). Interestingly, a larger percent-
age of neurons is immunoreactive for both pSyk and tau
pathogenic species (44.7 ± 8.6% (MC1); 39.7 ± 12.4%
pTau Y18; 22.5 ± 18.6% (PHF-1, pTau S396/404); 12.4 ±
8.1% (TOC1, tau oligomers) but only 5.7 ± 2.2% for pTau
(S202)). The neurons singly immunopositive for tau
complement these observations with relative values of
46.1 ± 8.2% (MC1), 50.6 ± 16.3% (Y18), 67.9 ± 24.9%
(S396/404), 82.8 ± 10.1% (TOC1), and 91.8 ± 3.2% (S202)
(Fig. 8). The differences in relative colocalization be-
tween pSyk and specific tau pathologic species suggest
that specific pathogenic forms of tau may have a differ-
ent impact on Syk activation or either that Syk activation
may contribute to the formation of specific tau patho-
genic species (Fig. 8). We therefore subsequently mea-
sured the fluorescent intensities of pSyk and of the
different tau epitopes to determine whether the level of
Syk activation correlates with the amount of specific tau
pathogenic species. In general, we found that neurons
that exhibit a high level of pSyk immunoreactivity also
demonstrate a higher level of tau pathogenic species
whereas neurons that are weakly immunopositive for
pSyk show less tau pathology (Figs. 9, 10, 11, 12 and 13).
In addition, neurons that are singly immunopositive for
tau pathogenic species (including hyperphosphorylated
tau and misfolded tau) show also less intense tau path-
ologies, as measured by fluorescent intensities, than neu-
rons that are displaying both pSyk and tau pathology,
further supporting a role of Syk in the formation of tau
pathogenic species. For instance, the level of pathogenic
tau conformers (MC1) is significantly increased in neu-
rons that are also strongly immunopositive for pSyk com-
pared to neurons that are singly immunopositive for MC1
(Fig. 9d, p < 0.05). Interestingly, the level of pSyk is also
significantly increased in neurons that display an accumu-
lation of MC1 pathogenic conformers compared to neu-
rons that are singly immunopositive for pSyk (Fig. 9e, p <
0.01). These data suggest that pathogenic tau conformers
and Syk activation may promote each other. We found
that tau phosphorylation at Y18 is significantly increased
in neurons that are also immunopositive for pSyk (Fig. 10d,
p < 0.05) which is consistent with previous data showing
that in vitro Syk can phosphorylates tau at Y18. We have
previously shown that Syk positively regulates GSK-3β
activity in vitro. It is therefore consistent with our obser-
vation that the GSK-3β-dependent phospho-tau epitope
(S396/404, PHF-1) is also increased in neurons that dis-
play Syk activation (Fig. 11d, p < 0.0001). The pSyk level,
however, is not statistically significantly increased in
(See figure on previous page.)
Fig. 4 pSyk is increased in hippocampal neurons of Tg Tau P301S mice compared to wild-type littermates. Representative confocal image
depicting 56 week-old male Tg Tau P301S and wild-type mice stained with antibodies against pTau (S202, purple) and pSyk (Y525/526, green).
a Wild-type mice did not exhibit any tau phosphorylation nor Syk activation in their hippocampi. b Tau-overexpressing Tg Tau P301S mice
exhibited a prominent tau phosphorylation at S202 that colocalized with Syk activation in hippocampal neurons. The scale bars represent 200 μm
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neurons that are immunopositive for both PHF-1 and
pSyk compared to neurons that are singly immunopositive
for pSyk suggesting that PHF-1 phosphorylated tau spe-
cies do not induce Syk activation (Fig. 11e). Similar
observations were obtained for tau oligomers (Fig. 12,
TOC1) and tau species phosphorylated at S202 (Fig. 13,
CP13). Altogether, these data suggest that only certain
pathogenic forms of tau (MC1, Y18) promote Syk
Fig. 5 pSyk is increased in cortical neurons of Tg Tau P301S mice compared to wild-type littermates. Representative confocal image depicting
56 week-old male Tg Tau P301S and wild-type mice stained with antibodies against pTau (S202, purple), pSyk (Y525/526, green). a Wild-type mice
did not exhibit any tau phosphorylation nor Syk activation in their cortices. b Tau-overexpressing Tg Tau P301S mice exhibited a prominent tau
phosphorylation at S202 that colocalized with Syk activation in cortical neurons. The scale bars represent 100 μm
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Fig. 6 pSyk is increased age-dependently in hippocampal neurons of Tg Tau P301S mice compared to wild-type littermates. Representative
confocal image depicting Tg Tau P301S and wild-type mice (n = 16) stained with antibodies against pTau (S202, purple), pSyk (Y525/526, green)
and Iba-1 (red). Nuclei were stained with DAPI. a-e Tau-overexpressing Tg Tau P301S mice exhibited a prominent tau phosphorylation (S202) that
increased with age and colocalized with Syk activation in hippocampal neurons. f Wild-type mice did not exhibit any tau phosphorylation nor
Syk activation in their hippocampi. The scale bar represents 10 μm
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Fig. 7 pSyk is increased age-dependently in cortical neurons of Tg Tau P301S mice compared to wild-type littermates. Representative confocal
image depicting Tg Tau P301S and wild-type mice (n = 16) stained with antibodies against pTau (S202, purple), pSyk (Y525/526, green) and Iba-1
(red). Nuclei were stained with DAPI. a-e Tau-overexpressing Tg Tau P301S mice exhibited a prominent tau phosphorylation (S202) that increased
with age and partially colocalized with Syk activation in cortical neurons. f Wild-type mice did not exhibit any tau phosphorylation nor Syk activation in
their cortices. The scale bar represents 10 μm
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activation, whereas Syk activation appears to directly in-
duce tau phosphorylation at Y18 and to indirectly regulate
tau phosphorylation at multiple epitopes (S396/404, S202)
as well as tau misfolding (MC1, TOC1).
Syk overexpression increases tau phosphorylation and
total tau levels in SH-SY5Y cells
To further investigate the impact of Syk on tau, we gen-
erated human neuronal-like (SH-SY5Y) cells overex-
pressing Syk (Syk-OX). Syk-OX SH-SY5Y cells show an
approximate 17-fold increase in Syk expression com-
pared to control SH-SY5Y cells transfected with the
empty vector (Fig. 14b, p < 0.0001). Interestingly, Syk up-
regulation in SH-SY5Y cells leads to a significant in-
crease (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c,
p < 0.01) and at S396/404 (Fig. 14d, 3-fold, p < 0.0001)
compared to control cells. Total tau levels are also sig-
nificantly increased following Syk overexpression
(Fig. 14e, 4.2-fold, p < 0.0001). We analyzed the possible
impact of Syk overexpression on Tau mRNA levels by
quantitative RT-PCR and found that Syk overexpression
does not affect Tau transcription (data not shown) sug-
gesting that Syk may regulate tau degradation or tau
protein translation. In summary, these results show that
the accumulation of tau pathogenic species can trigger
Syk activation, as shown in Tg Tau P301S mice (Figs. 8,
9, 10, 11, 12 and 13), whereas Syk itself appears to regu-
late total tau levels and tau phosphorylation at multiple
epitopes (Fig. 14) therefore influencing the development
of the tau pathology.
Syk activity is increased in cortical neurons
immunopositive for pTau (Y18), conformationally altered
Tau (MC1) and in dystrophic neurites in human AD
compared to non-demented control
We also performed different immunostainings against
Aβ, pSyk, GFAP, Iba-1, tau pathogenic conformers
(MC1) and phosphorylated tau at Y18 using brain sec-
tions from human AD and non-demented controls. We
found an increase in Syk activation in DNs surrounding
Aβ deposits as well as in neurons displaying an accumu-
lation of phosphorylated Tau at Y18 and elevated levels
of MC1 pathogenic tau conformers in AD brain sections
whereas only weak immunoreactivity for pSyk was ob-
served in brain sections from a non-demented control
(Figs. 15, 16 and 17). As observed in the AD mouse
models, astrocytes did not exhibit Syk activation in nei-
ther the AD brain section nor the control. Only a subset
of microglial cells exhibited a weak pSyk signal. Most of
the detected pSyk signal was of neuronal origin and ei-
ther localized in somata or DNs. These data complement
our observation in AD mouse models and reveal an as-
sociation between Syk activation and typical AD patho-
logical lesions in the human brain. Further studies will
be required using a larger sample of AD pathological
specimen to further clarify the role of Syk activation in
AD brains.
Discussion
Our previous studies have shown that tau hyperpho-
sphorylation, Aβ production and neuroinflammation are
reduced following Syk inhibition [28]. These data
Fig. 8 The degree of colocalization of pSyk and tau differs for various tau epitopes. Sections from Tg Tau P301S mice (n = 4, 47 ± 3.1-week-old)
were stained with antibodies against pTau (S202, S396/404, Y18), tau oligomers (TOC1) or tau conformers (MC1) and pSyk (Y525/526, green). The
cortices were divided in ROIs (each at a size of 50,000μm2) and neurons singly immunopositive for pSyk, singly immunoreactive for the respective
tau epitope and the neurons immunopositive for both pSyk and the respective tau epitope (colocalized) were counted and the percentages of
each neuronal fraction calculated using Zen Blue 2.1 (Zeiss) and Excel (MS Office), respectively. In average, 509 cortical fields were analyzed for
each epitope (total of 21,800 neurons counted). The percentage of neurons singly immunopositive for pSyk was at a similar level for all tau
epitopes investigated (pSyk only). MC1 and pTau Y18 show the highest colocalization with pSyk whereas the incidence of neurons immunopositive for
both pSyk and TOC1 or pTau S202 was much lower (colocalized fraction). The error bars represent SEM
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Fig. 9 The amount of MC1 tau conformers and pSyk (Y525/526) levels cross-influence each other. Sections from Tg Tau P301S (n = 4, 47 ± 3.1-
week-old) were stained with antibodies against tau conformers (MC1, purple) and pSyk (Y525/526, green). Fluorescent intensities of MC1 and pSyk
were measured using Zen Blue 2.1 (Zeiss). Three different neuronal fractions were differentiated: a neurons singly immunopositive for MC1,
(b) neurons singly immunopositive for pSyk and (c) neurons immunopositive for both MC1 and pSyk (colocalized). d Fluorescent intensities of
MC1 were compared between neurons singly MC1 positive (purple) and neurons exhibiting a colocalization of MC1 and pSyk (purple-green-striped).
Two-tailed Mann–Whitney test revealed a significant increase (p < 0.05) of MC1 fluorescent intensity in neurons exhibiting a colocalization of MC1 and
pSyk compared to neurons singly immunopositive for MC1. e Fluorescent intensities of pSyk were compared between neurons singly immunopositive
for pSyk (green) and neurons that show an immunoreactivity for both pSyk and MC1 (purple-green-striped). Two-tailed Mann–Whitney test revealed a
significant increase (p < 0.01) of pSyk fluorescent intensity in neurons immunoreactive for both pSyk and MC1 compared neurons that are
singly immunopositive for pSyk. The scale bar represents 10 μm. The error bars represent SEM
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Fig. 10 Tau phosphorylation at Y18 and Syk activation (Y525/526) cross-influence each other. Sections from Tg Tau P301S (n = 4, 47 ± 3.1-week-
old) were stained with antibodies against phosphorylated tau (Y18, purple) and pSyk (Y525/526, green). Fluorescent intensities of pTau (pY18) and
pSyk were measured using Zen Blue 2.1 (Zeiss). Three different neuronal fractions were differentiated: a neurons singly immunopositive for pY18,
(b) neurons singly immunopositive for pSyk and (c) neurons immunopositive for both (colocalized). d Fluorescent intensities of pY18 tau were
compared between singly pY18 immunopositive and the double immunopositive neurons (colocalized, purple-green-striped). Two-tailed Mann–
Whitney test revealed a significant increase (p < 0.05) of pY18 fluorescent intensity for neurons exhibiting a colocalization compared to the neurons
singly immunopositive for pY18 tau. e Fluorescent intensities of pSyk were compared between singly pSyk immunopositive neurons (green) and
double immunopositive neurons for pSyk and pY18 tau (purple-green-striped). Two-tailed Mann–Whitney test revealed a significant increase (p < 0.01)
of pSyk fluorescent intensity in neurons double immunopositive for pSyk and pY18 tau compared to singly pSyk immunopositive neurons. The scale
bar represents 10 μm. The error bars represent SEM
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Fig. 11 Syk activation (pSyk (Y525/526) influences the level of tau phosphorylation at S396/404. Sections from Tg Tau P301S (n = 4, 47 ± 3.1-week-old)
were stained with antibodies against phosphorylated tau (S396/404, purple) and pSyk (Y525/526, green). Fluorescent intensities of pTau (pS396/404)
and pSyk were measured using Zen Blue 2.1 (Zeiss). Three different neuronal fractions were differentiated: a neurons singly immunopositive for pS396/
404 tau, (b) neurons singly immunopositive for pSyk and (c) neurons immunopositive for both (colocalized). d Fluorescent intensities of pS396/404 tau
were compared between neurons singly immunopositive for pS396/404 (purple) and the neurons exhibiting a colocalization of pS396/404 and pSyk
(purple-green-striped). Two-tailed Mann–Whitney test revealed a significant increase (p < 0.0001) of pS396/404 fluorescent intensity in the neurons
exhibiting a colocalization compared to neurons singly immunopositive for pS396/404 tau. e Fluorescent intensities of pSyk were compared between
singly pSyk immunopositive neurons (green) and neurons exhibiting a colocalization of pSyk and pS396/404 tau (purple-green-striped). Two-tailed
Mann–Whitney test revealed no significant change of pSyk fluorescent intensity in neurons exhibiting a colocalization compared to singly pSyk
immunopositive neurons. The scale bar represents 10 μm. The error bars represent SEM
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Fig. 12 Syk activation (Y525/526) influences the level of tau oligomerization (TOC1). Sections from Tg Tau P301S (n = 4, 47 ± 3.1-week-old) stained with
antibodies against tau oligomers (TOC1, purple) and pSyk (Y525/526, green). Fluorescent intensities of oligomerized tau (TOC1) and pSyk were
measured using Zen Blue 2.1 (Zeiss). Three different neuronal fractions were differentiated: a) neurons singly immunopositive for TOC1, (b) neurons
singly immunopositive for pSyk and (c) neurons immunopositive for both (colocalized). d Fluorescent intensities of TOC1 were compared between
neurons singly immunopositive for TOC1 (purple) and neurons exhibiting a colocalization of pSyk and TOC1 (purple-green-striped). Two-tailed Mann–
Whitney test revealed a significant increase (p < 0.0001) of TOC1 fluorescent intensity in neurons exhibiting a colocalization with pSyk compared to
singly TOC1 immunopositive neurons. e Fluorescent intensities of pSyk were compared between neurons singly immunopositive for pSyk (green) and
neurons exhibiting a colocalization pf TOC1 and pSyk (purple-green-striped). Two-tailed Mann–Whitney test revealed no significant change of pSyk
fluorescent intensity in neurons exhibiting a colocalization compared to the singly pSyk immunopositive neurons. The scale bar represents 10 μm. The
error bars represent SEM
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Fig. 13 Syk activation (Y525/526) influences the level of tau phosphorylation at S202. Sections from Tg Tau P301S (n = 4, 47 ± 3.1-week-old)
stained with antibodies against phosphorylated tau (S202, purple) and pSyk (Y525/526, green). Fluorescent intensities of pTau (S202) and pSyk
were measured using Zen Blue 2.1 (Zeiss). Three different neuronal fractions were differentiated: a neurons singly immunopositive for S202,
(b) neurons singly immunopositive for pSyk and (c) neurons immunopositive for both (colocalized). d Fluorescent intensities of pS202 tau were
compared between neurons singly pS202 immunopositive (purple) and neurons exhibiting a colocalization between pS202 and pSyk
(purple-green-striped). Two-tailed Mann–Whitney test revealed a significant increase (p < 0.0001) of pS202 fluorescent intensity in neurons
exhibiting a colocalization compared to neurons singly immunopositive for pS202. e Fluorescent intensities of pSyk were compared between neurons
singly immunopositive for pSyk (green) and neurons exhibiting a colocalization of pSyk and pS202 tau (purple-green-striped). Two-tailed Mann–Whitney
test revealed no significant change of pSyk fluorescent intensity in neurons exhibiting a colocalization compared to singly pSyk immunopositive
neurons. The scale bar represents 10 μm. The error bars represent SEM
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prompted us to investigate the level of Syk activation in
different mouse models of AD and in brain sections
from a non-demented control and an AD patient. We
found that Syk activation occurs in three different mouse
models of AD, overexpressing Aβ or tau, showing that
Syk activation is triggered by both Aβ deposits and tau
pathological species. Most importantly, we made similar
observations in human AD brain sections.
Recent late phase clinical trials targeting the major
pathological hallmarks of AD, mainly extracellular Aβ
plaques or intra-neuronal tau aggregates, have been
unsuccessful so far and have failed to prevent cognitive
decline and brain atrophy in AD patients [7, 19, 37, 39].
As PET scan imaging of AD patients reveals that Aβ de-
posits and pathological tau accumulation occur during
the prodromal phase of AD [26], it has been suggested
Fig. 14 Syk overexpression increases tau phosphorylation and total tau levels in SH-SY5Y cells. SH-SY5Y cells were transfected with either the
empty plasmid as a control or with the same plasmid carrying the Syk sequence for overexpression (Syk OX). Proteins expressed by transfected
SH-SY5Y cells were analyzed by Western-blotting. Western-blots chemiluminescent signals were quantified and results were tested for normal
distribution using the Shapiro-Wilk test. A subsequent Mann–Whitney test was used to test for statistical significance. a Representative Western
blots are shown. b Level of Syk overexpression is in average 17.3 times higher than in control cells (p≤ 0.0001, n = 18). c Level of tau phosphorylation
at Y18 is 1.7 times higher in Syk overexpressing compared to control cells (p≤ 0.01, n = 11). d Level of tau phosphorylation at S396/404 is 3 times
higher in Syk overexpressing compared to control cells (p≤ 0.0001, n = 17). e Level of total tau (DA9) is 4.1 times higher in Syk overexpressing
compared to control cells (p ≤ 0.0001, n = 18). The error bars represent SEM
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Fig. 15 pSyk is increased in cortical neurons immunopositive for pTau (Y18) of human AD compared to non-demented controls. Representative
confocal images of the dorsolateral frontal cortex sections of human AD (b) were stained with antibodies against pTau (Y18) (purple), pSyk (525/
526) (green), Iba-1 (red) and GFAP (blue) and compared to control brain sections (a). a The non-demented control (102-year-old, male) does not
exhibit any tau phosphorylation nor increased Syk activation in the dorsolateral frontal cortex. b The AD brain (67-year-old, male) exhibits a prominent
tau phosphorylation at Y18 that colocalizes with Syk activation (Y525/526) in cortical neurons. The scale bars represent 10 μm
Fig. 16 pSyk is increased in cortical neurons immunopositive for MC1 pathogenic Tau conformers in AD compared to brain sections from a non-
demented control. Representative confocal images of the dorsolateral frontal cortex sections of human AD (b) were stained with antibodies
against conformationally altered tau species (MC1) (purple), pSyk (525/526) (green), Iba-1 (red) and GFAP (blue) and compared to non-demented
control brain sections (a). a The non-demented control (102-year-old, male) does not exhibit any cells immunopositive for MC1 nor increased in
Syk activation in the dorsolateral frontal cortex. b The AD brain (67-year-old, male) exhibits neurons strongly immunopositive for MC1 that colocalize
with Syk activation (Y525/526) in cortical neurons. The scale bars represent 10 μm
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that therapies that are targeting Aβ or pathological tau
accumulation must be implemented decades before the
appearance of the symptoms to be successful [26].
Hence, pharmacological intervention at downstream tar-
gets of Aβ and tau may represent a more promising
therapeutic strategy for AD patients. However, thera-
peutic targets downstream of the Aβ and tau patho-
logical lesions remain to be identified. Our work
supports the view that Syk may be such a therapeutic
target as it appears to be activated in vivo in response to
β-amyloidosis and the formation of pathological tau
species.
In this study, we report a hyperactivation of Syk in the
brains of three different AD mouse models versus wild-
type/littermate controls and human AD compared to
non-demented controls. In Tg PS1/APPsw, Tg APPsw
mice, Syk activity is largely increased in activated micro-
glia and in DNs around Aβ deposits. In addition, we
observed an activation of Syk in DNs around Aβ de-
posits in an AD pathological specimen. In Tg Tau P301S
mice and AD brain sections, Syk hyperactivation is colo-
calized with misfolded tau and hyperphosphorylated tau
in neurons.
The strong increase in activated Syk observed in dys-
trophic neurites (DNs) surrounding Aβ deposits may
suggest the involvement of Syk in the formation of these
DNs that ultimately leads to the synaptic loss observed
in AD [32]. DNs are characterized by an accumulation
of BACE-1 and sAPPβ which implies a contribution of
DNs to Aβ production and accumulation [31]. In fact,
several in vivo studies have shown that BACE-1 immu-
nopositive dystrophic neurites precede Aβ plaque forma-
tion in the brains of 3xTg-AD, 2xFAD and 5xFAD mice
and therefore, represent an early pathological event in
AD [2, 16, 45]. Our previous in vitro and in vivo data
have shown that Syk regulates Aβ and sAPPβ production
Fig. 17 pSyk is increased in dystrophic neurites associated with β-amyloid plaques of human AD patients compared to healthy controls. Representative
confocal images of dorsolateral frontal cortex sections of human AD (b) were stained with antibodies against Aβ (6E10) (purple), pSyk (525/526) (green),
Iba-1 (red) and compared to non-demented control brain sections (a). a The non-demented control (102-year-old, male) does not exhibit any Aβ
deposits nor increased Syk activation in neurons. b The AD brain (67-year-old, male) exhibits neurons strongly immunopositive for pSyk (Y525/526).
c The AD brain also exhibits dystrophic neurites immunopositive for pSyk (Y525/526) near/within Aβ deposits. The scale bars represent 10 μm
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via a modulation of BACE-1 expression [28] and there-
fore support a causative role of Syk activation in the ac-
cumulation of BACE-1 and sAPPβ in DNs.
The increased activation of Syk in activated microglia of
Aβ-overexpressing mice further supports a role of Syk in
microglial activation in vivo and suggests that Aβ accumu-
lation can lead to an activation of Syk in microglia. Previ-
ous in vitro studies have shown that Aβ fibrils and
oligomers can trigger a microglial inflammatory response
mediated by Syk and leading to neurotoxicity [3, 4, 23].
Recruitment and activation of Syk can also be medi-
ated by activation of triggering receptor expressed on
myeloid cells 2 (TREM2) [18]. TREM2 is a type I trans-
membrane protein and part of the immunoglobulin (Ig)
receptor superfamily. Since TREM2 does not have any
cytoplasmic signaling motifs, an adaptor protein DNAX-
activating protein of 12 kDa (DAP12, also known as
TYROBP) is needed for TREM2 signal transduction.
DAP12 interacts with the transmembrane domain of
TREM2. The cytoplasmic domain of DAP12 contains an
immunoreceptor tyrosine activation motif (ITAM) that
provides docking sites for Syk activation. Interestingly,
loss-of-function mutations in the DAP12 or TREM2
genes cause a rare autosomal recessive disorder called
Nasu-Hakola disease (NHD) whereas heterozygous car-
riers of these mutations show an elevated risk to develop
AD [27]. Symptoms of NDH include multifocal bone
cysts and presenile dementia. Interestingly, Syk activa-
tion (pSyk, Y525/526) is increased in NHD neurons
compared to controls [33] and was found to be also
present in microglia and macrophages but not in astro-
cytes or oligodendrocytes [33] supporting a role of Syk
activation in the development of NHD dementia.
Syk plays a key role in the activation of immune cells
and the production of inflammatory cytokines. We have
shown previously that activation of NFκB (nuclear factor
kappa-light-chain-enhancer of activated B cells) which is
known to play a regulatory role in neuroinflammation, is
prevented following either pharmacological Syk inhibition
or genetic knockdown of Syk [28]. Hence, this suggests a
role of Syk in the regulation of neuroinflammation. In
addition, Syk has been shown to mediate the neuroin-
flammation and neurotoxicity caused by Aβ [3, 23].
Furthermore, the Aβ-induced cytokine production by
microglia has been found to be mediated by Syk [4], sug-
gesting that Syk is involved in the microglial proinflamma-
tory response.
The pathological analysis of Tg Tau P301S mice shows
that Syk activation is associated with the formation of
hyperphosphorylated tau and misfolded tau in the
hippocampus and cortex while our previous work has
shown that Syk inhibition can reduce tau phosphoryl-
ation at multiple AD relevant epitopes [28]. Interest-
ingly, we show here that Syk upregulation in human
neuronal like SH-SY5Y cells induces tau accumulation
and tau phosphorylation further confirming a role of Syk
in the formation of tau pathogenic species. Altogether,
our data suggest that Syk activation may also promote
tau hyperphosphorylation and misfolding in vivo as neu-
rons that show higher levels of Syk activation also show
more accumulation of hyperphosphorylated tau and tau
pathogenic conformers. Pathological tau species accu-
mulation clearly results in Syk activation in Tg Tau
P301S mice while Syk activation appears to be a medi-
ator of the formation of tau pathogenic species, thereby
implying the existence of a positive feedback loop result-
ing in an enhanced progression of tau pathology. Given
that Syk is also present in DNs which exhibit tau accu-
mulation and tau phosphorylation [35, 40], this further
supports a pathological role of Syk in the formation of
DNs and ultimately synaptical loss.
Our previous in vivo and in vitro data show decreased
tau phosphorylation at multiple epitopes (S396/404,
S202, Y18) following Syk inhibition [28]. Interestingly,
we show here that Syk overexpression in SH-SY5Y cells
increases tau phosphorylation and total tau levels (Y18,
S396/404, DA9). The increase in total tau levels follow-
ing Syk upregulation is not caused by an increased tran-
scription, as tau mRNA levels do not vary between Syk
overexpressing and control cells (data not shown).
Therefore, increased Syk levels may lead to an increased
translation or decreased degradation of tau or a combin-
ation of both. However, the molecular mechanisms re-
sponsible for the increased tau levels following Syk
overexpression or decreased tau following Syk inhibition
remain to be further investigated and are currently being
studied in our laboratory.
In this study, we also provide evidence for an aber-
rant Syk activation in dystrophic neurites around Aβ
deposits and in neurons immunopositive for patho-
logical tau species in human AD brain sections further
validating the data obtained with different transgenic
mouse models of AD.
Conclusions
In conclusion, our data support a pathological role of Syk
in the formation of Aβ deposits and misfolded tau and
suggest additionally that reduction of Syk hyperactivity
through pharmacological inhibition may be a promising
therapeutic approach for the treatment of AD.
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